 EXHIBIT 2.1     

Exhibit 2.1

  

  

 


 

  

 

EXECUTION COPY

 

  

  

  

  

  

AGREEMENT AND PLAN OF MERGER

  

  

dated as of November 11, 2013,

  

  

among

  

  

SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED,

  

  

VENUS NEWCO, INC.,

  

  

VIROPHARMA INCORPORATED

  

  

and

  

  

SHIRE PLC

  

(solely for the purposes set forth in Section 10.16)

  

  

  

  

  

  

  


 

  

 

 

 

  

   

  

 

 

 

  

  

 

TABLE OF CONTENTS

 

  

  

     |  | Page  
---|---|--- 
   |  |   
  

ARTICLE I

  

  

THE OFFER

   
   |  |   
  

Section 1.1

  |  

The Offer

  |  

2

   
  

Section 1.2

  |  

Company Actions

  |  

4

   
  

Section 1.3

  |  

Directors

  |  

6

   
   |  |   
  

ARTICLE II

   
   |  |   
  

THE MERGER

   
   |  |   
  

Section 2.1

  |  

The Merger

  |  

7

   
  

Section 2.2

  |  

Closing

  |  

8

   
  

Section 2.3

  |  

Effective Time of the Merger

  |  

8

   
  

Section 2.4

  |  

Effects of the Merger

  |  

8

   
  

Section 2.5

  |  

Certificate of Incorporation and Bylaws

  |  

8

   
  

Section 2.6

  |  

Directors

  |  

8

   
  

Section 2.7

  |  

Officers

  |  

9

   
   |  |   
  

ARTICLE III

   
   |  |   
  

EFFECT OF THE MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS;
EXCHANGE OF CERTIFICATES

   
   |  |   
  

Section 3.1

  |  

Effect on Capital Stock

  |  

9

   
  

Section 3.2

  |  

Exchange of Certificates

  |  

10

   
  

Section 3.3

  |  

Treatment of Options and Other Stock-Based Awards

  |  

12

   
  

Section 3.4

  |  

Dissenter Rights

  |  

14

   
   |  |   
  

ARTICLE IV

   
  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

   
   |  |   
  

Section 4.1

  |  

Organization, Standing and Corporate Power

  |  

15

   
  

Section 4.2

  |  

Subsidiaries

  |  

15

   
  

Section 4.3

  |  

Capital Structure

  |  

16

   
  

Section 4.4

  |  

Authority

  |  

17

   
  

Section 4.5

  |  

Non-Contravention

  |  

18

   
  

Section 4.6

  |  

Required Filings and Consents

  |  

19

   
  

Section 4.7

  |  

Company SEC Documents and the Sarbanes-Oxley Act.

  |  

19

   
  

Section 4.8

  |  

No Undisclosed Liabilities

  |  

21

   
  

  

 

 

 

  

   

  

 

 

  

 

  

 

    

TABLE OF CONTENTS

  

(continued)

   
--- 
   |  | Page  
   |  |   
  

Section 4.9

  |  

Information Supplied.

  |  

21

   
  

Section 4.10

  |  

Absence of Certain Changes or Events

  |  

21

   
  

Section 4.11

  |  

Litigation

  |  

22

   
  

Section 4.12

  |  

Contracts

  |  

22

   
  

Section 4.13

  |  

Permits; Compliance with Laws

  |  

25

   
  

Section 4.14

  |  

Properties

  |  

26

   
  

Section 4.15

  |  

Environmental Matters

  |  

26

   
  

Section 4.16

  |  

Employee Benefits

  |  

27

   
  

Section 4.17

  |  

Labor Matters

  |  

30

   
  

Section 4.18

  |  

Taxes

  |  

31

   
  

Section 4.19

  |  

Intellectual Property

  |  

33

   
  

Section 4.20

  |  

Regulatory Compliance

  |  

35

   
  

Section 4.21

  |  

Rule 14d-10 Matters

  |  

39

   
  

Section 4.22

  |  

Brokers and Other Advisors

  |  

39

   
  

Section 4.23

  |  

Opinion of Financial Advisor

  |  

40

   
  

Section 4.24

  |  

Anti-takeover Statutes

  |  

40

   
  

Section 4.25

  |  

Insurance

  |  

40

   
   |  |   
  

ARTICLE V

   
   |  |   
  

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

   
   |  |   
  

Section 5.1

  |  

Organization, Standing and Corporate Power

  |  

41

   
  

Section 5.2

  |  

Authority

  |  

41

   
  

Section 5.3

  |  

Non-Contravention

  |  

41

   
  

Section 5.4

  |  

Required Filings and Consents

  |  

42

   
  

Section 5.5

  |  

Information Supplied

  |  

42

   
  

Section 5.6

  |  

Interim Operations of Merger Sub

  |  

42

   
  

Section 5.7

  |  

Sufficiency of Funds

  |  

43

   
  

Section 5.8

  |  

Company Stock

  |  

43

   
  

Section 5.9

  |  

Litigation

  |  

43

   
  

Section 5.10

  |  

Brokers and Other Advisors

  |  

43

   
   |  |   
  

ARTICLE VI

   
   |  |   
  

COVENANTS RELATING TO CONDUCT OF BUSINESS

   
   |  |   
  

Section 6.1

  |  

Conduct of Business

  |  

43

   
  

Section 6.2

  |  

No Solicitation

  |  

48

   
   |  |   
  

ARTICLE VII

   
   |  |   
  

ADDITIONAL AGREEMENTS

   
   |  |   
  

Section 7.1

  |  

Access to Information; Confidentiality

  |  

52

   
 

  

  

 

 

 

  

 

ii  

  

 

 

 

  

  

    

TABLE OF CONTENTS

  

(continued)

   
--- 
   |  | Page  
   |  |   
  

Section 7.2

  |  

Reasonable Best Efforts

  |  

53

   
  

Section 7.3

  |  

Notification of Certain Matters

  |  

55

   
  

Section 7.4

  |  

Director and Officer Indemnification, Exculpation and Insurance

  |  

56

   
  

Section 7.5

  |  

Public Announcements

  |  

57

   
  

Section 7.6

  |  

Merger Sub Compliance

  |  

58

   
  

Section 7.7

  |  

Section 16(b)

  |  

58

   
  

Section 7.8

  |  

Rule 14d-10 Matters

  |  

58

   
  

Section 7.9

  |  

Company Benefit Plan Matters

  |  

58

   
  

Section 7.10

  |  

Convertible Notes

  |  

61

   
  

Section 7.11

  |  

Call-Spread Warrants and Company Hedge Options.

  |  

61

   
  

Section 7.12

  |  

Termination of Credit Facility

  |  

61

   
  

Section 7.13

  |  

Sanquin Matters

  |  

61

   
  

Section 7.14

  |  

Takeover Statutes

  |  

62

   
  

Section 7.15

  |  

Stock Exchange Delisting

  |  

62

   
   |  |   
  

ARTICLE VIII

   
   |  |   
  

CONDITIONS TO CONSUMMATION OF THE MERGER

   
   |  |   
  

Section 8.1

  |  

Conditions to Each Party's Obligation to Effect the Merger

  |  

62

   
   |  |   
  

ARTICLE IX

   
   |  |   
  

TERMINATION, AMENDMENT AND WAIVER

   
   |  |   
  

Section 9.1

  |  

Termination

  |  

63

   
  

Section 9.2

  |  

Effect of Termination

  |  

65

   
  

Section 9.3

  |  

Fees and Expenses

  |  

65

   
   |  |   
  

ARTICLE X

   
   |  |   
  

GENERAL PROVISIONS

   
   |  |   
  

Section 10.1

  |  

No Other Representations or Warranties; Investigation by Parent

  |  

66

   
  

Section 10.2

  |  

Nonsurvival of Representations and Warranties

  |  

67

   
  

Section 10.3

  |  

Amendment

  |  

67

   
  

Section 10.4

  |  

Extension; Waiver

  |  

67

   
  

Section 10.5

  |  

Notices

  |  

67

   
  

Section 10.6

  |  

Counterparts

  |  

68

   
  

Section 10.7

  |  

Entire Agreement; No Third-Party Beneficiaries

  |  

69

   
  

Section 10.8

  |  

Assignment

  |  

69

   
  

Section 10.9

  |  

Governing Law

  |  

69

   
  

Section 10.10

  |  

Consent to Jurisdiction; Service of Process; Venue

  |  

69

   
  

Section 10.11

  |  

Waiver of Jury Trial

  |  

70

   
  

Section 10.12

  |  

Specific Enforcement

  |  

70

   
  

  

 

 

 

  

 

iii  

  

 

 

  

 

  

    TABLE OF CONTENTS   

(continued)

   
--- 
   |  | Page  
   |  |   
  

Section 10.13

  |  

Consents and Approvals

  |  

70

   
  

Section 10.14

  |  

Severability

  |  

70

   
  

Section 10.15

  |  

Joint and Several Liability; Obligation of Parent

  |  

71

   
  

Section 10.16

  |  

Parent Holdco Guarantee

  |  

71

   
   |  |   
  

ARTICLE XI

   
   |  |   
  

DEFINITIONS AND EXHIBITS

   
   |  |   
  

Section 11.1

  |  

Definitions

  |  

72

   
  

Section 11.2

  |  

Exhibits, Appendix and Schedules; Interpretation

  |  

75

   
   |  |   
   |  |   
   |  |   
 Appendix A |  

Defined Terms

  |   
   |  |   
 Exhibit A | Offer Conditions |   
 

 

 

 

  


 

  

 

 

 

  

 

iv  

  

 

 

 

  

  

AGREEMENT AND PLAN OF MERGER

  

  

This AGREEMENT AND PLAN OF MERGER, dated as of November 11, 2013 (this
"Agreement"), is by and among SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, a
company incorporated in Ireland ("Parent"), VENUS NEWCO, INC., a Delaware
corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and
VIROPHARMA INCORPORATED, a Delaware corporation (the "Company"), and, solely
for the purposes set forth in Section 10.16, SHIRE PLC, a company incorporated
in Jersey ("Parent Holdco").

  

  

RECITALS

  

  

WHEREAS, Parent desires to acquire all of the outstanding shares of common
stock, par value $0.002 per share, of the Company ("Company Common Stock"), on
the terms and subject to the conditions set forth in this Agreement;

  

  

WHEREAS, in furtherance of the acquisition of the outstanding shares of
Company Common Stock by Parent on the terms and subject to the conditions set
forth in this Agreement, Parent proposes to cause Merger Sub to make a tender
offer to purchase any (for the avoidance of doubt, subject to the Minimum
Tender Condition) and all of the outstanding shares of Company Common Stock
(as it may be amended from time to time as permitted under this Agreement, the
"Offer") for consideration of a price per share of Company Common Stock of
$50.00 (such amount, or any other amount per share paid pursuant to the Offer
and this Agreement, the "Offer Price"), net to the seller in cash, without
interest, on the terms and subject to the conditions set forth in this
Agreement;

  

  

WHEREAS, following consummation of the Offer, pursuant to the provisions of
Section 251(h) of Delaware General Corporation Law ("DGCL"), Merger Sub will
be merged with and into the Company (the "Merger"), on the terms and subject
to the conditions set forth in this Agreement, with the Company surviving the
Merger as a wholly owned Subsidiary of Parent and, subject to certain
limitations set forth herein, each share of Company Common Stock that is not
tendered and accepted pursuant to the Offer will thereupon be cancelled and
converted into the right to receive cash in an amount equal to the Offer
Price;

  

  

WHEREAS, the Board of Directors of the Company has unanimously (a) adopted and
declared the advisability of this Agreement, the Offer, the Merger and the
other transactions contemplated by this Agreement, (b) declared that it is in
the best interests of the Company and the stockholders of the Company (other
than Parent and its Subsidiaries) that the Company enter into this Agreement
and consummate the Merger and the other transactions contemplated by this
Agreement and that the stockholders of the Company tender their shares of
Company Common Stock pursuant to the Offer, in each case on the terms and
subject to the conditions set forth herein, (c) declared that the terms of the
Offer and the Merger are fair to the Company and the Company's stockholders
(other than Parent and its Subsidiaries) and (d) resolved to recommend that
the Company's stockholders accept the Offer and tender their shares of Company
Common Stock pursuant to the Offer;

  

  

WHEREAS, the Board of Directors of each of Parent and Merger Sub has
unanimously (i) determined that the Offer, the Merger, this Agreement and the
other transactions

  

  

 

 

 

  

   

  

 

 

 

  

  

contemplated hereby are fair to and in the best interests of Parent and Merger
Sub and (ii) approved, adopted and declared advisable this Agreement,
including the Offer and the Merger; and

  

  

WHEREAS, Parent, Merger Sub and the Company desire to make certain
representations, warranties, covenants and agreements in connection with the
Offer and the Merger and also to prescribe various Offer Conditions and
conditions to the Merger.

  

  

NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth herein, the
parties hereto agree as follows:

  

  

ARTICLE I

  

  

THE OFFER

  

  

Section 1.1 The Offer.

  

  

(a) Commencement of the Offer. Provided that this Agreement shall not have
been terminated in accordance with Section 9.1 and none of the events set
forth in clause (iii) (other than in paragraph (f) thereof) of Exhibit A shall
exist or have occurred and be continuing, subject to the terms of this
Agreement, as promptly as practicable (but in no event later than ten (10)
Business Days) after the date of this Agreement, Merger Sub shall, and Parent
shall cause Merger Sub to, commence, within the meaning of Rule 14d-2 under
the Securities Exchange Act of 1934, as amended (together with the rules and
regulations promulgated thereunder, the "Exchange Act"), the Offer. The
obligations of Merger Sub to, and of Parent to cause Merger Sub to, accept for
payment, and pay for, any shares of Company Common Stock tendered pursuant to
the Offer are subject to the conditions set forth in Exhibit A (the "Offer
Conditions").

  

  

(b) Expiration of the Offer. The Offer shall expire at midnight, New York City
time, on the 20th Business Day following the commencement of the Offer
(determined pursuant to Rule 14d-1(g)(3) under the Exchange Act); provided,
that if the initial expiration of the Offer would otherwise be scheduled to
occur on December 20, 2013, December 23, 2013 or December 24, 2013, the Offer
shall expire at 6:00 p.m., New York City time, on December 26, 2013 (such
time, or such subsequent time to which the expiration of the Offer is extended
in accordance with the terms of this Agreement, the "Expiration Date"). Merger
Sub expressly reserves the right, in its sole discretion, to waive, in whole
or in part, any Offer Condition or modify the terms of the Offer; provided,
however, that, without the prior written consent of the Company, Merger Sub
shall not (i) reduce the number of shares of Company Common Stock sought in
the Offer, (ii) reduce the Offer Price, (iii) change, modify or waive the
Minimum Tender Condition, (iv) add to the conditions set forth in Exhibit A or
modify or change any Offer Condition in a manner adverse to any holders of
Company Common Stock, (v) except as otherwise provided in this Section 1.1(b),
extend or otherwise change the Expiration Date of the Offer, (vi) change the
form of consideration payable in the Offer or (vii) otherwise amend, modify or
supplement any of the terms of the Offer in a manner adverse to any holders of
Company Common Stock. Notwithstanding anything in this Agreement to the
contrary, Merger Sub may, in its sole discretion, without consent of the
Company, (A) without limiting Parent's or Merger Sub's obligations under the
following

  

  

 

 

 

  

 

2  

  

 

 

 

  

  

sentence, extend the Offer on one or more occasions, in consecutive increments
not more than ten (10) Business Days (or such longer period as the parties
hereto may agree) each, if on any then-scheduled Expiration Date of the Offer
any of the Offer Conditions shall not have been satisfied or, to the extent
waivable by Parent or Merger Sub, waived and (B) extend the Offer for any
period required by any rule, regulation, interpretation or position of the
Securities and Exchange Commission (the "SEC") or the staff thereof applicable
to the Offer or any period otherwise required by applicable Law. Parent and
Merger Sub agree that, to the extent requested in writing by the Company prior
to any then-scheduled Expiration Date of the Offer, Merger Sub shall (and
Parent shall cause Merger Sub to) (I) if any of the Offer Conditions set forth
in clause (ii) of Exhibit A or in paragraph (a) or (b) of clause (iii) of
Exhibit A shall not have been satisfied or, to the extent waivable by Parent
or Merger Sub, waived, and provided, that it is reasonably expected that such
condition or conditions shall be satisfied prior to the Termination Date,
extend the Offer on one or more occasions, in consecutive increments of up to
ten (10) Business Days each (or such longer period as the parties hereto may
agree), until such time as such Offer Conditions are satisfied (but not beyond
the Termination Date) and (II) if any of the Minimum Tender Condition or the
Offer Conditions set forth in paragraph (d) or (e) of clause (iii) of Exhibit
A shall not have been satisfied or, to the extent waivable by Parent or Merger
Sub, waived on such then-scheduled Expiration Date, but all the other Offer
Conditions set forth in Exhibit A (other than in paragraph (f) of clause (iii)
of Exhibit A) shall be satisfied on such then-scheduled Expiration Date,
extend the Offer on one or more occasions, in consecutive increments of up to
ten (10) Business Days (or such longer period as the parties hereto may agree)
each, for an aggregate period of time of not more than twenty (20) Business
Days; provided, however, that Merger Sub shall not be required to extend the
Offer beyond the Termination Date. In no event shall Merger Sub be required to
extend the Offer at any time that Parent or Merger Sub is permitted to
terminate this Agreement.

  

  

(c) Offer Closing. On the terms of this Agreement and subject to the
satisfaction or, to the extent waivable by Parent or Merger Sub, waiver of the
Offer Conditions, Merger Sub shall, and Parent shall cause Merger Sub to,
accept and pay for (subject to any withholding of Tax pursuant to Section
1.1(g)) all shares of Company Common Stock validly tendered and not validly
withdrawn pursuant to the Offer that Merger Sub becomes obligated to purchase
pursuant to the Offer promptly after the Expiration Date of the Offer.
Acceptance for payment of shares of Company Common Stock pursuant to and
subject to the Offer Conditions is referred to in this Agreement as the "Offer
Closing," and the date on which the Offer Closing occurs is referred to in
this Agreement as the "Offer Closing Date."

  

  

(d) Termination of Offer. The Offer may not be terminated prior to its
Expiration Date, unless this Agreement is validly terminated in accordance
with Article IX. If the Offer is terminated or withdrawn by Merger Sub, or
this Agreement is terminated in accordance with Section 9.1, in each case
prior to the Offer Closing, Merger Sub shall promptly return, and shall cause
any depository acting on behalf of Merger Sub to return, all tendered Company
Common Stock to the registered holders thereof.

  

  

(e) Schedule TO; Offer Documents. On the date of commencement of the Offer,
Parent and Merger Sub shall file with the SEC a Tender Offer Statement on
Schedule TO filed under cover of Schedule TO with respect to the Offer, which
shall contain an offer to

  

  

 

 

 

  

 

3  

  

 

 

 

  

  

purchase and a related letter of transmittal and summary advertisement (such
Schedule TO and the documents included therein pursuant to which the Offer
will be made, together with any supplements or amendments thereto, the "Offer
Documents"). The Company shall promptly furnish to Parent and Merger Sub all
information concerning the Company required by the Exchange Act to be set
forth in the Offer Documents. Each of Parent, Merger Sub and the Company shall
promptly correct any information supplied by it for inclusion or incorporation
by reference in the Offer Documents if and to the extent that such information
shall have become false or misleading in any material respect, and each of
Parent and Merger Sub shall take all steps necessary to amend or supplement
the Offer Documents and to cause the Offer Documents as so amended or
supplemented to be filed with the SEC and disseminated to the holders of
Company Common Stock, in each case as and to the extent required by applicable
federal securities Laws. Parent and Merger Sub shall promptly notify the
Company upon the receipt of any comments from the SEC, or any request from the
SEC for amendments or supplements, to the Offer Documents, and shall provide
the Company with copies of all correspondence between them and their
Representatives, on the one hand, and the SEC, on the other hand, and shall
use its reasonable best efforts to give the Company the opportunity to
participate in any substantive telephonic or in-person communications with the
staff of the SEC related thereto. Prior to the filing of the Offer Documents
(including any amendment or supplement thereto) with the SEC or dissemination
thereof to the stockholders of the Company, or responding to any comments of
the SEC with respect to the Offer Documents, Parent and Merger Sub shall
provide the Company a reasonable opportunity to review and comment on such
Offer Documents or response, and Parent and Merger Sub shall give reasonable
consideration to any such comments.

  

  

(f) Parent shall provide or cause to be provided to Merger Sub on a timely
basis the funds necessary to pay for any shares of Company Common Stock that
Merger Sub becomes obligated to accept for payment, and pay for, pursuant to
the Offer.

  

  

(g) Parent, Merger Sub or the Paying Agent, as applicable, shall be entitled
to deduct and withhold from the consideration otherwise payable pursuant to
the Offer to any holder of shares of Company Common Stock such amounts as
Parent, Merger Sub or the Paying Agent is required to deduct and withhold with
respect to the making of such payment under the Internal Revenue Code of 1986,
as amended (the "Code"), or any other applicable Law. To the extent that
amounts are so withheld and paid over by Merger Sub, Parent or the Paying
Agent to the appropriate Governmental Entity, such withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the holder
of the shares of Company Common Stock in respect of which such deduction and
withholding was made by Merger Sub, Parent or the Paying Agent.

  

  

Section 1.2 Company Actions.

  

  

(a) The Company hereby approves of and consents to the Offer, the Merger and
the other transactions contemplated by this Agreement. The Company represents
that it has been advised that all of its directors and executive officers who
own shares of Company Common Stock intend to tender such shares pursuant to
the Offer.

  

  

 

 

 

  

 

4  

  

 

 

  

 

  

(b) On the date the Offer Documents are filed with the SEC, the Company shall
file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9
with respect to the Offer (such Schedule 14D-9, together with any supplements
or amendments thereto, the "Schedule 14D-9") containing the Company
Recommendation and shall mail the Schedule 14D-9 to the stockholders of the
Company. The Company shall also include in the Schedule 14D-9, (i) in its
entirety, copies of the opinion of the Company Financial Advisor described in
Section 4.23 and (ii) a notice of appraisal rights in accordance with Section
262 of the DGCL. Parent and Merger Sub shall promptly furnish to the Company
all information concerning Parent and Merger Sub required by the Exchange Act
to be set forth in the Schedule 14D-9. Each of the Company, Parent and Merger
Sub shall promptly correct any information supplied by it for inclusion or
incorporation by reference in the Schedule 14D-9 if and to the extent that
such information shall have become false or misleading in any material
respect, and the Company shall take all steps necessary to amend or supplement
the Schedule 14D-9 and to cause the Schedule 14D-9 as so amended or
supplemented to be filed with the SEC and disseminated to the stockholders of
the Company, in each case as and to the extent required by applicable federal
securities Laws. The Company shall promptly notify Parent upon the receipt of
any comments from the SEC, or any request from the SEC for amendments or
supplements, to the Schedule 14D-9, and shall provide Parent with copies of
all correspondence between the Company and its Representatives, on the one
hand, and the SEC, on the other hand, and shall use its reasonable best
efforts to give Parent the opportunity to participate in any substantive
telephonic or in-person communications with the staff of the SEC related
thereto. Prior to the filing of the Schedule 14D-9 (including any amendment or
supplement thereto) with the SEC or mailing thereof to the stockholders of the
Company, or responding to any comments of the SEC with respect to the Schedule
14D-9, the Company shall provide Parent a reasonable opportunity to review and
comment on such Schedule 14D-9 or response, and the Company shall give
reasonable consideration to any such comments. The Company hereby consents to
the inclusion in the Offer Documents of the Company Recommendation contained
in the Schedule 14D-9.

  

  

(c) In connection with the Offer and the Merger, the Company shall cause its
transfer agent to furnish Parent and Merger Sub promptly with mailing labels
containing the names and addresses of the record holders of Company Common
Stock as of the most recent practicable date and of those Persons becoming
record holders subsequent to such date, together with copies of all lists of
stockholders, security position listings and computer files and all other
information in the Company's possession or control regarding the beneficial
owners of Company Common Stock, and shall furnish to Merger Sub such
information and assistance (including updated lists of stockholders, security
position listings and computer files regarding the beneficial owners of
Company Common Stock) as Parent may reasonably request in communicating the
Offer to holders of Company Common Stock. Subject to the requirements of
applicable Law, and except for such steps as are necessary to disseminate the
Offer Documents and any other documents necessary to consummate the
transactions contemplated by this Agreement, Parent and Merger Sub shall hold
in confidence the information contained in any such labels, listings and files
in accordance with the requirements of the Confidentiality Agreement, dated
June 20, 2013, between Parent and the Company (as it may be amended from time
to time, the "Confidentiality Agreement"), shall use such information only in
connection with the Offer and the Merger and, if this Agreement shall be
terminated, upon request by the

  

  

 

 

 

  

 

5  

  

 

 

 

  

  

Company, shall dispose of all copies of such information then in their
possession or control, subject to, and in accordance with, the terms of the
Confidentiality Agreement.

  

  

Section 1.3 Directors.

  

  

(a) Effective upon the Offer Closing, and at all times thereafter, Parent
shall be entitled to designate, from time to time, such number of members of
the Board of Directors of the Company as will give Parent, subject to
compliance with Section 14(f) of the Exchange Act and Rule 14f-1 thereunder,
representation equal to at least that number of directors, rounded up to the
next whole number, that is the product of (i) the total number of directors
(giving effect to the directors elected or appointed pursuant to this
sentence) multiplied by (ii) the percentage that (A) the number of shares of
Company Common Stock beneficially owned by Parent and its Subsidiaries
(including shares of Company Common Stock accepted for payment pursuant to the
Offer) bears to (B) the number of shares of the Company Common Stock then
outstanding; provided, however, that in the event that Parent's designees are
appointed or elected to the Board of Directors of the Company, until the
Effective Time the Board of Directors of the Company shall have at least three
Continuing Directors.

  

  

(b) The Company shall promptly take all action requested by Parent necessary
or desirable to effect any such election or appointment, including (i)
increasing the size of the Board of Directors of the Company, (ii) filling
vacancies or newly created directorships on the Board of Directors of the
Company and (iii) obtaining the resignation of such number of its current
directors as is, in each case, necessary to enable such designees to be so
elected or appointed to the Board of Directors of the Company in compliance
with applicable Law (including, to the extent applicable prior to the
Effective Time, Rule 10A-3 under the Exchange Act and applicable NASDAQ
rules).

  

  

(c) The Company shall promptly take all actions required pursuant to Section
14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder in order to
fulfill its obligations under Section 1.3(a), including mailing to its
stockholders the Information Statement containing the information required by
Section 14(f) of the Exchange Act and Rule 14f-1 thereunder, and the Company
agrees to make such mailing concurrently with the mailing of the Schedule
14D-9. Parent and Merger Sub shall provide to the Company on a timely basis
all information required to be included in the Information Statement with
respect to such designees and with respect to Parent's officers, directors and
Affiliates.

  

  

(d) After the Offer Closing, the Company shall also, upon Parent's request,
cause the directors elected or designated by Parent to the Board of Directors
of the Company to serve on and constitute the same percentage (rounded up to
the next whole number) as is on the Board of Directors of the Company of (i)
each committee of the Board of Directors of the Company, except for any
committee established to take action with respect to the subject matter of
this Agreement, (ii) the board of directors of each Subsidiary of the Company
and (iii) each committee (or similar body) of each such board, in each case to
the extent permitted by applicable Law and applicable NASDAQ rules.

  

  

 

 

 

  

 

6  

  

 

 

 

  

  

(e) Following the election or appointment of Parent's designees pursuant to
Section 1.3(a) through 1.3(c) and prior to the Effective Time, the affirmative
vote of a majority of the Continuing Directors then in office (or, if there
shall only be one or two Continuing Directors then in office, all of such
Continuing Directors then in office) shall be required to authorize the
Company to consent (i) to amend or terminate this Agreement, (ii) to waive any
of the Company's rights or remedies under this Agreement, (iii) to extend the
time for the performance of any of the obligations or other acts of Parent or
Merger Sub, (iv) to amend the Company Charter or Company Bylaws, (v) to
authorize any agreement between the Company and any of its Subsidiaries, on
the one hand, and Parent, Merger Sub or any of their Affiliates (other than
the Company and its Subsidiaries) on the other hand or (vi) to make any other
consent by the Company with respect to the Offer, the Merger or any of the
other transactions contemplated by this Agreement; provided, that any such
authorization shall (A) not be effective unless there is in office at least
one Continuing Director and (B) constitute the authorization of the Board of
Directors of the Company, and no other action on the part of the Company,
including any action by any committee thereof or any other director of the
Company, shall, unless otherwise required by Law, be required or permitted.

  

  

(f) For purposes of this Agreement, a "Continuing Director" shall mean a
member of the Company's Board of Directors who is a member of the Company's
Board of Directors on the date of this Agreement and who are independent
directors for purposes of the continuing listing requirements of NASDAQ. If
the number of directors who are Continuing Directors is reduced to below three
prior to the Effective Time, the remaining Continuing Directors shall be
entitled to designate an individual to fill such vacancy who is not a current
or former officer, director, employee or consultant of Parent or any of its
Subsidiaries or of the Company or any of its Subsidiaries (a "Parent Insider")
and who shall be deemed a Continuing Director for all purposes of this
Agreement, and the Company shall cause such designee to be appointed to the
Board of Directors of the Company. If, notwithstanding compliance with the
foregoing provisions, the number of Continuing Directors is reduced to zero,
then the other directors on the Board of Directors of the Company shall
designate and appoint to the Board of Directors of the Company three
individuals who are not Parent Insiders who shall be deemed Continuing
Directors for all purposes of this Agreement. The Continuing Directors shall
have the authority to retain such counsel (which may include current counsel
to the Company) and other advisors at the expense of the Company as determined
by the Continuing Directors and shall have the authority to institute any
action on behalf of the Company to enforce performance of this Agreement or
any of the Company's rights hereunder, in each case to the extent reasonably
appropriate to the exercise and discharge of their fiduciary and other duties.

  

  

ARTICLE II

  

  

THE MERGER

  

  

Section 2.1 The Merger. Upon the terms and subject to the conditions set forth
in this Agreement, and in accordance with the DGCL, Merger Sub shall be merged
with and into the Company at the Effective Time. At the Effective Time, the
separate corporate existence of Merger Sub shall cease and the Company shall
continue as the surviving corporation (the

  

  

 

 

 

  

 

7  

  

 

 

 

  

  

"Surviving Corporation"). The Merger shall be governed by Section 251(h) of
the DGCL and shall be effected as soon as practicable following the Offer
Closing.

  

  

Section 2.2 Closing. The closing of the Merger (the "Closing") will take place
at the offices of Davis Polk and Wardwell LLP, 450 Lexington Avenue, New York,
New York 10017 as soon as practicable following the Offer Closing, on a date
to be specified by the parties, which shall be not later than the third
Business Day after satisfaction or waiver of the conditions set forth in
Article VIII, other than those conditions that by their terms are to be
satisfied at the Closing, but subject to the satisfaction or waiver of those
conditions, unless another time, date or place is agreed to in writing by
Parent and the Company. The date on which the Closing occurs is referred to in
this Agreement as the "Closing Date."

  

  

Section 2.3 Effective Time of the Merger. Upon the terms and subject to the
conditions set forth in this Agreement, at the Closing, a certificate of
merger (the "Certificate of Merger") shall be duly prepared by the parties in
such form as is required by, and executed in accordance with, the relevant
provisions of the DGCL, and Parent and the Company shall cause such
Certificate of Merger to be filed with the Secretary of State of the State of
Delaware (the "Secretary of State"). The Merger shall become effective on such
date and at such time as the Certificate of Merger is duly filed with the
Secretary of State or at such subsequent date and time as Parent and the
Company shall agree and specify in the Certificate of Merger. The date and
time at which the Merger becomes effective is referred to in this Agreement as
the "Effective Time."

  

  

Section 2.4 Effects of the Merger. The Merger shall have the effects specified
in the DGCL.

  

  

Section 2.5 Certificate of Incorporation and Bylaws.

  

  

(a) The certificate of incorporation of the Company, as heretofore amended
(the "Company Charter"), shall be amended and restated in its entirety at the
Effective Time to be identical to the certificate of incorporation of Merger
Sub in effect immediately prior to the Effective Time, except that all
references therein to Merger Sub shall be automatically amended and shall
become references to the Surviving Corporation and the provisions of the
certificate of incorporation of Merger Sub relating to the incorporator of
Merger Sub shall be omitted, until thereafter changed or amended as provided
therein or by applicable Law.

  

  

(b) The bylaws of Merger Sub as in effect immediately prior to the Effective
Time shall become the bylaws of the Surviving Corporation at the Effective
Time, except that all references to Merger Sub shall be automatically amended
and shall become references to the Surviving Corporation, until thereafter
changed or amended as provided therein or by applicable Law.

  

  

Section 2.6 Directors. From and after the Effective Time, the directors of
Merger Sub immediately prior to the Effective Time shall be the directors of
the Surviving Corporation until the earlier of their resignation or removal or
until their respective successors are duly elected and qualified, as the case
may be. At Parent's request, the Company shall obtain and deliver to

  

  

 

 

 

  

 

8  

  

 

 

 

  

  

Parent the written resignations of each of the directors of the Company, to be
effective at the Effective Time.

  

  

Section 2.7 Officers. From and after the Effective Time, the officers of the
Company immediately prior to the Effective Time shall be the officers of the
Surviving Corporation until the earlier of their resignation or removal or
until their respective successors are duly elected and qualified, as the case
may be.

  

  

ARTICLE III

  

  

EFFECT OF THE MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS;
EXCHANGE OF CERTIFICATES

  

  

Section 3.1 Effect on Capital Stock. At the Effective Time, by virtue of the
Merger and without any action on the part of the Company, Parent or Merger
Sub, or the holder of any shares of capital stock or other securities of the
Company or Merger Sub:

  

  

(a) Capital Stock of Merger Sub. Each share of common stock of Merger Sub, par
value $0.01 per share, issued and outstanding immediately prior to the
Effective Time shall be converted into and become one validly issued, fully
paid and nonassessable share of common stock, without par value, of the
Surviving Corporation.

  

  

(b) Cancellation of Treasury Stock and Parent-Owned Stock. All shares of
Company Common Stock that are owned as treasury stock by the Company or any
Subsidiary of the Company or owned by Parent or Merger Sub immediately prior
to the Effective Time shall automatically be canceled and shall cease to
exist, and no consideration shall be delivered or deliverable in exchange
therefor.

  

  

(c) Conversion of Company Common Stock. Subject to Section 3.1(d), each share
of Company Common Stock issued and outstanding immediately prior to the
Effective Time (other than any Dissenting Shares and any shares to be canceled
in accordance with Section 3.1(b)) shall be converted into the right to
receive from the Surviving Corporation, in cash and without interest, an
amount equal to the Offer Price paid in the Offer (the "Merger Consideration")
upon surrender of such share of Company Common Stock pursuant to Section 3.2
and in compliance therewith. At the Effective Time, such shares shall no
longer be outstanding and shall automatically be canceled and shall cease to
exist, and each holder of a certificate, or evidence of shares held in book-
entry form, that immediately prior to the Effective Time represented any such
shares (a "Certificate") shall cease to have any rights with respect thereto,
except the right to receive the Merger Consideration in accordance with the
terms of this Agreement.

  

  

(d) Adjustment Events. If, between the date of this Agreement and the
Effective Time, the outstanding shares of Company Common Stock are changed
into, or exchanged for, a different number or class of shares by reason of any
stock dividend, split, combination, subdivision or reclassification of shares,
reorganization, recapitalization or other similar transaction, then the Offer
Price and the Merger Consideration (as applicable) payable

  

  

 

 

 

  

 

9  

  

 

 

 

  

  

per share of Company Common Stock shall be adjusted to fairly reflect the
effects of such transaction.

  

  

Section 3.2 Exchange of Certificates.

  

  

(a) Paying Agent. Prior to the Effective Time, Parent shall enter into an
agreement with such bank or trust company as may be designated by Parent and
reasonably acceptable to the Company to act as agent for the payment of the
Merger Consideration upon surrender of Certificates (the "Paying Agent"). At
the Effective Time, Parent shall, or shall cause the Surviving Corporation to,
deposit with the Paying Agent funds in amounts and at the times necessary for
the payment of the Merger Consideration pursuant to Section 3.1(c) upon
surrender of Certificates, it being understood that any and all interest or
other amounts earned with respect to such funds shall be for the account of
and turned over to Parent in accordance with Section 3.2(g).

  

  

(b) Exchange Procedure. As soon as reasonably practicable after the Effective
Time, Parent shall cause the Paying Agent to mail to each holder of record of
a Certificate (i) a form of letter of transmittal (which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates
held by such Person shall pass, only upon proper delivery of the Certificates
to the Paying Agent and shall be in a form and have such other provisions as
Parent may reasonably specify) and (ii) instructions for use in effecting the
surrender of the Certificates in exchange for the Merger Consideration. Upon
surrender of a Certificate for cancellation to the Paying Agent or to such
other agent or agents as may be appointed by Parent, together with such letter
of transmittal, duly completed and validly executed (or, if such shares of
Company Common Stock are held in uncertificated, book-entry form, receipt of
an "agent's message" (or such other evidence of transfer as the Paying Agent
may reasonably request) by the Paying Agent (it being understood that any
references herein to "Certificates" shall be deemed to include references to
book-entry account statements relating to the ownership of shares of Company
Common Stock, provided, that the holders of any book-entry shares shall be
deemed to have surrendered any Certificates representing book-entry shares
upon receipt by the Paying Agent of receipt of an "agent's message" (or such
other evidence of transfer as the Paying Agent may reasonably request)), and
such other documents as may reasonably be required by the Paying Agent, the
holder of such Certificate shall be entitled to receive in exchange therefor
the amount of Merger Consideration that such holder has the right to receive
pursuant to Section 3.1(c), and the Certificate so surrendered shall forthwith
be canceled. In the event of a transfer of ownership of Company Common Stock
that is not registered in the stock transfer books of the Company, payment of
the Merger Consideration in exchange therefor may be made to a Person other
than the Person in whose name the Certificate so surrendered is registered if,
upon presentation to the Paying Agent, such Certificate shall be properly
endorsed or otherwise be in proper form for transfer and the Person requesting
such payment shall pay any Taxes required by reason of the payment to a Person
other than the registered holder of such Certificate or establish to the
satisfaction of the Surviving Corporation that such Taxes have been paid or
are not applicable. No interest shall be paid or shall accrue on the cash
payable upon surrender of any Certificate.

  

  

 

 

 

  

 

10  

  

 

 

  

 

  

(c) No Further Ownership Rights in Company Common Stock. All cash paid upon
the surrender of a Certificate in accordance with the terms of this Article
III shall be deemed to have been paid in full satisfaction of all rights
pertaining to the shares of Company Common Stock formerly represented by such
Certificate. At the close of business on the day on which the Effective Time
occurs, the stock transfer books of the Company shall be closed, and there
shall be no further registration of transfers on the stock transfer books of
the Surviving Corporation of the shares that were outstanding immediately
prior to the Effective Time. If, after the close of business on the day on
which the Effective Time occurs, Certificates are presented to the Surviving
Corporation or the Paying Agent for transfer or any other reason, they shall
be canceled and exchanged as provided in this Article III.

  

  

(d) No Liability. None of Parent, Merger Sub, the Company, the Surviving
Corporation or the Paying Agent shall be liable to any Person in respect of
any cash that would otherwise have been payable in respect of any Certificate
that is delivered to a public official in accordance with any applicable
abandoned property, escheat or similar Law. Any amounts remaining unclaimed by
holders of the Company Common Stock immediately prior to the date on which any
Merger Consideration would otherwise escheat to or become the property of any
Governmental Entity shall, to the extent permitted by applicable Law, become
the property of Parent or one of its designated Affiliates, free and clear of
all claims or interest of any Person previously entitled thereto.

  

  

(e) Lost Certificates. If any Certificate shall have been lost, stolen,
defaced or destroyed, upon the making of an affidavit of that fact in form and
substance reasonably satisfactory to Parent by the Person claiming such
Certificate to be lost, stolen, defaced or destroyed and, if required by the
Surviving Corporation, the posting by such Person of a bond in such amount as
the Surviving Corporation may direct as indemnity against any claim that may
be made against it with respect to such Certificate, the Paying Agent shall
pay the Merger Consideration in respect of such lost, stolen, defaced or
destroyed Certificate.

  

  

(f) Withholding Rights. Parent, the Surviving Corporation or the Paying Agent,
as applicable, shall be entitled to deduct and withhold from the Merger
Consideration otherwise payable pursuant to this Agreement to any holder of
shares of Company Common Stock such amounts as Parent, the Surviving
Corporation or the Paying Agent is required to deduct and withhold with
respect to the making of such payment under the Code or any other Law. To the
extent that amounts are so withheld and paid over to the appropriate
Governmental Entity by Parent, the Surviving Corporation or the Paying Agent,
such withheld amounts shall be treated for all purposes of this Agreement as
having been paid to the holder of the shares of Company Common Stock in
respect of which such deduction and withholding was made by Parent, the
Surviving Corporation or the Paying Agent.

  

  

(g) Termination of Fund. At any time following the date which is twelve (12)
months after the Effective Time, Parent or the Surviving Corporation shall be
entitled to require the Paying Agent to deliver to it any funds (including any
interest or other amounts earned with respect thereto) that had been made
available to the Paying Agent and which have not been disbursed to holders of
Certificates, and thereafter, subject to the time limitations in Section
3.2(d), such holders shall be entitled to look only to the Surviving
Corporation (subject to

  

  

 

 

 

  

 

11  

  

 

 

 

  

  

abandoned property, escheat or similar Laws) as general creditors thereof with
respect to the payment of any Merger Consideration that may be payable upon
surrender of any Certificates held by such holders, as determined pursuant to
this Agreement, without any interest thereon. Notwithstanding anything to the
contrary in this Section 3.2, any portion of the Merger Consideration made
available to the Paying Agent pursuant to this Section 3.2 to pay for shares
of Company Common Stock as to which a Dissenting Stockholder thereof has
properly exercised a demand for appraisal pursuant to Section 262 of the DGCL
shall be returned to Parent or one of its designated Affiliates upon demand.

  

  

Section 3.3 Treatment of Options and Other Stock-Based Awards.

  

  

(a) The Company shall take such actions as may be required to effect the
following:

  

  

(i) Company Stock Options. Effective as of five (5) Business Days prior to,
and conditional upon the occurrence of, the Offer Closing, each holder of an
outstanding and unexercised Company Stock Option intended to qualify as an
"incentive stock option" within the meaning of Section 422 of the Code (an
"Incentive Stock Option"), whether such Incentive Stock Option is then vested
or unvested, shall be entitled to exercise such Incentive Stock Option in full
(subject to any applicable withholding Tax) by providing the Company with a
notice of exercise and full payment of the applicable exercise price in
accordance with the terms of the applicable Company Stock Plan and related
award agreement. Each Incentive Stock Option that is not exercised in
accordance with the prior sentence, and each other Company Stock Option that
is outstanding and unexercised immediately prior to the Offer Closing (whether
vested or unvested), shall be cancelled as of the Offer Closing and converted
into the right of the holder to receive an amount in cash equal to the product
of (A) the total number of shares of Company Common Stock subject to such
Company Stock Option immediately prior to such cancellation and (B) the
excess, if any, of the Offer Price over the exercise price per share of
Company Common Stock of such Company Stock Option, less any required
withholding Taxes (the "Option Cash Payment"), and as of the Offer Closing
each holder of such a Company Stock Option shall cease to have any rights with
respect thereto, except the right to receive the Option Cash Payment (it being
understood that each Company Stock Option that is outstanding and unexercised
immediately prior to the Offer Closing that has an exercise price equal to or
greater than the Offer Price shall be cancelled as of the Offer Closing
without consideration therefor). The Option Cash Payment shall be made
promptly (and in any event within five (5) Business Days) following the Offer
Closing.

  

  

(ii) Company RSUs. Each Company RSU that is outstanding immediately prior to
the Offer Closing (whether vested or unvested) shall be cancelled as of the
Offer Closing and converted into the right of the holder to receive an amount
in cash equal to the product of (A) the total number of shares of Company
Common Stock subject to such Company RSU immediately prior to such
cancellation and (B) the Offer Price, less any required withholding Taxes (the

  

  

 

 

 

  

 

12  

  

 

 

 

  

  

"RSU Cash Payment"), and as of the Offer Closing each holder of a Company RSU
shall cease to have any rights with respect thereto, except the right to
receive the RSU Cash Payment. The RSU Cash Payment shall be made promptly (and
in any event within five (5) Business Days) following the Offer Closing.

  

  

(iii) Company PSUs. Each Company PSU that is outstanding immediately prior to
the Offer Closing (whether vested or unvested) shall be cancelled as of the
Offer Closing and converted into the right of the holder to receive an amount
in cash equal to the product of (A) the total number of shares of Company
Common Stock that would be delivered in respect of such Company PSU assuming
achievement of the applicable performance metrics at the maximum level (200%
of target) as of the end of the applicable performance period and (B) the
Offer Price, less any required withholding Taxes (the "PSU Cash Payment"), and
as of the Offer Closing each holder of a Company PSU shall cease to have any
rights with respect thereto, except the right to receive the PSU Cash Payment.
The PSU Cash Payment shall be made promptly (and in any event within five (5)
Business Days) following the Offer Closing.

  

  

(iv) ESPP. With respect to the Purchase Plan, (A) participation in the
Purchase Plan shall be limited to those employees who are participants in the
Purchase Plan on the date of this Agreement; (B) no new Offering Period (as
defined in the Purchase Plan), other than the Offering Period in effect as of
the date of this Agreement, shall be authorized, continued or commenced on or
after the date of this Agreement; (C) participants in the Purchase Plan may
not increase their payroll deductions or purchase elections from those in
effect on the date of this Agreement; (D) if the Offer Closing occurs prior to
the Offering Termination Date (as defined in the Purchase Plan) with respect
to the Offering Period in effect on the date of this Agreement, then
immediately prior to, and conditional upon the occurrence of, the Offer
Closing, each then-outstanding purchase right under the Purchase Plan shall be
used to purchase from the Company whole shares of Company Common Stock at the
applicable price determined under the terms of the Purchase Plan using the
tenth (10th) Business Day prior to the Offer Closing Date as the Offering
Termination Date for such Offering Period (subject to such other pro-rata
adjustments as may be necessary to reflect any shortening of the Offering
Period but otherwise treating such Offering Period as a fully effective and
completed Offering Period for all purposes under the Purchase Plan); (E) any
fractional shares of Company Common Stock that would result from the
application of subsection (D) will be settled in cash promptly (and in any
event within five (5) Business Days) following the Offer Closing; and (F) the
Purchase Plan shall terminate, effective upon the earlier of the Offering
Termination Date for the Offering Period in effect on the date of this
Agreement and the Offer Closing Date.

  

  

(b) Parent or Merger Sub shall ensure that the Company or the Surviving
Corporation, as applicable, has an amount in cash at least equal to the
aggregate amount of any cash consideration to be paid to holders of Company
Stock Options, Company RSUs and Company PSUs pursuant to the provisions of
this Section 3.3, and the Company or the Surviving

  

  

 

 

 

  

 

13  

  

 

 

 

  

  

Corporation, as applicable, shall cause such consideration to be paid to such
holders in accordance with this Section 3.3, without interest and net of such
amounts as the Company, the Surviving Corporation or any other Person is
required to deduct and withhold with respect to the making of such payment
under the Code or any other Law. To the extent that amounts are so withheld
and paid over by any Person pursuant to this Section 3.3 to the appropriate
Governmental Entity, such withheld amounts shall be treated for all purposes
of this Agreement as having been paid to the Person entitled to payment under
this Section 3.3 in respect of which such deduction and withholding was made
by a Person pursuant to this Section 3.3.

  

  

Section 3.4 Dissenter Rights. Notwithstanding any provision of this Agreement
to the contrary, shares of Company Common Stock that are outstanding
immediately prior to the Effective Time and that are held by a stockholder who
is entitled to demand, and who properly demands, appraisal of such shares
pursuant to, and who complies in all respects with, Section 262 of the DGCL (a
"Dissenting Stockholder") shall not be converted into the right to receive the
Merger Consideration. For purposes of this Agreement, "Dissenting Shares"
means any shares of Company Common Stock as to which a Dissenting Stockholder
thereof has properly exercised a demand for appraisal pursuant to Section 262
of the DGCL. No Dissenting Stockholder shall be entitled to any Merger
Consideration in respect of any Dissenting Shares unless and until such holder
shall have failed to perfect or shall have effectively withdrawn or lost such
holder's right to seek appraisal of its Dissenting Shares under the DGCL, and
any Dissenting Stockholder shall be entitled to receive only the payment
provided by Section 262 of the DGCL with respect to the Dissenting Shares
owned by such Dissenting Stockholder and not any Merger Consideration. If any
Person who otherwise would be deemed a Dissenting Stockholder shall have
failed properly to perfect or shall have effectively withdrawn or lost the
right to seek appraisal with respect to any Dissenting Shares, such Dissenting
Shares shall thereupon be treated as though such Dissenting Shares had been
converted into the Merger Consideration pursuant to this Agreement if
conditions to payment are met. The Company shall give Parent (a) prompt notice
of any written demands for appraisal, attempted withdrawals of such demands
and any other instruments served pursuant to applicable Law received by the
Company relating to stockholders' demands for appraisal and (b) the
opportunity to direct all negotiations and proceedings with respect to demands
for appraisal under the DGCL. The Company shall not, except with the prior
written consent of Parent, voluntarily make any payment with respect to any
demands for appraisal of Dissenting Shares, offer to settle or settle any such
demands or approve any withdrawal of any such demands.

  

  

ARTICLE IV

  

  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  

  

Except as set forth (a) in the Company SEC Documents filed with or furnished
to the SEC since December 31, 2010 and publicly available prior to the
execution of this Agreement (the "Filed Company SEC Documents") (other than
any forward-looking disclosures contained in "Forward Looking Statements" and
"Risk Factors" sections of the Filed Company SEC Documents and any other
disclosures included therein to the extent they are predictive, cautionary or
forward-looking in nature) or (b) in the disclosure schedule to this Agreement
dated as of the date hereof and delivered by the Company to Parent prior to
the execution of this

  

  

 

 

 

  

 

14  

  

 

 

 

  

  

Agreement (the "Company Disclosure Schedule") (which Company Disclosure
Schedule sets forth items of disclosure with specific reference to the
particular Section or subsection of this Agreement to which the information in
the Company Disclosure Schedule relates; provided, however, that any
information set forth in one Section or subsection of the Company Disclosure
Schedule shall be deemed to apply to each other Section or subsection thereof
or hereof to which its relevance is readily apparent on its face), the Company
represents and warrants to Parent and Merger Sub as follows:

  

  

Section 4.1 Organization, Standing and Corporate Power. The Company is a
corporation duly incorporated and validly existing and in good standing under
the laws of the State of Delaware. Each Subsidiary of the Company is a
corporation, limited liability company or other entity duly incorporated or
formed, validly existing and in good standing (in the jurisdictions that
recognize the concept of good standing) under the laws of the jurisdiction of
its incorporation or formation, as the case may be, except where the failure
to be in good standing, individually or in the aggregate, has not had and
would not reasonably be expect to have, a Material Adverse Effect. Each of the
Company and its Subsidiaries has all requisite power and authority and
possesses all governmental licenses, franchises, permits, authorizations and
approvals necessary to enable it to use its corporate or other name and to
own, lease or otherwise hold and operate its properties and other assets and
to carry on its business as presently conducted, except where the failure to
have such power or authority or possess such governmental licenses,
franchises, permits, authorizations or approvals, individually or in the
aggregate, has not had and would not reasonably be expected to have a Material
Adverse Effect. Each of the Company and its Subsidiaries is duly qualified to
do business and is in good standing (in jurisdictions that recognize the
concept of good standing) in each jurisdiction in which the nature of its
business or the ownership, leasing or operation of its properties makes such
qualification necessary, other than in such jurisdictions where the failure to
be so qualified or to be in good standing, individually or in the aggregate,
has not had and would not reasonably be expected to have a Material Adverse
Effect. The Company has made available to Parent, prior to the execution of
this Agreement, complete and accurate copies of the Company Charter and the
bylaws of the Company (the "Company Bylaws"), and the comparable
organizational documents of each of its Subsidiaries, in each case as amended
to the date hereof.

  

  

Section 4.2 Subsidiaries. Section 4.2 of the Company Disclosure Schedule lists
each Subsidiary of the Company and, for each such Subsidiary, the jurisdiction
of incorporation or formation. All issued and outstanding shares of capital
stock of, or other equity interests in, each such Subsidiary have been validly
issued and are fully paid and nonassessable and are owned directly or
indirectly by the Company free and clear of all pledges, liens, charges,
encumbrances or security interests of any kind or nature whatsoever
(collectively, "Liens") other than those described in clause (vii) of the
definition of Permitted Liens, and free of any restriction on the right to
vote, sell or otherwise dispose of such capital stock or other equity
interests. Except for the capital stock of, or voting securities or equity
interests in, its Subsidiaries or as set forth in Section 4.2 of the Company
Disclosure Schedule, the Company does not own, directly or indirectly, any
capital stock of, or other voting securities or equity interests in, any
corporation, limited liability company, partnership, joint venture,
association or other entity.

  

  

 

 

 

  

 

15  

  

 

 

 

  

  

Section 4.3 Capital Structure.

  

  

(a) The authorized capital stock of the Company consists of 175,000,000 shares
of Company Common Stock and 5,000,000 shares of Preferred Stock, par value
$0.001 per share (the "Preferred Stock").

  

  

(b) At the close of business on November 8, 2013, (i) 65,967,198 shares of
Company Common Stock were issued and outstanding, (ii) 16,042,202 shares of
Company Common Stock were held by the Company in its treasury, (iii)
10,864,323 shares of Company Common Stock were reserved for issuance upon
conversion of the Company's 2.0% Senior Convertible Notes due 2017 (the
"Convertible Notes"), (iv) no shares of Preferred Stock were issued or
outstanding, (v) 10,864,323 shares of Company Common Stock were reserved for
issuance upon the exercise of the Call-Spread Warrants and (vi) 20,350,000
shares of Company Common Stock were reserved for issuance pursuant to the
Company's Amended and Restated 2005 Equity Incentive Plan, the Company's 2001
Equity Incentive Plan and the Company's Amended and Restated 1995 Stock Option
and Restricted Share Plan (such plans, together with the Company's Amended and
Restated 2000 Employee Stock Purchase Plan (the "Purchase Plan"), the "Company
Stock Plans"), of which 10,046,890 shares of Company Common Stock were subject
to outstanding options (other than purchase rights under the Purchase Plan) to
acquire shares of Company Common Stock from the Company (the "Company Stock
Options"), 35,667 shares of Company Common Stock were subject to issuance upon
settlement of outstanding restricted share units (the "Company RSUs") and
612,250 shares of Company Common Stock were subject to issuance upon
settlement of outstanding performance share units (the "Company PSUs"),
assuming achievement of the target level of performance at the end of the
applicable performance period. As of the date of this Agreement, before giving
effect to any "make-whole" adjustments set forth therein, the conversion ratio
of the Convertible Notes is 52.9998 shares of Company Common Stock per $1,000
aggregate principal amount. As of the close of business on November 8, 2013,
the Company held Company Hedge Options entitling the Company to receive up to
10,864,323 shares of Company Common Stock upon exercise of the Company Hedge
Options, subject to adjustments, pursuant to the terms thereof. Prior to the
date hereof, the Company has provided Parent with a complete and correct list
of (A) each outstanding Company Stock Option, including the holder, date of
grant, exercise price, vesting schedule and number of shares of Company Common
Stock subject thereto and (B) each outstanding Company RSU and Company PSU,
including the holder, date of grant, vesting schedule and number of shares of
Company Common Stock thereof (for each Company PSU, assuming achievement of
the target level of performance).

  

  

(c) Since the close of business on November 8, 2013 until the date of this
Agreement, (i) there have been no issuances by the Company of shares of
capital stock or other voting securities or equity interests of the Company,
other than issuances of shares of Company Common Stock pursuant to the
exercise of Company Stock Options, Company RSUs, Company PSUs and purchase
rights under the Purchase Plan, in each case outstanding as of the close of
business on November 8, 2013 and (ii) there have been no issuances by the
Company of securities convertible into, or exchangeable or exercisable for, or
options, warrants or other rights to acquire, or shares of deferred stock,
restricted stock units, stock-based performance units, stock appreciation
rights or "phantom" stock awards with respect to, any such stock, interests or

  

  

 

 

 

  

 

16  

  

 

 

 

  

  

securities, or derivative securities or other rights that are linked to the
value of Company Common Stock or the value of the Company or any part thereof,
other than purchase rights under the Purchase Plan.

  

  

(d) All outstanding shares of capital stock of the Company are, and all shares
which may be issued pursuant to the Convertible Notes, Company Stock Options,
Company RSUs, Company PSUs, purchase rights under the Purchase Plan, Call-
Spread Warrants or otherwise will be, when issued in accordance with the terms
thereof, duly authorized, validly issued, fully paid and nonassessable and not
subject to preemptive rights. There are no outstanding bonds, debentures,
notes or other indebtedness of the Company having the right to vote (or,
except for the Convertible Notes, convertible into, or exchangeable for,
securities having the right to vote) on any matters on which stockholders of
the Company may vote. Except as set forth above in this Section 4.3 and for
changes since the close of business on November 8, 2013 resulting from the
exercise or settlement of Company Stock Options, Company RSUs, Company PSUs
and purchase rights under the Purchase Plan outstanding on such date, (i)
there are no issued, reserved for issuance or outstanding (A) shares of
capital stock or other voting securities or equity interests of the Company or
any of its Subsidiaries, (B) securities of the Company or any of its
Subsidiaries convertible into or exchangeable or exercisable for shares of
capital stock or other voting securities or equity interests of the Company or
any of its Subsidiaries, (C) warrants, calls, options or other rights to
acquire from the Company or any of its Subsidiaries, and no obligation of the
Company or any of its Subsidiaries to issue, any capital stock, voting
securities, equity interests or securities convertible into or exchangeable or
exercisable for capital stock or voting securities of the Company or any of
its Subsidiaries or (D) shares of deferred stock, restricted stock units,
equity-based performance units, stock appreciation rights or "phantom" stock
awards with respect to any capital stock of the Company or any of its
Subsidiaries, or derivative securities or other rights that are directly or
indirectly linked to the value of the Company Common Stock, or the value of
the Company, any of its Subsidiaries or any assets or securities thereof and
(ii) there are not any outstanding obligations of the Company or any of its
Subsidiaries to repurchase, redeem or otherwise acquire any such securities or
to issue, deliver or sell, or cause to be issued, delivered or sold, any such
securities (except pursuant to the forfeiture of Company Stock Options,
Company RSUs or Company PSUs or the acquisition by the Company of shares of
Company Common Stock in settlement of the exercise price of a Company Stock
Option or the Tax withholding obligations of holders of Company Stock Options,
Company PSUs or Company RSUs, in each case in accordance with their terms as
in effect on the date of this Agreement).

  

  

(e) None of the Company Common Stock is owned by any Subsidiary of the
Company.

  

  

Section 4.4 Authority. The Company has all requisite corporate power and
authority to execute and deliver this Agreement, to consummate the Merger and
the other transactions contemplated by this Agreement and to comply with the
provisions of and perform its obligations under this Agreement. The execution
and delivery of this Agreement by the Company, the consummation by the Company
of the Merger and the other transactions contemplated by this Agreement and
the compliance by the Company with the provisions of this Agreement have been
duly authorized by all necessary corporate action on the part of the

  

  

 

 

 

  

 

17  

  

 

 

 

  

  

Company, and no other corporate proceedings on the part of the Company are
necessary to authorize this Agreement, to consummate the Merger and the other
transactions contemplated by this Agreement or to comply with the provisions
of and perform its obligations under this Agreement. This Agreement has been
duly executed and delivered by the Company and, assuming the due
authorization, execution and delivery by each of the other parties hereto,
constitutes a legal, valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms except as enforceability may
be limited by bankruptcy, insolvency, reorganization, moratorium or other
applicable Laws relating to or affecting creditors' rights generally or by
equitable principles (regardless of whether enforcement is sought at law or in
equity). The Board of Directors of the Company, at a meeting duly called and
held and at which a quorum was present, duly adopted resolutions unanimously
(a) adopting and declaring the advisability of this Agreement, the Offer, the
Merger and the other transactions contemplated by this Agreement, (b)
declaring that it is in the best interests of the Company and the stockholders
of the Company (other than Parent and its Subsidiaries) that the Company enter
into this Agreement and consummate the Merger and the other transactions
contemplated by this Agreement and that the stockholders of the Company tender
their shares of Company Common Stock pursuant to the Offer, in each case on
the terms and subject to the conditions set forth herein, (c) declaring that
the terms of the Offer and the Merger are fair to the Company and the
Company's stockholders (other than Parent and its Subsidiaries) and (d)
recommending that the Company's stockholders accept the Offer and tender their
shares of Company Common Stock pursuant to the Offer (collectively, the
"Company Recommendation"), which resolutions, except to the extent permitted
by Section 6.2, have not been rescinded, modified or withdrawn in any way.

  

  

Section 4.5 Non-Contravention. The execution and delivery of this Agreement by
the Company do not, and the consummation of the Offer, the Merger and the
other transactions contemplated by this Agreement and compliance by the
Company with the provisions of this Agreement will not, conflict with, require
any payment to or consent or other action by any Person, or result in any
violation or breach of, or default (with or without notice or lapse of time,
or both) under, or give rise to a right of, or result in, termination,
cancellation or acceleration or other change of any right or obligation or to
the loss of a benefit under, or result in the creation of any Lien in or upon
any of the properties or other assets of the Company or any of its
Subsidiaries under, (a) the Company Charter or the Company Bylaws or the
comparable organizational documents of any of the Company's Subsidiaries, (b)
any loan or credit agreement, bond, debenture, note, mortgage, indenture,
lease, supply agreement, license agreement, development agreement,
distribution agreement or other contract, agreement, obligation, commitment,
arrangement, understanding, instrument, permit, franchise, license or
authorization, whether oral or written, that is or by its terms purports to be
legally binding (each, including all amendments thereto, a "Contract"), to
which the Company or any of its Subsidiaries is a party or any of their
respective properties or other assets is subject or (c) any (i) federal, state
or local, domestic or foreign, statute, law (statutory or otherwise), code,
ordinance, rule, regulation or treaty of any Governmental Entity (each, a
"Law") or (ii) federal, state or local, domestic or foreign, judgment,
injunction, order, writ or decree of any Governmental Entity or arbitrator
(each, a "Judgment"), in each case applicable to the Company or any of its
Subsidiaries or their respective properties or other assets, subject to the
governmental filings and the other matters referred to in Section 4.6 below,
other than, in the case of clauses (b) and (c), any such conflicts,

  

  

 

 

 

  

 

18  

  

 

 

 

  

  

violations, breaches, defaults, rights, losses or Liens that, individually or
in the aggregate, have not had and would not reasonably be expected to have a
Material Adverse Effect.

  

  

Section 4.6 Required Filings and Consents. No consent, approval, order or
authorization of, action or non-action by or in respect of, or registration,
declaration or filing with, any transnational, federal, state or local,
domestic or foreign government, any court, administrative, regulatory or other
governmental agency, commission or authority or any non-governmental self-
regulatory agency, commission or authority (each, a "Governmental Entity") is
required by or with respect to the Company or any of its Subsidiaries in
connection with the execution and delivery of this Agreement by the Company or
the consummation of the Offer, the Merger or the other transactions
contemplated by this Agreement or the compliance by the Company with the
provisions of this Agreement, except for (a) compliance with the Hart-Scott-
Rodino Antitrust Improvements Act of 1976, as amended (including the rules and
regulations promulgated thereunder, the "HSR Act"); (b) compliance with any
other applicable federal, state or foreign statute, rule, regulation, order,
decree, administrative and judicial doctrine or other Law that is designed or
intended to prohibit, restrict or regulate actions having the purpose or
effect of monopolization, restraint of trade, lessening of competition or
foreign investment (together with the HSR Act, the Sherman Act, as amended,
the Clayton Act, as amended, the Federal Trade Commission Act, as amended,
each a "Competition Law" and, collectively, the "Competition Laws"), (c) the
filing with the SEC of (i) the Schedule 14D-9, (ii) an information statement
required in connection with the Offer under Rule 14f-1 under the Exchange Act
(as amended or supplemented from time to time, the "Information Statement")
and (iii) such reports under the Exchange Act as may be required in connection
with this Agreement, the Offer, the Merger and the other transactions
contemplated by this Agreement, (d) the filing of the Certificate of Merger
with the Secretary of State and appropriate documents with the relevant
authorities of other states in which the Company or any of its Subsidiaries is
qualified to do business, (e) any filings required under the rules and
regulations of The NASDAQ Stock Market LLC ("NASDAQ") and (f) such other
consents, approvals, orders, authorizations, actions, registrations,
declarations and filings the failure of which to be obtained or made,
individually or in the aggregate, has not had and would not reasonably be
expected to have a Material Adverse Effect.

  

  

Section 4.7 Company SEC Documents and the Sarbanes-Oxley Act.

  

  

(a) The Company has timely filed or furnished, as applicable, all registration
statements, reports, schedules, forms, statements and other documents
(including exhibits and other information incorporated therein) with the SEC
required to be filed or furnished, as applicable, by the Company since and
including December 31, 2010, including under the Securities Act of 1933, as
amended (including the rules and regulations promulgated thereunder, the
"Securities Act"), the Exchange Act and the Sarbanes-Oxley Act of 2002
(including the rules and regulations promulgated thereunder, "SOX") (such
documents, together with any documents and information incorporated therein by
reference and any other documents filed by the Company with the SEC, as have
been supplemented, modified or amended since the time of filing, collectively,
the "Company SEC Documents"). Each of the audited consolidated financial
statements and unaudited consolidated interim financial statements (including
the related notes) of the Company included in the Company SEC Documents
complied at the time it

  

  

 

 

 

  

 

19  

  

 

 

 

  

  

was filed as to form in all material respects with the applicable accounting
requirements and the published rules and regulations of the SEC with respect
thereto in effect at the time of filing, has been prepared in accordance with
generally accepted accounting principles in the United States ("GAAP")
(except, in the case of unaudited statements, as permitted by the rules and
regulations of the SEC) applied on a consistent basis during the periods
involved (except as may be indicated in the notes thereto) and fairly
presented in all material respects the consolidated financial position of the
Company and its consolidated Subsidiaries as of the dates thereof and the
consolidated results of their operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments).

  

  

(b) As of their respective dates, or, if amended, as of the date of the last
such amendment, the Company SEC Documents complied in all material respects
with the requirements of the Securities Act, the Exchange Act and SOX, as the
case may be, and the applicable rules and regulations promulgated thereunder,
and none of the Company SEC Documents at the time it was filed contained any
untrue statement of a material fact or omitted to state any material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, or are to be made, not
misleading. To the Knowledge of the Company, as of the date hereof, none of
the Company SEC Documents is the subject of ongoing SEC review or outstanding
SEC investigation and there are no outstanding or unresolved comments received
from the SEC with respect to any of the Company SEC Documents. There has been
no material correspondence between the SEC and the Company since December 31,
2010 through the date hereof that is not available on the SEC's Electronic
Data Gathering and Retrieval database. As of its filing date (and as of the
date of any amendment), each Company SEC Document complied, and each Company
SEC Document filed subsequent to the date hereof, when filed, distributed
and/or disseminated, as applicable, will comply as to form in all material
respects with the applicable requirements of NASDAQ, the Securities Act, the
Exchange Act and SOX, as the case may be.

  

  

(c) Each of the principal executive officer of the Company and principal
financial officer of the Company (or each former such officer) has made all
certifications required by Rule 13a-14 or 15d-14 under the Exchange Act and
Sections 302 and 906 of SOX with respect to the Company SEC Documents, and the
statements contained in such certifications were true and accurate as of the
date such certifications were made. The Company maintains a system of
"internal control over financial reporting" (as defined in Rules 13a-15(f) and
15d-15(f) of the Exchange Act) as required under Rules 13a-15(a) and 15d-15(a)
under the Exchange Act and is in compliance in all material respects with such
system. The Company and its Subsidiaries maintain and keep in all material
respects books, records and accounts, which, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of the
Company. The "disclosure controls and procedures" (as defined in Rules
13a-15(e) and 15d-15(e) of the Exchange Act) of the Company comply with Rules
13a-15(a) and 15d-15(a) under the Exchange Act and are designed to ensure that
all material information relating to the Company and its Subsidiaries is
communicated to the Company's management, including the chief executive
officer and chief financial officer of the Company. Since December 31, 2010,
the Company's principal executive officer and its principal financial officer
have disclosed to the Company's auditors and the audit committee of the Board
of Directors of the Company, (i) all known significant deficiencies and
material weaknesses in the design or operation of internal

  

  

 

 

 

  

 

20  

  

 

 

 

  

  

controls over financial reporting that are reasonably likely to adversely
affect in any material respect the Company's ability to record, process,
summarize and report financial information and (ii) any fraud, whether or not
material, that involves management or other employees who have a significant
role in the Company's internal controls and the Company has provided to Parent
copies of any non-privileged written materials in its possession relating to
each of the foregoing. The Company has made available to Parent all such
disclosures made by management to the Company's auditors and audit committee
since December 31, 2010.

  

  

(d) There are no outstanding loans or other extensions of credit made by the
Company or any of its Subsidiaries to any executive officer (as defined in
Rule 3b-7 under the Exchange Act) or director of the Company. The Company has
not, since the enactment of SOX, taken any action prohibited by Section 402 of
SOX.

  

  

(e) Section 4.7(e) of the Company Disclosure Schedule describes, and the
Company has made available to Parent copies of the documentation creating or
governing, any securitization transactions and other off-balance sheet
arrangements (as defined in Item 303 of Regulation S-K of the SEC) that
existed or were effected by the Company or its Subsidiaries since December 31,
2010.

  

  

Section 4.8 No Undisclosed Liabilities. Except (a) as reflected or reserved
against in the Company's financial statements or notes thereto for the fiscal
year ended December 31, 2012 included in the Company SEC Documents, (b) for
liabilities or obligations incurred in the ordinary course of business
consistent with past practice since the date of such financial statements and
(c) for liabilities expressly contemplated by this Agreement, neither the
Company nor any of its Subsidiaries has any liabilities or obligations of any
nature, whether or not accrued, contingent or otherwise, and whether due or to
become due, other than those which have not had and would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.

  

  

Section 4.9 Information Supplied. None of the information included or
incorporated by reference in the Schedule 14D-9 or the Information Statement
(and none of the information supplied by the Company in writing specifically
for inclusion or incorporation by reference in the Offer Documents) will, at
the respective times the Schedule 14D-9, the Information Statement and the
Offer Documents are filed with the SEC or first published, amended or
supplemented or sent or given to the Company's stockholders contain any
statement that, in light of the circumstances under which it is made, is false
or misleading with respect to any material fact or omit to state any material
fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made,
not false or misleading, except that no representation or warranty is made by
the Company with respect to statements made or incorporated by reference in
the Schedule 14D-9, the Information Statement based on information supplied by
Parent or Merger Sub specifically for inclusion or incorporation by reference
therein. Each of the Schedule 14D-9 and the Information Statement will comply
as to form in all material respects with the requirements of the Exchange Act.

  

  

Section 4.10 Absence of Certain Changes or Events. Between December 31, 2012
and the date of this Agreement, (a) the Company and its Subsidiaries have
conducted their respective

  

  

 

 

 

  

 

21  

  

 

 

 

  

  

businesses only in the ordinary course consistent with past practice, (b) the
Company and its Subsidiaries have not taken or have not agreed to take any
action that would be prohibited by Section 6.1(a)(vi), Section 6.1(a)(xv) or
Section 6.1(a)(xviii) (as it relates to Section 6.1(a)(vi) or Section
6.1(a)(xv)) if such action were taken during the period between the date of
this Agreement and the Effective Time and (c) there have not been any Events
in such period that, individually or in the aggregate, has had or would
reasonably be expected to have a Material Adverse Effect.

  

  

Section 4.11 Litigation. (a) There is no claim, suit, action, investigation,
complaint or proceeding pending or, to the Knowledge of the Company,
threatened against the Company or any of its Subsidiaries, or any of their
respective assets or properties, except for stockholder litigation arising
after the date hereof that relates to this Agreement or the transactions
contemplated hereby, (b) there is no Judgment outstanding against the Company
or any of its Subsidiaries or any of their respective assets or properties and
(c) the Company has not received any written notification of, and to the
Knowledge of the Company there is no, investigation by any Governmental Entity
involving the Company or any of its Subsidiaries, any of their respective
assets or properties, that in the case of each of clauses (a), (b) and (c),
individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect.

  

  

Section 4.12 Contracts.

  

  

(a) Section 4.12 of the Company Disclosure Schedule contains a complete and
correct list, as of the date of this Agreement, of each Contract described
below in this Section 4.12(a) under which the Company or any of its
Subsidiaries has any current or future rights, responsibilities, obligations
or liabilities (in each case, whether contingent or otherwise) or to which any
of their respective properties or assets is subject, in each case as of the
date of this Agreement:

  

  

(i) each Contract to which the Company or any of its Subsidiaries is a party
that grants any material right of first refusal or first offer to any Person
or restricts in any material respect the ability of the Company or any of its
Subsidiaries (or, after the Effective Time, that purports to restrict in any
material respect the ability of Parent or any of its Subsidiaries) to (A)
compete with any Person in any area, (B) engage in any activity or business,
(C) own, operate, sell, transfer, pledge or otherwise dispose of any material
amount of assets or businesses, (D) sell any products or services to any other
Person or in any geographic region or (E) obtain products or services from any
Person;

  

  

(ii) each joint venture, strategic alliance or partnership agreement or
similar arrangement;

  

  

(iii) each Contract that involves future expenditures or receipts by the
Company or any Subsidiary of the Company of more than $1,000,000 in any one-
year period and that cannot be terminated by the Company or its Subsidiaries
on less than sixty (60) days' notice without material payment or penalty;

  

  

 

 

 

  

 

22  

  

 

 

 

  

  

(iv) each acquisition or divestiture Contract that contains representations,
covenants, indemnities or other obligations (including "earn-out" or other
contingent payment obligations) that, individually or in the aggregate,
obligate the Company to make, or entitle the Company to receive (or could
reasonably be expected to result in the receipt or making of) future payments
in excess of $1,000,000;

  

  

(v) each lease or sublease of real property under which the Company or one of
its Subsidiaries is a landlord, sublessor, tenant or subtenant involving
annual rental payments in excess of $250,000;

  

  

(vi) each Contract relating to indebtedness for borrowed money or any
financial guaranty other than (A) Contracts solely among the Company and its
wholly owned Subsidiaries and (B) financial guarantees entered into in the
ordinary course of business consistent with past practice not exceeding
$250,000 individually or in the aggregate (other than surety or performance
bonds or similar agreements entered into in the ordinary course of business
consistent with past practice);

  

  

(vii) each Contract between the Company or any of its Subsidiaries, on the one
hand, and any officer, director or Affiliate (other than a wholly owned
Subsidiary) of the Company or any of its Subsidiaries or any of their
respective "associates" or "immediate family" members (as such terms are
defined in Rule 126-2 and Rule 16a-1 of the Exchange Act), on the other hand,
including any Contract pursuant to which the Company or any of its
Subsidiaries has an obligation to indemnify such officer, director, Affiliate
or family member, but not including any Employee Plans;

  

  

(viii) any other Contract which would prohibit or materially delay the
consummation of the Offer or the Merger or any other transaction contemplated
by this Agreement;

  

  

(ix) any Contract (excluding (x) licenses for commercial off the shelf
computer software that are generally available on nondiscriminatory pricing
terms and (y) service contracts related to pre-clinical or clinical
development of any Medicine to the extent the licenses contained therein are
incidental to such contracts, immaterial, non-exclusive and granted in the
ordinary course of business) under which the Company or any of its
Subsidiaries is granted any material license, option or other right or
immunity (including a covenant not to be sued or right to enforce or prosecute
any patents) with respect to any Intellectual Property Right of a third party;

  

  

(x) any Contract (excluding licenses contained in service contracts related to
pre-clinical or clinical development of any Medicine to the extent the
licenses contained therein are incidental to such contract, immaterial, non-
exclusive and granted in the ordinary course of business) under which the

  

  

 

 

 

  

 

23  

  

 

 

 

  

  

Company or any of its Subsidiaries has granted to a third party any material
license, option or other right or immunity (including a covenant not to be
sued or right to enforce or prosecute any patents) with respect to any
Intellectual Property Right;

  

  

(xi) any Contract not described in any other subsection of this Section
4.12(a) that relates to the research, development, distribution, marketing,
supply, license, collaboration, co-promotion or manufacturing of any Key
Product, which, if terminated or not renewed, would reasonably be expected to
have a material and adverse effect on the Company's Key Products, taken as a
whole;

  

  

(xii) any stockholders, investors rights, registration rights or similar
agreement or arrangement;

  

  

(xiii) any Contract (A) with any sole-source supplier of material tangible
products or services relating to any Key Product (or any supplier of such
products or services that cannot be obtained from another source) or (B) that
includes (x) any material "most favored nations" terms and conditions
(including, without limitation, with respect to pricing) or (y) any minimum
purchase arrangement in excess of $1,000,000 over any 12-month period;

  

  

(xiv) any Contract pursuant to which the Company or any of its Subsidiaries
has continuing obligations or interests involving (A) milestone or similar
payments, including upon the achievement of regulatory or commercial
milestones or (B) payment of royalties or other amounts calculated based upon
any revenues or income of the Company or any of its Subsidiaries, in each case
that cannot be terminated by the Company or its Subsidiaries without penalty
without more than sixty (60) days' notice without material payment or penalty;

  

  

(xv) any Contract that relates to any swap, forward, futures, warrant, option
or other derivative transaction;

  

  

  

(xvi) any Contract relating to any loan or other extension of credit (other
than trade credits and accounts receivable in the ordinary course of business
consistent with past practice) made by the Company or any of its Subsidiaries,
except as described in Section 4.12(a)(vi)(A); or

  

  

(xvii) any "material contract" (as such term is defined in Item 601(b)(10) of
Regulation S-K of the SEC), but not including any Employee Plans.

  

  

(b) Each Contract of the Company or any of its Subsidiaries that is required
to be set forth on Section 4.12 of the Company Disclosure Schedule or required
to be filed as an exhibit to the Filed Company SEC Documents (a "Material
Contract") is in full force and effect (except for those Contracts that have
expired in accordance with their terms) and is a legal, valid and binding
agreement of the Company or its Subsidiary, as the case may be, and, to the
Knowledge of the Company, of each other party thereto, enforceable against the
Company or such Subsidiary, as the case may be, and, to the Knowledge of the
Company, each other party thereto, in each case, in accordance with its terms,
except for such failures to be in full force and

  

  

 

 

 

  

 

24  

  

 

 

 

  

  

effect or to be legal, valid, binding or enforceable that, individually or in
the aggregate, have not had and would not reasonably be expected to have a
Material Adverse Effect. Each of the Company and its Subsidiaries has
performed or is performing all obligations required to be performed by it
under the Material Contracts and is not in breach or default thereunder, and
has not waived or failed to enforce any rights or benefits thereunder, and, to
the Knowledge of the Company, no other party to any of the Material Contracts
is in breach or default thereunder, and no event has occurred which, with or
without notice, lapse of time, or both, would constitute a default under the
provisions of such Material Contract or would give to others any right of
termination, amendment or cancellation of any Material Contract or any license
thereunder, except for, in each case, any such failures to perform, breaches,
defaults, waivers, failures to enforce or events that, individually or in the
aggregate, have not had and would not reasonably be expected to have a
Material Adverse Effect. The Company has prior to the date of this Agreement
made available to Parent a true and complete copy of each Material Contract
(including all amendments, modifications, extensions and renewals thereof and
waivers thereunder).

  

  

Section 4.13 Permits; Compliance with Laws.

  

  

(a) The Company and its Subsidiaries have (whether directly or pursuant to
Contracts in which third parties have effectively granted to the Company or
its Subsidiaries the rights of such third parties) in effect all certificates,
permits, licenses, franchises, approvals, concessions, qualifications,
registrations, certifications and similar authorizations from any Governmental
Entity (collectively, "Permits") that are necessary for the Company and its
Subsidiaries to own, lease or operate their properties and assets and to carry
on their businesses as currently conducted, except where the failure to have
such Permits, individually or in the aggregate, has not had and would not
reasonably be expected to have a Material Adverse Effect. Since December 31,
2010, each of the Company and its Subsidiaries has been in compliance with,
and to the Knowledge of the Company is not under investigation with respect to
or has not been threatened to be charged with any violation of, the terms of
its Permits and all applicable Laws and Judgments, except for those failures
to be in compliance that, individually or in the aggregate, have not had and
would not reasonably be expected to have a Material Adverse Effect. Neither
the Company nor any of its Subsidiaries has received any notification since
December 31, 2010 from any Governmental Entity that alleges that the Company
or any of its Subsidiaries is not in compliance in all material respects with,
or is subject to any material liability under, any material Permit, Law or
Judgment or relating to the revocation or modification of any material Permit.
There is no Judgment outstanding against the Company or any of its
Subsidiaries that is or would reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.

  

  

(b) None of the Company, any of its Subsidiaries, or to the Company's
Knowledge, any of their respective directors, officers, consultants, agents or
other Persons acting for or on their behalf, has taken any action that would
result in a violation in any material respect by such Person of the Foreign
Corrupt Practices Act (15 U.S.C.  78m(b), 78dd-1, 78dd-2, 78ff), The Bribery
Act of 2010 of the United Kingdom, or any other anti-corruption or anti-
bribery Law (but, in each case, only to the extent such Law is applicable to
the Company, its Subsidiaries or such Persons). The Company has instituted and
maintained policies and

  

  

 

 

 

  

 

25  

  

 

 

 

  

  

procedures designed to prevent such Persons from taking such actions (but, in
each case, only to the extent such Law is applicable to the Company, its
Subsidiaries or such Persons).

  

  

(c) This Section 4.13 does not relate to environmental matters, employee
benefit matters, labor relations matters or Tax matters.

  

  

Section 4.14 Properties. Except as would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect, the Company and
its Subsidiaries have good title to, or valid leasehold interests in, all
property and assets (i) reflected on the Company's financial statements or
notes thereto for the fiscal year ended December 31, 2012 included in the
Company SEC Documents or (ii) acquired or leased after December 31, 2012,
except, in each case, as have been disposed of since December 31, 2012 in the
ordinary course of business consistent with past practice. Except as would not
reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect, no such property or assets is subject to any Lien (other than
Permitted Liens).

  

  

Section 4.15 Environmental Matters.

  

  

(a) Except where it would not reasonably be expected to have a Material
Adverse Effect, (i) the Company and its Subsidiaries are and have been since
December 31, 2010 in compliance with all applicable Environmental Laws, and
neither the Company nor any of its Subsidiaries has received any written
communication alleging that the Company or any of its Subsidiaries is in
violation of, or has any liability under, any applicable Environmental Law or
Environmental Permit, (ii) each of the Company and its Subsidiaries has
obtained and is operating in compliance with all applicable Environmental
Permits, (iii) there is no Environmental Claim pending or threatened against
the Company or any of its Subsidiaries, (iv) there has been no Release of
Hazardous Materials at, from, to, on or under any of the properties that are
currently or formerly owned, leased, operated or used by the Company or any of
its Subsidiaries or, to the Knowledge of the Company, any properties to which
the Company or any of its Subsidiaries has sent waste, and (v) neither the
Company nor any Subsidiary owns, leases or operates any property in New Jersey
or Connecticut.

  

  

(b) The representations and warranties set forth in Section 4.15(a) are the
Company's sole and exclusive representations and warranties with respect to
Environmental Law, the Release of Hazardous Materials and environmental
matters.

  

  

(c) The term "Environmental Claim" means any administrative, regulatory or
judicial action, suit, proceeding, order, claim, directive, Lien, or written
notice, demand or request or investigation by or from any Governmental Entity
or any other Person alleging liability relating to or arising out of any
Environmental Law or Environmental Permit, including a Release of, or human
exposure to, any Hazardous Material. The term "Environmental Permit" means any
Permit required under any applicable Environmental Law for the Company or its
Subsidiaries to conduct or own its respective businesses. The term
"Environmental Law" means any Law or Judgment relating to pollution, the
environment, natural resources, or human health as it relates to the
environment, including Laws or Judgments relating to Releases or threatened
Releases of Hazardous Materials or otherwise relating to the handling,
disposal, use,

  

  

 

 

 

  

 

26  

  

 

 

 

  

  

treatment, storage or transport of Hazardous Materials. The term "Hazardous
Material" means any (i) medical, biological or biohazardous material
(including any infectious material, biological product, bodily fluid, stock,
culture, diagnostic specimen, regulated animal, or medical waste) that is
regulated under any Environmental Law, (ii) petroleum product, derivative or
by-product, asbestos, asbestos-containing material, radon, urea formaldehyde
foam insulation, polychlorinated biphenyls, or radioactive materials or (iii)
other chemical, substance, material or waste that in relevant form, quantity
or concentration is regulated under any Environmental Law. The term "Release"
means any release, spill, emission, leaking, pumping, emitting, depositing,
discharging, injecting, escaping, leaching, dispersing, dumping, pouring,
disposing or migrating into, onto or through the environment (including
ambient air, surface water, ground water, land surface or subsurface strata).

  

  

Section 4.16 Employee Benefits.

  

  

(a) Section 4.16(a) of the Company Disclosure Schedule sets forth a complete
list of (i) all "employee benefit plans," as defined in Section 3(3) of ERISA,
(ii) all other employment, consulting, severance pay, termination protection,
change in control, salary continuation, bonus, incentive, transaction bonus,
retention, equity or equity-based award, retirement, pension, profit sharing,
deferred compensation, vacation, medical, dental, vision, prescription or
fringe benefit, life insurance, relocation or expatriate benefit, perquisite,
disability or sick leave benefit, employee assistance, supplemental
unemployment benefit or post-employment or retirement benefit (including
compensation, pension, health, medical or insurance benefits) plans,
contracts, programs, funds or arrangements and (iii) all other employee
benefit plans, contracts, programs, funds, or arrangements, in each case
whether or not written, (A) that are maintained, sponsored or contributed to
by the Company or any of its Subsidiaries in respect of any current or former
Service Providers or (B) to which the Company or any of its Subsidiaries is a
party or may have any direct or indirect liability (collectively, the
"Employee Plans"). Section 4.16(a) of the Company Disclosure Schedule further
specifies whether each such Employee Plan covers current or former Service
Providers located primarily within the United States or covers current or
former Service Providers located primarily outside the United States (each
such plan, an "International Plan").

  

  

(b) Copies of the following materials have been made available to Parent (in
each case to the extent applicable): (i) the plan document for each Employee
Plan (or a description if such plan is not written) and all amendments
thereto, (ii) the current determination letter from the Internal Revenue
Service ("IRS") with respect to each Employee Plan, (iii) the current
prospectus or summary plan description and any summary of material
modifications with respect to each Employee Plan, (iv) the most recent annual
report (Form 5500 Series) with respect to each Employee Plan, (v) each current
trust agreement, insurance contract and other document relating to the funding
or payment of benefits under any Employee Plan and any amendments thereto,
(vi) the most recently prepared actuarial reports and financial statements
with respect to any Employee Plan, (vii) all material documents and
correspondence relating to any Employee Plan provided by or to any applicable
Governmental Entity during the past three (3) years, (viii) all current
administrative and other service contracts with respect to any Employee Plan,
and amendments thereto, (ix) all current employee handbooks, manuals and
policies of the Company and its Subsidiaries and (x) for each Employee Plan
that is an

  

  

 

 

 

  

 

27  

  

 

 

 

  

  

International Plan, any applicable documents that are substantially comparable
(taking into account differences in applicable Laws and practices) to the
documents required to be provided in clauses (ii) through (iv).

  

  

(c) Each Employee Plan has been maintained, operated and administered in
material compliance with its terms and in material compliance with all
applicable Laws. With respect to any Employee Plan covered by Subtitle B, Part
4 of Title I of ERISA or Section 4975 of the Code, no non-exempt prohibited
transaction has occurred that has caused or would reasonably be expected to
cause the Company or any of its Subsidiaries to incur any material liability
under ERISA or the Code.

  

  

(d) Each Employee Plan intended to be qualified under Section 401(a) of the
Code has received a favorable determination or opinion letter from the IRS or
has applied to the IRS for such a letter within the applicable remedial
amendment period or such period has not expired and, to the Company's
Knowledge, no circumstances exist that would reasonably be expected to result
in any such letter being revoked or not being reissued or a penalty under the
IRS Closing Agreement Program if discovered during an IRS audit or
investigation. Each trust created thereunder has been determined by the IRS to
be exempt from tax under the provisions of Section 501(a) of the Code.

  

  

(e) Except as set forth on Section 4.16(e) of the Company Disclosure Schedule,
(i) neither the Company nor any trade or business (whether or not
incorporated) under common control with the Company within the meaning of
Section 4001(b)(1) of the Employee Retirement Income Security Act of 1974, as
amended ("ERISA"), or which together with the Company is treated as a single
employer under Section 414(t) of the Code (each, an "ERISA Affiliate"),
currently has, or in the past six (6) years had, an obligation to contribute
to a "defined benefit plan" as defined in Section 3(35) of ERISA, a pension
plan subject to the funding standards of Section 302 of ERISA or Section 412
of the Code or a "multiemployer plan" as defined in Section 3(37) of ERISA or
Section 414(f) of the Code and (ii) no liability under Title IV or Section 302
of ERISA has been incurred by the Company or any ERISA Affiliate that has not
been satisfied in full, and no condition exists that could reasonably be
expected to present a material risk to the Company or any ERISA Affiliate of
incurring any such liability.

  

  

(f) With respect to each group health plan benefiting any current or former
employee of the Company or any ERISA Affiliate that is subject to Section
4980B of the Code, the Company and each ERISA Affiliate has complied in all
material respects with the continuation coverage requirements of Section 4980B
of the Code and Part 6 of Subtitle B of Title I of ERISA.

  

  

(g) There is no pending or to the Knowledge of the Company, threatened,
assessment, complaint, proceeding or investigation of any kind in any court or
government agency with respect to any Employee Plan (other than routine claims
for benefits).

  

  

(h) No Employee Plan provides benefits, including, without limitation, death
or medical benefits, beyond termination of service or retirement other than
(i) coverage

  

  

 

 

 

  

 

28  

  

 

 

 

  

  

mandated by law or (ii) death or retirement benefits under any Employee Plan
that is intended to be qualified under Section 401(a) of the Code.

  

  

(i) Except as set forth in Section 4.16(i) of the Company Disclosure Schedule,
neither the execution of this Agreement nor the consummation of the
transactions contemplated by this Agreement (either alone or together with any
other event) will (i) entitle any current or former Service Provider to any
payment or benefit, including any bonus, retention, severance, retirement or
job security payment or benefit, (ii) accelerate the time of payment or
vesting or trigger any payment or funding (through a grantor trust or
otherwise) of compensation or benefits under, or increase the amount payable
or trigger any other obligation under, any Employee Plan or (iii) limit or
restrict the right of the Company or any of its Subsidiaries or, after the
Offer Closing, Parent, to merge, amend or terminate any Employee Plan. No
amount that could be received (whether in cash or property or the vesting of
property) as a result of the execution of this Agreement or the consummation
of the transactions contemplated by this Agreement (either alone or together
with any other event) by any employee, officer or director of the Company or
any of its Affiliates who is a "disqualified individual" (as such term is
defined in U.S. Treasury Regulations Section 1.280G-1) under any employment,
severance or termination agreement, other compensation arrangement or Employee
Plan currently in effect would reasonably be expected to be characterized as
an "excess parachute payment" (as such term is defined in Section 280G(b)(1)
of the Code).

  

  

(j) Each Employee Plan, and any award thereunder, that is or forms part of a
"nonqualified deferred compensation plan" within the meaning of Section 409A
of the Code is in documentary compliance with, and the Company and its
Subsidiaries have, since January 1, 2009, complied in practice and operation
with, all applicable requirements of Section 409A of the Code. Neither the
Company nor any of its Subsidiaries has any obligation to gross-up, indemnify
or otherwise reimburse any current or former Service Provider for any Tax
incurred by such Service Provider, including under Section 409A or 4999 of the
Code, or any interest or penalty related thereto.

  

  

(k) Each International Plan (i) has been maintained in material compliance
with its terms and applicable Laws, (ii) if intended to qualify for special
tax treatment, meets all the requirements for such treatment and (iii) if
required, to any extent, to be funded, book-reserved or secured by an
insurance policy, is fully funded, book-reserved or secured by an insurance
policy, as applicable, based on reasonable actuarial assumptions in accordance
with applicable accounting principles.

  

  

(l) The exercise price of each Company Stock Option is not less than the fair
market value of a share of Company Common Stock on the date of grant of such
Company Stock Option.

  

  

(m) Sections 4.3, 4.5 \- 4.12, 4.17, 4.18, and 4.21 and this Section 4.16
contain the sole representations and warranties in this Agreement for all
employee benefits matters.

  

  

 

 

 

  

 

29  

  

 

 

  

 

  

Section 4.17 Labor Matters.

  

  

(a) The Company and its Subsidiaries are or since December 31, 2010 have been
in material compliance with all applicable Laws relating to labor and
employment, including those relating to labor management relations, wages,
hours, overtime, employee classification, discrimination, sexual harassment,
civil rights, affirmative action, work authorization, immigration, safety and
health, information privacy and security, workers compensation, continuation
coverage under group health plans and wage payment, except for those failures
to be in compliance that, individually or in the aggregate, have not had and
would not reasonably be expected to have a Material Adverse Effect.

  

  

(b) Neither the Company nor any of its Subsidiaries is or since December 31,
2010 has been a party to or subject to, or is currently negotiating in
connection with entering into, any collective bargaining agreement, and, to
the Company's Knowledge, there has not been any organizational campaign,
petition or other unionization activity seeking recognition of a collective
bargaining unit relating to any Service Provider's employment with the Company
or its Subsidiaries. There are no unfair labor practice complaints or union
representation proceedings involving current or former Service Providers
pending or, to the Company's Knowledge, threatened in writing against the
Company or any of its Subsidiaries before the National Labor Relations Board
or any other Governmental Entity. There is no labor strike, slowdown,
stoppage, picketing, interruption of work or lockout pending or, to the
Company's Knowledge, threatened in writing against or affecting the Company or
any of its Subsidiaries.

  

  

(c) Except as set forth in Section 4.17(c) of the Company Disclosure Schedule,
(i) the consent or consultation of, or the rendering of formal advice by, any
labor or trade union, works council or other employee representative body is
not required by applicable Law or any agreement with such employee
representative body for the Company to enter into this Agreement or to
consummate any of the transactions contemplated hereby and (ii) the Company
and its Subsidiaries have complied in all material respects with their
respective obligations under applicable Law or any agreement with an employee
representative body described in clause (i) of this Section 4.17(c) to inform,
consult with and/or obtain consent from any such entity during the two-year
period prior to the date hereof.

  

  

(d) The Company and each of its Subsidiaries is, and has been since December
31, 2010, in material compliance with the Workers Adjustment and Retraining
Notification Act and any comparable applicable foreign, state, or local Law
pertaining to plant closings and mass layoffs ("WARN") and has no material
liabilities thereunder. Neither the Company nor any of its Subsidiaries has
engaged in any plant closings or mass layoffs (or similar actions under
applicable foreign, state or local Law) that would reasonably be expected to
cause Buyer or any of its Affiliates to have any material liability or other
material obligation following the Closing Date under WARN.

  

  

(e) Sections 4.5 \- 4.12, 4.16 and 4.18 and this Section 4.17 contain the sole
representations and warranties in this Agreement for all labor matters.

  

  

 

 

 

  

 

30  

  

 

 

  

 

  

Section 4.18 Taxes. Except as has not had, and would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect
on the Company:

  

  

(a) All Tax Returns required to be filed by the Company and its Subsidiaries
have been timely filed (taking into account applicable extensions), and all
such Tax Returns were true, correct and complete in all respects. All Taxes
due and payable by the Company or its Subsidiaries have been paid on a timely
basis (whether or not such Taxes were shown as due and payable on any Tax
Returns) or, where payment is not yet due or has not been made, the Company
and each of its Subsidiaries, as applicable, has established (or has had
established on its behalf and for its sole benefit and recourse) in accordance
with GAAP an accrual for all Taxes through the end of the last period for
which the Company and its Subsidiaries ordinarily record items on their
respective books or, to the extent such amounts are being contested in good
faith by the Company or its Subsidiaries, has established reserves on its
books or records in accordance with GAAP.

  

  

(b) The U.S. federal income Tax Returns of the Company and its U.S.
Subsidiaries through the Tax year ended December 31, 2009 are closed to
assessment except to the extent of amended Tax Returns filed for the Tax years
ended December 31, 2008 and 2009. Section 4.18(b) of the Company Disclosure
Schedule lists all amended United States federal and state, Belgian and, to
the Knowledge of the Company, Swedish and United Kingdom income or income-
based franchise Tax Returns filed by the Company and its Subsidiaries with
respect to any Tax year ending after December 31, 2007.

  

  

(c) Neither the Company nor any of its Subsidiaries is or has ever been a
member of a group of corporations with which it has filed (or been required to
file) consolidated, combined or unitary Tax Returns other than a group of
which the Company is the common parent. Neither the Company nor any of its
Subsidiaries has any actual liability for any Taxes of any Person other than
the Company or any of its Subsidiaries (i) under U.S. Treasury Regulations
Section 1.1502-6 (or any other comparable or similar Law) or (ii) as a
transferee or successor. Neither the Company nor any of its Subsidiaries has
entered into any agreement, arrangement, Tax ruling, Tax holiday or has taken
advantage of or expects to take advantage of any incentive regime which
results in an effective Tax rate lower than the statutory Tax rate with any
Taxing authority with regard to the Tax liability of the Company or any of its
Subsidiaries affecting any Tax period for which the applicable statute of
limitations, after giving effect to extensions or waivers, has not expired.

  

  

(d) No audit, claim, action, suit or investigation or other proceeding with
respect to any Taxes due from the Company or any of its Subsidiaries, any Tax
asset or any Tax Return of the Company or any of its Subsidiaries, is pending
or, to the Company's Knowledge, threatened. Each assessed deficiency resulting
from any audit, claim, action, suit, investigation or other proceeding with
respect to Taxes by any Governmental Entity has been timely paid and fully
satisfied.

  

  

(e) No extension of the statute of limitations on the assessment or collection
of any Taxes has been granted by the Company or any of its Subsidiaries that
is currently in effect.

  

  

 

 

 

  

 

31  

  

 

 

 

  

  

(f) No Liens for Taxes exist with respect to any assets or properties of the
Company or any of its Subsidiaries, except for Permitted Liens.

  

  

(g) Neither the Company nor any of its Subsidiaries has been a "controlled
corporation" or a "distributing corporation" in any distribution occurring
during a two-year period ending on the date hereof that was purported or
intended to qualify for tax-free treatment pursuant to Section 355(a) of the
Code.

  

  

(h) The Company and each of its Subsidiaries has properly withheld, and paid
over to the appropriate Taxing authority, all Taxes that it was required to
withhold from any payment (including any dividend or interest payment) to any
employee, independent contractor, creditor, shareholder, vendor or other
Person.

  

  

(i) Neither the Company nor any of its Subsidiaries has participated in any
"listed transaction" within the meaning of U.S. Treasury Regulations Section
1.6011-4. The Company has disclosed on its United States federal income Tax
Returns all positions taken therein that could give rise to a substantial
understatement of United States federal income Tax within the meaning of
Section 6662 of the Code or any similar provision of applicable Law in any
non-U.S. jurisdiction.

  

  

(j) No jurisdiction where the Company or any of its Subsidiaries does not file
a Tax Return has made a claim in writing that the Company or any of its
Subsidiaries is required to file a Tax Return for such jurisdiction.

  

  

(k) With respect to finished goods transactions between the Company,
ViroPharma Biologics, Inc. and ViroPharma SPRL, the Company has prepared or
caused to have been prepared sufficient documentation to provide a level of
comfort to the Company of at least a "more likely than not" standard that such
transfer prices (i) comply with applicable law and (ii) satisfy the
requirements necessary to mitigate potential penalties under Section 6662 of
the Code for all fiscal years ended December 31, 2010 and thereafter. The
Company has provided to Parent the only final formal written report for the
year ended December 31, 2012 related to such transactions.

  

  

(l) Neither the Company nor any Subsidiary is a party to or is bound by any
Tax Sharing Agreement.

  

  

(m) For purposes of this Agreement, (i) "Tax" and "Taxes" mean all taxes,
charges, fees, levies or other similar assessments or liabilities in the
nature of taxes, including income, gross receipts, ad valorem, premium, value-
added, excise, real property, personal property, sales, use, services,
transfer, withholding, employment, payroll and franchise taxes imposed by any
Governmental Entity, and any interest, penalties, assessments, additions to
tax and additional amounts imposed with respect thereto and (ii) "Tax Returns"
means all reports, returns, declarations, statements or other information or
filing required to be supplied to a Governmental Entity with respect to Taxes
(including any schedule or attachment thereto or amended return), including
information returns, any documents with respect to or accompanying payments of
estimated Taxes, or any documents with respect to or accompanying requests for
the extension of time in which to file any such report, return, document,
declaration or other

  

  

 

 

 

  

 

32  

  

 

 

 

  

  

information. "Tax Sharing Agreement" means any agreement or arrangement
(whether or not written) entered into prior to the Effective Time binding the
Company or any of its Subsidiaries that provide for the allocation,
apportionment, sharing or assignment of any Tax liability or benefit, or the
transfer or assignment of income, revenues, receipts, or gains for the purpose
of determining any Person's Tax liability.

  

  

(n) Sections 4.7, 4.10, 4.14, and 4.16 and this Section 4.18 contain the sole
representations and warranties in this Agreement for all matters relating to
Taxes.

  

  

Section 4.19 Intellectual Property.

  

  

(a) Each of the Company and its Subsidiaries is the sole and exclusive owner
of, or is licensed or otherwise has the right to use (in each case, free and
clear of any Liens other than Permitted Liens) all Intellectual Property
Rights used or held for use in or necessary for the conduct of its business as
currently conducted and as proposed to be conducted in the Filed Company SEC
Documents, including the research, development, clinical testing,
manufacturing, commercialization and other exploitation of any and all Key
Products and Medicines, except for those failures to so own, license or
otherwise have the right to use that, individually or in the aggregate, have
not had and would not reasonably be expected to have a Material Adverse
Effect.

  

  

(b) Except for any such infringement, misappropriation or other violation
that, individually or in the aggregate, has not had and would not reasonably
be expected to have a Material Adverse Effect, to the Company's Knowledge,
neither the Company nor any of its Subsidiaries has infringed, misappropriated
or otherwise violated, has been accused of infringing, misappropriating or
otherwise violating, is infringing, misappropriating or otherwise violating,
or, upon the commercialization of any product, product candidate or compound,
will infringe, misappropriate or otherwise violate, any Intellectual Property
Right of any Person. To the Company's Knowledge, no Person has infringed,
misappropriated or otherwise violated, has been accused of infringing,
misappropriating or otherwise violating, is infringing misappropriating or
otherwise violating or, upon commercialization of any product, product
candidate or compound, will infringe, misappropriate or otherwise violate any
Intellectual Property Right owned by or exclusively licensed to the Company or
any of its Subsidiaries, except for any infringements, misappropriations or
other violations that, individually or in the aggregate, have not had and
would not reasonably be expected to have a Material Adverse Effect.

  

  

(c) There is no claim, suit, action, investigation, complaint or proceeding
pending, or, to the Knowledge of the Company, threatened against the Company
or any of its Subsidiaries alleging that the use of any Intellectual Property
Rights or any services provided, processes used or products manufactured,
used, imported, offered for sale or sold by the Company or any of its
Subsidiaries do or may conflict with, misappropriate, infringe, contribute to
the infringement of, or otherwise violate any Intellectual Property Right of
any Person, in each case that, individually or in the aggregate, has had or
would reasonably be expected to have a Material Adverse Effect. Except as
disclosed in the Filed Company SEC Documents, no claims, cancellations,
oppositions, interferences, reissuances, reexaminations, declaratory judgment
actions or other actions or proceedings are pending or, to the Company's

  

  

 

 

 

  

 

33  

  

 

 

 

  

  

Knowledge, threatened, in each case, with regard to the ownership or license
rights of the Company or any of its Subsidiaries in any of their respective
Intellectual Property Rights or the validity or enforceability thereof, except
for any claims, cancellations, oppositions, interferences, reissuances,
reexaminations, declaratory judgment actions or other actions or proceedings
that, individually or in the aggregate, have not had and would not reasonably
be expected to have a Material Adverse Effect. None of the Intellectual
Property Rights of the Company or any of its Subsidiaries has been adjudged
invalid or unenforceable in whole or part, or in the case of any pending
patent applications of the Company or any of its Subsidiaries, has been the
subject of a final and non-appealable finding of unpatentability, in each case
except for any such judgments or findings that, individually or in the
aggregate, have not had and would not reasonably be expected to have a
Material Adverse Effect. Except as, individually or in the aggregate, has not
had and would not reasonably be expected to have a Material Adverse Effect, to
the Company's Knowledge, all issued patents, registered trademarks and
registered copyrights owned by or exclusively licensed to the Company or any
of its Subsidiaries are valid, enforceable, in full force and effect and
subsisting.

  

  

(d) All material (i) patents and applications therefor and (ii) registered
trademarks and applications therefor, domain name registrations (if any) and
copyright registrations (if any), in each case, comprising Intellectual
Property Rights, that are owned (wholly or jointly) by or exclusively licensed
to the Company or any of its Subsidiaries as of the date hereof are listed in
Section 4.19(d) of the Company Disclosure Schedule, specifying as to each such
item, as applicable, (A) the owner and title thereof, (B) the jurisdiction in
which such item is issued or registered or in which an application for
issuance or registration has been filed, (C) the respective issuance,
registration or application number of such item and (D) the date of
application and issuance or registration of such item.

  

  

(e) Except as, individually or in the aggregate, has not had and would not
reasonably be expected to have a Material Adverse Effect, the consummation of
the transactions contemplated by this Agreement will not alter, encumber,
impair or extinguish any Intellectual Property Right used or held for use by,
or necessary for the conduct of the business of, the Company or any of its
Subsidiaries or impair the right of Parent to develop, use, sell, license or
dispose of, or to bring any action for the infringement of, any Intellectual
Property Right used or held for use by, or necessary for the conduct of the
business of, the Company or any of its Subsidiaries.

  

  

(f) The Company and its Subsidiaries have used commercially reasonable efforts
and taken commercially reasonable steps to maintain and protect their trade
secrets and other confidential Intellectual Property Rights in confidence,
including the development and implementation of a policy reasonably designed
for the protection of such trade secrets and other confidential Intellectual
Property Rights requiring all employees of the Company and its Subsidiaries
and any other Person with access to such trade secrets or other confidential
Intellectual Property Rights, to execute confidentiality agreements with
respect to the confidentiality and use of such trade secrets and other
confidential Intellectual Property Rights developed for or obtained from the
Company or any of its Subsidiaries, except in each case, for any failures to
use commercially reasonable efforts, to take commercially reasonable steps, or
to obtain any such agreements that, individually or in the aggregate, have not
had and would not

  

  

 

 

 

  

 

34  

  

 

 

 

  

  

reasonably be expected to have a Material Adverse Effect. No trade secrets or
other confidential Intellectual Property Rights of the Company or its
Subsidiaries' have been disclosed other than to employees, representatives and
agents of the Company or its Subsidiaries, all of whom are bound by written
confidentiality agreements, except for any disclosure that, individually or in
the aggregate, has not had and would not reasonably be expected to have a
Material Adverse Effect.

  

  

(g) To the extent that any Intellectual Property Right has been developed or
created by a third party (including any current or former employee of the
Company or any of its Subsidiaries) for the Company or any of its
Subsidiaries, the Company or one of its Subsidiaries, as the case may be, has
a written agreement with such third party with respect thereto, and the
Company or one of its Subsidiaries thereby either (i) has obtained ownership
of and is the exclusive owner of or (ii) has obtained a valid and unrestricted
right to exploit, sufficient for the conduct of its business as currently
conducted and as proposed to be conducted in the Filed Company SEC Documents,
such Intellectual Property Right, in each case except for any failure to
obtain such rights that, individually or in the aggregate, has not had and
would not reasonably be expected to have a Material Adverse Effect.

  

  

(h) Except as, individually or in the aggregate, has not had and would not
reasonably be expected to have a Material Adverse Effect, (i) the IT Assets
operate and perform in a manner that permits the Company and its Subsidiaries
to conduct their respective businesses as currently conducted and, to the
Knowledge of the Company, no Person has gained unauthorized access to the IT
Assets and (ii) the Company and each of its Subsidiaries take commercially
reasonable actions, consistent with current industry standards, to protect the
confidentiality, integrity and security of the IT Assets (and all information
and transactions stored or contained therein or transmitted thereby) against
any unauthorized use, access, interruption, modification or corruption,
including but not limited to the implementation of commercially reasonable (A)
data backup, (B) disaster avoidance and recovery procedures and (C) business
continuity procedures, in each case consistent with industry practices. For
purposes of this Agreement, "IT Assets" means computers, computer software,
firmware, middleware, servers, workstations, routers, hubs, switches, data
communications lines, and all other information technology equipment, and all
associated documentation owned by the Company or its Subsidiaries or licensed
or leased by the Company or its Subsidiaries pursuant to written agreement
(excluding any public networks).

  

  

Section 4.20 Regulatory Compliance.

  

  

(a) Except as disclosed in the Filed Company SEC Documents:

  

  

(i) Each medicinal or pharmaceutical product that is or has been researched,
developed, manufactured, labeled, supplied, promoted, co-promoted, co-
developed, co-marketed, tested, distributed, marketed, commercialized or sold
by or on behalf of the Company or any of its Subsidiaries (each, a "Medicine")
is being done so in compliance with all applicable Health Laws, except for any
noncompliance that, individually or in the aggregate, has not had and would
not reasonably be expected to have a Material Adverse Effect.

  

  

 

 

 

  

 

35  

  

 

 

 

  

  

(ii) Except as would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect, none of the Company, any of its
Subsidiaries or, to the Company's Knowledge, any partner or other third party
which pursuant to a Contract with the Company or any of its Subsidiaries co-
develops, co-promotes, co-markets or otherwise has a license to develop,
market or sell any Medicine of the Company or any of its Subsidiaries (such
third party, a "Collaboration Partner") has received any written notice or
other communication from any Health Authority (A) withdrawing approval of any
Medicine of the Company or any of its Subsidiaries or placing on "clinical
hold" any clinical trial sponsored by the Company or any of its Subsidiaries
or (B) alleging any violation or lack of compliance with any Health Law with
respect to the research, development, marketing, manufacturing or distribution
of any Medicine. Since December 31, 2010, neither the Company nor any of its
Subsidiaries have received any notices of inspectional observations (including
those reported on Form FDA 483), establishment inspection reports, warning
letters, action letters or untitled letter, except for those reports or
notices that would not reasonably be expected to have a Material Adverse
Effect.

  

  

(iii) To the Company's Knowledge, there are no investigations, suits, claims,
actions or proceedings against the Company or any of its Subsidiaries relating
to or arising under (A) Health Laws, (B) the Social Security Act of 1935, as
amended (the "Social Security Act") (or the regulations thereunder) or similar
Laws or (C) any applicable Laws relating to government health care programs,
private health care plans or the privacy and confidentiality of patient health
information, except for any investigations, suits, claims, actions or
proceedings that would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect.

  

  

(iv) Except as would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect:

  

  

(1) the manufacture of each Medicine by the Company, any of its Subsidiaries
and, to the Knowledge of the Company, any of their respective Collaboration
Partners is being, and since December 31, 2010 has been, conducted in
compliance with the current good manufacturing practice regulations, rules and
guidances for industry for biological and drug products of the U.S. Food and
Drug Administration ("FDA") (including 21 C.F.R. Parts 210, 211) and all
similar requirements in any other jurisdiction in which such Medicine is sold
or intended to be sold;

  

  

(2) no Medicine is under consideration by the Company, any of its Subsidiaries
or, to the Knowledge of the Company, any of their respective Collaboration
Partners for recall, field correction, suspension, detention, discontinuance
or withdrawal from the market, or has been recalled, corrected in the field,
suspended, detained, discontinued, or withdrawn from the market, or

  

  

 

 

 

  

 

36  

  

 

 

 

  

  

subject to an enforcement action as a result of any action by the FDA or any
other Governmental Entity, voluntarily or otherwise; and

  

  

(3) none of the Company, any of its Subsidiaries or, to the Knowledge of the
Company, any of their respective Collaboration Partners has received any
notice that the FDA or any other Governmental Entity has initiated or is
considering initiating any steps, procedures or action to withdraw approval or
the license for, suspend, detain, discontinue the development, manufacture,
distribution, marketing, offering for sale or sale of, or reimbursement for,
request the recall or field correction of, or take any enforcement action with
respect to, any Medicine.

  

  

(v) All animal studies or other preclinical tests in respect of a Medicine
performed in connection with or as the basis for any submission to or filing
with the FDA or other comparable Governmental Entity have been conducted in
accordance with applicable good laboratory practice regulations, rules, and
guidances for industry for biological and drug products of the FDA and all
similar requirements in any other jurisdiction in which the applicable
Medicine is sold or intended to be sold, except as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect.

  

  

(vi) Except as would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect:

  

  

(1) all clinical trials being conducted in respect of a Medicine by the
Company, any of its Subsidiaries and, to the Knowledge of the Company, any of
their respective Collaboration Partners, wherever conducted, have been and are
being conducted in compliance with all requirements of applicable Health Laws
relating to protection of human subjects, including those contained in the
International Conference on Harmonization E6: Good Clinical Practices
Consolidated Guideline and 21 C.F.R. Parts 50, 54, 56, 312, 314 and 601; and

  

  

(2) no clinical trial conducted by the Company, any of its Subsidiaries or, to
the Knowledge of the Company, any of their respective Collaboration Partners
has been terminated or suspended prior to completion for safety reasons, and
neither the FDA nor any other Governmental Entity, clinical investigator or
institutional review board has initiated or, to the Knowledge of the Company,
threatened to initiate, any action to place a clinical hold order on, or
otherwise terminate, materially delay or suspend any such ongoing clinical
trial, suspend or terminate any Investigational New Drug Application or other
foreign equivalent sponsored by the Company or any of its Subsidiaries,
disqualify, restrict or debar any clinical investigator or other Person
involved in any such clinical trial or otherwise restrict the preclinical
research on or clinical study of any Medicine.

  

  

 

 

 

  

 

37  

  

 

 

  

 

  

(b) Complete and accurate copies of all material scientific and clinical data
of the Company or any of its Subsidiaries and all material written
correspondence with all Health Authorities with respect to each Medicine of
the Company or any of its Subsidiaries have been made available to Parent.

  

  

(c) None of the Company, any of its Subsidiaries, nor to Knowledge of the
Company, any of their respective officers, employees, Collaboration Partners
or agents, has made an untrue statement of a material fact or fraudulent
statement to any Health Authority, failed to disclose a material fact required
to be disclosed to any Health Authority, or committed an act, made a
statement, or failed to make a statement, including with respect to any
scientific data or information, that, at the time such disclosure was made or
failure to disclose occurred, would reasonably be expected to provide a basis
for the FDA to invoke its policy respecting "Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities," set forth in 56 Fed. Reg.
46191 (September 10, 1991), or for any other Health Authority to invoke any
similar policy, except for any act or disclosure or failure to disclose that,
individually or in the aggregate, would not reasonably be expected to have a
Material Adverse Effect. None of the Company, any of its Subsidiaries, nor to
Knowledge of the Company, any of their respective officers, employees,
Collaboration Partners or agents, has been convicted of any crime or engaged
in any conduct for which debarment is mandated by 21 U.S.C.  335a(a) or any
similar Laws or authorized by 21 U.S.C.  335a(b) or any similar Laws
applicable in other jurisdictions in which any of the Medicines are sold or
intended to be sold.

  

  

(d) There are no pending or, to the Knowledge of the Company, threatened
filings of an action against the Company or any of its Subsidiaries relating
to the Company or any Medicine under any federal or state whistleblower
statute, including under the False Claims Act of 1863 (31 U.S.C.  3729 et
seq.).

  

  

(e) None of the Company, any of its Subsidiaries, nor to Knowledge of the
Company, any of their respective officers, employees or agents: (i) is a party
to, or bound by, any order, individual integrity agreement, corporate
integrity agreement or other formal or informal agreement with any
Governmental Entity concerning compliance with federal health care program
requirements; (ii) has been debarred, excluded or suspended from participation
in any federal health care program; (iii) has had a civil monetary penalty
assessed against it, him or her under Section 1128A of the Social Security
Act, codified at Title 42, Chapter 7, of the United States Code; (iv) is
currently listed on the General Services Administration published list of
parties excluded from federal procurement programs and non-procurement
programs; (v) is the target or subject of any current investigation by a
Governmental Authority relating to any federal health care program-related
offense; or (vi) is currently charged with or convicted of any criminal
offense relating to the delivery of an item or service under any federal
health care program.

  

  

(f) None of the Company, any of its Subsidiaries, or, to the Knowledge of the
Company, any of their respective agents has failed to comply with any
applicable security and privacy standards regarding protected health
information under the Health Insurance Portability and Accountability Act of
1996 (18 U.S.C. Section 3801 et. seq.) or similar Law in any other

  

  

 

 

 

  

 

38  

  

 

 

 

  

  

jurisdiction in which any Medicine is sold or intended to be sold, except as
would not reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect.

  

  

(g) For purposes of this Agreement, (i) the term "Health Law" means any Law of
any Governmental Entity (including multi-country organizations) the purpose of
which is to ensure the safety, efficacy and quality of medicinal and
pharmaceutical products by regulating the research, development, manufacturing
and distribution of these products, including Laws relating to good laboratory
practices, good clinical practices, investigational use, product marketing
authorization, manufacturing facilities compliance and approval, good
manufacturing practices, labeling, advertising, promotional practices, safety
surveillance, record keeping and filing of required reports, including the
U.S. Food, Drug and Cosmetic Act of 1938, as amended, the Public Health
Service Act, as amended, the associated rules and regulations promulgated
thereunder and all of their foreign equivalents and (ii) the term "Health
Authority" means the Governmental Entities which administer Health Laws
including the FDA, the European Medicines Agency and other equivalent
agencies.

  

  

Section 4.21 Rule 14d-10 Matters. All amounts payable pursuant to the Employee
Plans or any other plan, program, agreement or arrangement pursuant to which
compensation is paid or payable or pursuant to which benefits are provided
(collectively, the "Arrangements") to holders of Company Common Stock and
other securities of the Company (the "Covered Securityholders") (a) are being
paid or granted as compensation for past services performed, future services
to be performed or future services to be refrained from performing by the
Covered Securityholders (and matters incidental thereto) and (b) are not
calculated based on the number of shares tendered or to be tendered into the
Offer by the applicable Covered Securityholder. The Board of Directors of the
Company has determined that each member of the Compensation Committee of the
Board of Directors of the Company (the "Compensation Committee") is an
"Independent Director" within the meaning of the applicable NASDAQ rules and
is an "Independent Director" in accordance with the requirements of Rule
14d-10(d)(2) under the Exchange Act. The Compensation Committee (i) at a
meeting duly called and held at which all members of the Compensation
Committee were present, duly and unanimously adopted resolutions approving as
an "employment compensation, severance or other employee benefit arrangement"
within the meaning of Rule 14d-10(d)(1) under the Exchange Act (an "Employment
Compensation Arrangement") (A) each Company Stock Plan, (B) the treatment of
the Company Stock Options, Company RSUs, Company PSUs and rights to purchase
shares of Company Common Stock under the Purchase Plan in accordance with the
terms set forth in this Agreement, the applicable Company Stock Plan and any
applicable Arrangement, (C) the terms of Section 3.3 of this Agreement and (D)
each other Arrangement, which resolutions have not been rescinded, modified or
withdrawn in any way and (ii) has taken all other actions necessary to satisfy
the requirements of the non-exclusive safe harbor under Rule 14d-10(d)(2)
under the Exchange Act with respect to the foregoing arrangements.

  

  

Section 4.22 Brokers and Other Advisors. No broker, investment banker,
financial advisor or other Person (other than Goldman, Sachs and Co. (the
"Company Financial Advisor"), the fees and expenses of which will be paid by
the Company), is entitled to any broker's, finder's, financial advisor's or
other similar fee or commission in connection with this Agreement and the
transactions contemplated hereby based upon arrangements made by or on behalf
of the

  

  

 

 

 

  

 

39  

  

 

 

 

  

  

Company. Prior to the date hereof, the Company has provided to Parent correct
and complete copies of all agreements under which any such fees and
commissions are payable to the Company Financial Advisor and all
indemnification and other agreements related to the engagement of the Company
Financial Advisor.

  

  

Section 4.23 Opinion of Financial Advisor. The Company has received the
opinion of the Company Financial Advisor to the effect that, as of the date
hereof, and based upon and subject to the qualifications and assumptions set
forth therein, $50.00 per share of Company Common Stock to be paid to the
holders (other than Parent and its affiliates) of Company Common Stock
pursuant to this Agreement is fair, from a financial point of view, to such
holders. A written copy of such opinion will be delivered promptly after the
date hereof to Parent for informational purposes only.

  

  

Section 4.24 Anti-takeover Statutes. The Company has no "rights plan," "rights
agreement," or "poison pill" in effect. Assuming that neither Parent nor any
of its Affiliates is an "interested stockholder" (as defined in Section 203 of
the DGCL) as of immediately prior to the execution and delivery of this
Agreement, the Company has taken all action necessary to exempt the Offer, the
Merger, this Agreement and the transactions contemplated hereby from the
restrictions on business combinations of Section 203 of the DGCL. To the
Knowledge of the Company, except for Section 203 of the DGCL, no other
"control share acquisition," "fair price," "moratorium" or other anti-takeover
laws enacted under U.S. state or federal laws apply to this Agreement or any
of the transactions contemplated hereby.

  

  

Section 4.25 Insurance. The Company has delivered or otherwise made available
to Parent a copy of all material insurance policies and all material self-
insurance programs and arrangements relating to the business, assets and
operations of the Company and its Subsidiaries in effect as of the date
hereof. Except as would not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect: (a) all such insurance policies are
in full force and effect and all premiums thereon have been timely paid or, if
not yet due, accrued, (b) there is no claim pending under the Company's or any
of its Subsidiaries' insurance policies or fidelity bonds as to which coverage
has been questioned, denied or disputed by the underwriters of such policies
or bonds, (c) the Company and its Subsidiaries are in compliance with the
terms of such policies and bonds and (d) the Company has no knowledge as of
the date of this Agreement of any threatened termination of, or material
premium increase with respect to, any of such policies or bonds.

  

  

ARTICLE V

  

  

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  

  

Except as set forth in the disclosure schedule to this Agreement dated as of
the date hereof and delivered by Parent to the Company prior to the execution
of this Agreement (the "Parent Disclosure Schedule") (which Parent Disclosure
Schedule sets forth items of disclosure with specific reference to the
particular Section or subsection of this Agreement to which the information in
the Parent Disclosure Schedule relates; provided, however, that any
information set forth in one Section or subsection of the Parent Disclosure
Schedule shall be deemed to apply

  

  

 

 

 

  

 

40  

  

 

 

 

  

  

to each other Section or subsection thereof or hereof to which its relevance
is readily apparent on its face), Parent and Merger Sub represent and warrant
to the Company as follows:

  

  

Section 5.1 Organization, Standing and Corporate Power. Each of Parent and
Merger Sub is (a) a corporation or other entity duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
organization and (b) is duly licensed or qualified to do business as a foreign
corporation and is in good standing (in jurisdictions that recognize the
concept of good standing) in which the nature of its business or the
ownership, leasing or operation of its properties makes such qualification
necessary and has all requisite corporate power and authority to carry on its
business as now being conducted, except where the failure to be so
incorporated, validly existing or in good standing, or to have such power or
authority, would not, individually or in the aggregate with such other
failures, reasonably be expected to prevent, materially impede or materially
delay the consummation of the Offer, the Merger or the other transactions
contemplated by this Agreement.

  

  

Section 5.2 Authority. Each of Parent and Merger Sub has all requisite
corporate power and authority to execute and deliver this Agreement, to
consummate the Offer, the Merger and the other transactions contemplated by
this Agreement, subject, in the case of the Merger if required by applicable
Law, to the affirmative vote of Parent as the sole stockholder of Merger Sub
in favor of adopting this Agreement, or if not so required, to the taking by
Parent of such action as is necessary to cause the Merger to become effective
in accordance with the DGCL (collectively, the "Parent Approval"), and to
comply with the provisions of this Agreement. The execution and delivery of
this Agreement by Parent and Merger Sub, the consummation by Parent and Merger
Sub of the Offer, the Merger and the other transactions contemplated by this
Agreement and the compliance by Parent and Merger Sub with the provisions of
this Agreement have been duly authorized by all necessary corporate action on
the part of Parent and Merger Sub and no other corporate proceedings on the
part of Parent or Merger Sub are necessary to authorize this Agreement, to
consummate the Offer, the Merger and the other transactions contemplated by
this Agreement, subject, in the case of the Merger, to obtaining the Parent
Approval, or to comply with the provisions of this Agreement. This Agreement
has been duly executed and delivered by each of Parent and Merger Sub and,
assuming the due authorization, execution and delivery by the Company,
constitutes legal, valid and binding obligations of Parent and Merger Sub, as
applicable, enforceable against Parent and Merger Sub, as applicable, in
accordance with its terms, except as enforceability may be limited by
bankruptcy, insolvency, reorganization, moratorium or other applicable Laws
relating to or affecting creditors' rights generally or by equitable
principles (regardless of whether enforcement is sought at law or in equity).

  

  

Section 5.3 Non-Contravention. The execution and delivery of this Agreement by
Parent and Merger Sub do not, and the consummation by Parent and Merger Sub of
the Offer, the Merger and the other transactions contemplated by this
Agreement and compliance by Parent and Merger Sub with the provisions of this
Agreement will not, conflict with, require any payment to or consent or other
action by any Person, or result in any violation or breach of, or default
(with or without notice or lapse of time, or both) under, or give rise to a
right of, or result in, termination, cancellation or acceleration or other
change of any right or obligation or to the loss of a benefit under, or result
in the creation of any Lien in or upon any of the properties or

  

  

 

 

 

  

 

41  

  

 

 

 

  

  

other assets of Parent or Merger Sub under (a) the certificate of
incorporation or bylaws or other organizational documents of Parent or the
certificate of incorporation or bylaws of Merger Sub, (b) any Contract to
which Parent or Merger Sub is a party or any of their respective properties or
other assets is subject or (c) subject to the governmental filings and other
matters referred to in Section 5.4 below, any Law or Judgment, in each case
applicable to Parent or Merger Sub or their respective properties or other
assets, other than, in the case of clauses (b) and (c), any such conflicts,
violations, breaches, defaults, rights, losses or Liens that would not
reasonably be expected to prevent, materially impede or materially delay the
consummation by Parent of the Offer, the Merger or the other transactions
contemplated by this Agreement.

  

  

Section 5.4 Required Filings and Consents. No consent, approval, order or
authorization of, action by or in respect of, or registration, declaration or
filing with, any Governmental Entity is required by or with respect to Parent
or Merger Sub in connection with the execution and delivery of this Agreement
by Parent and Merger Sub or the consummation by Parent and Merger Sub of the
Offer, the Merger or the other transactions contemplated by this Agreement or
the compliance by Parent and Merger Sub with the provisions of this Agreement,
except for (a) compliance with the HSR Act, (b) compliance with other
applicable Competition Laws, (c) the filing with the SEC of (i) the Offer
Documents and (ii) reports under the Exchange Act as may be required in
connection with this Agreement, the Offer, the Merger and the other
transactions contemplated by this Agreement, (d) the filing of the Certificate
of Merger with the Secretary of State and appropriate documents with the
relevant authorities of other states in which the Company or any of its
Subsidiaries is qualified to do business, (e) any filings required under the
rules and regulations of NASDAQ and compliance with the requirements of the UK
Financial Conduct Authority Listing Rules and (f) such other consents,
approvals, orders, authorizations, actions, registrations, declarations and
filings, the failure of which to be obtained or made, individually or in the
aggregate, would not reasonably be expected to prevent, materially impede or
materially delay the consummation of the Offer, the Merger or the other
transactions contemplated by this Agreement.

  

  

Section 5.5 Information Supplied. None of the information included or
incorporated by reference in the Offer Documents (and none of the information
supplied by Parent or Merger Sub in writing specifically for inclusion or
incorporation by reference in the Schedule 14D-9 or the Information Statement)
will, at the respective times the Offer Documents, the Schedule 14D-9 and the
Information Statement are filed with the SEC or first published, amended or
supplemented or sent or given to the Company's stockholders contain any
statement that, in light of the circumstances under which it is made, is false
or misleading with respect to any material fact or omit to state any material
fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made,
not false or misleading, except that no representation or warranty is made by
Parent or Merger Sub with respect to statements made or incorporated by
reference in the Offer Documents based on information supplied by the Company
specifically for inclusion or incorporation by reference therein. The Offer
Documents will comply as to form in all material respects with the
requirements of the Exchange Act.

  

  

Section 5.6 Interim Operations of Merger Sub. All of the issued and
outstanding share capital of Merger Sub is, and immediately prior to the
Effective Time will be owned, directly or

  

  

 

 

 

  

 

42  

  

 

 

 

  

  

indirectly, by Parent. Merger Sub was formed solely for the purpose of
engaging in the Offer, the Merger and the other transactions contemplated by
this Agreement and has engaged in no business other than in connection with
the Offer, the Merger and the other transactions contemplated by this
Agreement.

  

  

Section 5.7 Sufficiency of Funds. Parent has or will have sufficient funds, or
access to sufficient funds, to consummate the Offer and the Merger on the
terms contemplated by this Agreement, and, at the Offer Closing and the
Effective Time, Parent will have available all of the funds necessary for (a)
the acquisition of all shares of Company Common Stock pursuant to the Offer,
(b) the payment of the Merger Consideration pursuant to the Merger and (c) the
payment to the Company of funds sufficient to pay holders of Company Stock
Options, Company RSUs and Company PSUs in accordance with the provisions of
Section 3.3.

  

  

Section 5.8 Company Stock. Neither Parent nor Merger Sub, nor any of their
respective "affiliates" or "Associates" (as such terms are defined in Rule
12b-2 under the Exchange Act) has Beneficial Ownership of any Company Common
Stock or other securities of the Company or any of its Subsidiaries, except as
contemplated by this Agreement and except for any securities that may be owned
by any employee benefit plan or other benefit plan administered by or on
behalf of Parent or any of its Subsidiaries. Neither Parent nor Merger Sub nor
any of their respective affiliates is or has been within the last three (3)
years an "interested stockholder" (as defined in Section 203 of the DGCL) of
the Company.

  

  

Section 5.9 Litigation. (a) There is no claim, suit, action or proceeding
pending or, to the knowledge of Parent, threatened against Parent or any of
its Subsidiaries or any of their respective assets or properties, (b) there is
no Judgment outstanding against Parent or any of its Subsidiaries or any of
their respective assets and (c) Parent has not received any written
notification of, and to the knowledge of Parent there is no, investigation by
any Governmental Entity involving Parent or any of its Subsidiaries or any of
their respective assets that, in the case of each of clauses (a), (b) and (c),
individually or in the aggregate, would reasonably be expected to prevent,
materially impede or materially delay the consummation of the Offer, the
Merger or the other transactions contemplated by this Agreement.

  

  

Section 5.10 Brokers and Other Advisors. No broker, investment banker,
financial advisor or other Person (other than Lazard Freres and Co. LLC and
Morgan Stanley and Co. International Plc), the fees and expenses of which will
be paid by Parent, is entitled to any broker's, finder's, financial advisor's
or other similar fee or commission in connection with this Agreement and the
transactions contemplated hereby based upon arrangements made by or on behalf
of Parent or Merger Sub.

  

  

ARTICLE VI

  

  

COVENANTS RELATING TO CONDUCT OF BUSINESS

  

  

Section 6.1 Conduct of Business.

  

  

(a) Conduct of Business by the Company. During the period from the date of
this Agreement to the Effective Time, except (i) with the prior written
consent of Parent (which

  

  

 

 

 

  

 

43  

  

 

 

 

  

  

consent shall not be unreasonably withheld, conditioned or delayed), (ii) as
may be required by applicable Law (including the rules of NASDAQ), (iii) as
specifically contemplated or permitted by this Agreement or (iv) as set forth
in Section 6.1(a) of the Company Disclosure Schedule, the Company shall, and
shall cause each of its Subsidiaries to, (A) carry on its respective
businesses in the ordinary course, including by using commercially reasonable
efforts to continue current plans to develop subcutaneous and low-volume
intravenous formulations of Cinryze, (B) comply in all material respects with
all applicable Laws, all Permits and all Material Contracts, (C) use its
commercially reasonable efforts to keep available the services of its present
officers and other employees, (D) use its commercially reasonable efforts to
maintain in effect all of its foreign, federal, state and local licenses,
permits, consents, franchises, approvals and authorizations, (E) use its
commercially reasonable efforts to cause the Company's auditors to complete
their audit for the year ending December 31, 2013 in a timely manner
consistent with past practice and, at the request of Parent, to perform a
review of the consolidated interim financial statements of the Company for any
period beginning thereafter and (F) use its commercially reasonable efforts to
maintain its relationships with its customers, lenders, suppliers, insurers
and others having significant business relationships with it. Further, during
the period from the date of this Agreement to the Effective Time, except (1)
with the prior written consent of Parent (which consent shall not be
unreasonably withheld, conditioned or delayed), (2) as may be required by
applicable Law (including the rules of NASDAQ), (3) as specifically
contemplated by this Agreement or (4) as set forth in Section 6.1(a) of the
Company Disclosure Schedule, the Company shall not, and shall not permit any
of its Subsidiaries to:

  

  

(i) (A) declare, set aside or pay any dividends on, or make any other
distributions (whether in cash, property, stock or other securities) in
respect of, any of its capital stock or other equity or voting interests,
except for dividends by a direct or indirect wholly owned Subsidiary of the
Company to its parent, (B) split, combine or reclassify any of its capital
stock or other equity or voting interests, or issue or authorize the issuance
of any other securities in respect of, in lieu of or in substitution for
shares of its capital stock or other equity or voting interests or (C)
purchase, redeem or otherwise acquire any shares of capital stock or any other
securities of the Company or any of its Subsidiaries or any options, warrants,
calls or rights to acquire any such shares or other securities (except
pursuant to the forfeiture of Company Stock Options, Company RSUs or Company
PSUs or the acquisition by the Company of shares of Company Common Stock in
settlement of the exercise price of Company Stock Options or Company Hedge
Options (in each case, that are outstanding on the date hereof in accordance
with their terms on the date hereof) or the Tax withholding obligations in
respect of Company Stock Options, Company RSUs or Company PSUs);

  

  

(ii) issue, deliver, sell, promise, pledge or otherwise encumber any shares of
its capital stock, any other equity or voting interests or any securities
convertible into, or exchangeable or exercisable for, or any options,
warrants, calls or rights to acquire, any such stock, interests or securities
or any stock appreciation rights, restricted stock units, stock-based
performance units, "phantom" stock awards or other rights that are linked to
the value of Company Common Stock or the value of the Company or any part
thereof; provided, however, that the Company may issue shares of Company
Common Stock (A) pursuant to the exercise of Company Stock Options, the
exercise of purchase rights under the Purchase Plan,

  

  

 

 

 

  

 

44  

  

 

 

 

  

  

the settlement of Company RSUs or Company PSUs, in each case, that are
outstanding on the date hereof in accordance with their terms on the date
hereof; (B) upon the conversion of the Convertible Notes that are outstanding
on the date hereof in accordance with their terms on the date hereof; and (C)
upon the exercise of the Call-Spread Warrants that are outstanding on the date
hereof in accordance with their terms on the date hereof;

  

  

(iii) amend the Company Charter or the Company Bylaws or other comparable
charter or organizational documents of any of the Company's Subsidiaries;

  

  

(iv) acquire or agree to acquire any assets, securities or properties
(including, whether by merging or consolidating with, or by purchasing all or
a substantial portion of the assets of, or by purchasing all or a substantial
equity or voting interest in, or by any other manner, any Person or business
or division thereof), other than supplies or inventory in the ordinary course
of business consistent with past practice;

  

  

(v) sell, lease, license, sell and lease back, mortgage or otherwise subject
to any Lien (other than Permitted Liens) or otherwise dispose of, abandon or
permit to lapse any of its properties or assets (including any shares of
capital stock, equity or voting interests or other rights, instruments or
securities, and Intellectual Property Rights), except for (A) sales of
inventory or obsolete equipment in the ordinary course of business consistent
with past practice; (B) sales of properties or assets in the ordinary course
of business with a sale price that does not exceed $500,000 individually or
$1,000,000 in the aggregate; and (C) transfers among the Company and its
Subsidiaries in the ordinary course of business consistent with past practice
and that (x) are not and would not reasonably be expected to be, individually
or in the aggregate, material to the Company and its Subsidiaries (including
with respect to Taxes), and (y) are not otherwise prohibited by Section
6.1(b);

  

  

(vi) (A) incur, create or assume any indebtedness for borrowed money,
including by way of a guarantee or an issuance or sale of debt securities
(other than short-term borrowings in an amount not to exceed $1,000,000 in the
aggregate incurred in the ordinary course of business consistent with past
practice to finance the Company's and its Subsidiaries' working capital needs)
or issue and sell options, warrants, calls or other rights to acquire any debt
securities of the Company or any of its Subsidiaries or (B) make any loans,
advances or capital contributions to, or investments in, any other Person,
other than the Company or any direct or indirect wholly owned Subsidiary of
the Company, and except for advances to employees in respect of travel or
other related ordinary expenses, in each case in the ordinary course of
business consistent with past practice;

  

  

(vii) incur or commit to incur any capital expenditures, or any obligations or
liabilities in connection therewith, other than (A) those set forth in

  

  

 

 

 

  

 

45  

  

 

 

 

  

  

Section 6.1(a)(vii) of the Company Disclosure Schedule or (B) other capital
expenditures that do not exceed $500,000 individually or $1,000,000 in the
aggregate;

  

  

(viii) pay, discharge, settle or satisfy (or cause any insurer to pay,
discharge, settle or satisfy), or offer to pay, discharge, settle or satisfy,
(A) any claims of stockholders or any stockholder litigation relating to this
Agreement or any transaction contemplated by this Agreement or otherwise, (B)
any litigation, investigation, arbitration, proceeding or other claim,
including with respect to the matters listed on Section 4.11 of the Company
Disclosure Schedule, other than for an amount not to exceed $500,000
individually or $1,000,000 in the aggregate; provided, that such payment,
discharge, settlement or satisfaction thereof (1) includes an express and
unconditional release of the Company and its Subsidiaries and their respective
officers and directors with respect thereto and (2) does not provide for any
remedies other than money damages or (C) any other liabilities or obligations
(whether absolute, accrued, asserted or unasserted, contingent or otherwise),
other than, in the case of this clause (C), the payment, discharge, settlement
or satisfaction in the ordinary course of business consistent with past
practice, or as required by their terms as in effect on the date of this
Agreement, of claims, liabilities or obligations reserved against in the
Company's most recent financial statements (including the notes thereto)
included in the Filed Company SEC Documents (for amounts not in excess of such
reserves) or incurred since the date of such financial statements in the
ordinary course of business consistent with past practice, other than the fees
and expenses of the Company Financial Advisor and other transaction costs
related to this Agreement and the transactions contemplated hereunder;

  

  

(ix) (A) enter into any Material Contract or a Contract that would be a
Material Contract if it had been entered into prior to the date hereof
(including by amending of any Contract such that such Contract becomes a
Material Contract), (B) modify or amend in any material respect any Material
Contract, (C) waive, release, assign or fail to exercise or pursue any
material rights or claims under any Material Contract or (D) accelerate,
terminate or cancel any Material Contract;

  

  

(x) (A) increase the compensation or benefits payable or to become payable,
grant any severance, termination or retention pay, or pay or award any
pension, retirement allowance or other equity or non-equity incentive awards
to, or discretionarily accelerate the vesting or payment of any equity award
held by, any current or former Service Provider, (B) amend or modify any
Employee Plan or adopt or enter into any employee benefit plan, agreement or
arrangement that would be an Employee Plan if in effect on the date hereof,
(C) make any loans to any current or former Service Provider or (D) hire any
employee at a rate of base compensation exceeding $100,000, except, in the
case of clauses (A), (B) and (C), (I) as required by applicable Law or any
Contract entered into prior to the date hereof, (II) as required by the terms
of any Employee Plan or (III) for any employee who is not a director or
officer of the Company and whose base salary does not

  

  

 

 

 

  

 

46  

  

 

 

 

  

  

exceed $100,000, an increase in base compensation or broad-based benefits in
the ordinary course of business consistent with past practice; provided, that,
in no event will the Company be permitted to grant any equity incentive awards
during the period from the date of this Agreement to the Effective Time;

  

  

(xi) form any Subsidiary of the Company;

  

  

(xii) adopt or enter into any collective bargaining agreement or other labor
union Contract applicable to the employees of the Company or any of its
Subsidiaries; provided, however, the Company and its Subsidiaries shall be
permitted to form employee representative bodies and works councils in
accordance with applicable Law;

  

  

(xiii) subject to Section 6.2, enter into, approve or recommend (or propose
publicly to approve or recommend), or permit any of the Company's Subsidiaries
to enter into, any agreement requiring, or reasonably be expected to cause,
the Company to abandon, terminate, delay or fail to consummate, or that would
otherwise impede, interfere or be inconsistent with, the Offer, the Merger or
any of the other transactions contemplated by this Agreement or requiring, or
reasonably expected to cause, the Company to fail to comply with this
Agreement;

  

  

(xiv) adopt a plan of complete or partial liquidation, dissolution, merger,
consolidation, restructuring, recapitalization or other reorganization of such
entity;

  

  

(xv) change the Company's methods of accounting, except as required by
concurrent changes in GAAP or in Regulation S-X under the Exchange Act, as
agreed to by its independent public accountants;

  

  

(xvi) fail to use commercially reasonable efforts to maintain existing
insurance policies or comparable replacement policies to the extent available
for a reasonable cost;

  

  

(xvii) subject to Section 6.2, take any action intended to result in any of
the Offer Conditions set forth on Exhibit A or to the Merger set forth in
Article VIII not being satisfied or intended to prevent, delay or impair the
ability of the Company to consummate the Merger; or

  

  

(xviii) authorize any of, or commit, resolve or agree to take any of, the
foregoing actions.

  

  

(b) Certain Tax Matters. During the period from the date of this Agreement to
the Effective Time, except (i) as required by applicable Tax Law, (ii) with
Parent's prior written consent or (iii) as set forth in Section 6.1(b) of the
Company Disclosure Schedule, neither the Company nor any of its Subsidiaries
will make or change any material Tax election, change any annual Tax
accounting period, adopt or change any method of Tax accounting, amend any
material Tax Return, claim any material Tax refund, enter into any closing
agreement relating to

  

  

 

 

 

  

 

47  

  

 

 

 

  

  

any material Tax, commence or enter into any advance pricing agreement,
execute (in whole or in part) any material Tax planning, undertake any
material correspondence relating to any advance pricing agreement, change any
policies relating to transfer pricing, settle or compromise any material Tax
claim, audit or assessment, surrender any right to claim a material Tax
refund, offset or other reduction in Tax liability, or consent to any
extension of waiver of the statute of limitations period applicable to any
material Tax claim or assessment.

  

  

(c) Conduct of Business by Parent and Merger Sub. During the period from the
date of this Agreement to the Closing Date, each of Parent and Merger Sub
agrees that it, and its respective Affiliates, shall not engage in any
business combination, including an asset acquisition, that would reasonably be
expected to result in any of the Offer Conditions set forth in Exhibit A or
any of the conditions to the Merger set forth in Article VIII not being
satisfied prior to the Termination Date.

  

  

(d) No Control of the Company's Business. The Company, on the one hand, and
Parent and Merger Sub on the other, acknowledge and agree that: (i) nothing
contained in this Agreement shall give Parent or Merger Sub, directly or
indirectly, the right to control or direct the Company's or its Subsidiaries'
operations prior to the Offer Closing, (ii) prior to the Offer Closing, the
Company shall exercise, consistent with the terms and conditions of this
Agreement, complete control and supervision over its and its Subsidiaries'
respective operations and (iii) notwithstanding anything to the contrary set
forth in this Agreement, no consent of Parent or Merger Sub shall be required
with respect to any matter set forth in Section 6.1(a) or Section 6.1(b) or
elsewhere in this Agreement to the extent the requirement of such consent
would be inconsistent with applicable Law.

  

  

Section 6.2 No Solicitation.

  

  

(a) Subject to this Section 6.2(a), from the date of this Agreement to the
earlier of the Effective Time or the date on which this Agreement is
terminated pursuant to Section 9.1, the Company shall not, nor shall it permit
any of its controlled Affiliates to, nor shall it authorize or permit any of
its or its controlled Affiliates' directors, officers, employees, investment
bankers, attorneys, accountants or other advisors or representatives
(collectively, "Representatives") to, directly or indirectly, (i) solicit,
initiate, propose or knowingly encourage, or take any other action to
knowingly facilitate, any Takeover Proposal or any inquiries or offers or the
making of any proposal or any other efforts or attempt that could reasonably
be expected to lead to a Takeover Proposal or (ii) enter into, continue or
otherwise knowingly participate in any communications or negotiations
regarding, or furnish to any Person any information with respect to, or
otherwise knowingly cooperate in any way with any Person with respect to, any
Takeover Proposal or any inquiries or offers or the making of any proposal or
any other efforts or attempt that could reasonably be expected to lead to a
Takeover Proposal. The Company shall, and shall cause its Subsidiaries and
direct its Representatives to, immediately cease and cause to be terminated
all existing communications and negotiations with any Person conducted
heretofore with respect to any Takeover Proposal and shall request the prompt
return or destruction of all confidential information previously furnished in
connection therewith. Notwithstanding anything in this Agreement to the
contrary, if, at any time prior to the Offer Closing, the Company, in response
to a bona fide written Takeover Proposal received after the

  

  

 

 

 

  

 

48  

  

 

 

 

  

  

date hereof and provided, that the Board of Directors of the Company
determines in good faith (after consultation with its outside legal counsel
and financial advisor) that (A) such Takeover Proposal constitutes or could
reasonably be expected to lead to a Superior Proposal and (B) failure to
respond to such Takeover Proposal would be inconsistent with its fiduciary
duties to the stockholders of the Company under applicable Law, and which
Takeover Proposal did not result from a breach of this Section 6.2(a), may,
and may permit and authorize its Affiliates and its and its Affiliates'
Representatives to, in each case subject to compliance with the provisions of
this Agreement, (I) furnish information with respect to the Company and its
Subsidiaries to the Person making such Takeover Proposal (and its
Representatives and financing sources) pursuant to a confidentiality agreement
which contains terms with respect to the maintenance of confidentiality and
restrictions on use of Company information that are no less favorable to the
Company than those contained in the Confidentiality Agreement (it being
understood that such confidentiality agreement need not contain a standstill
provision) and (II) participate in discussions or negotiations with the Person
making such Takeover Proposal (and its Representatives) regarding such
Takeover Proposal; provided, that the Company shall concurrently provide or
make available to Parent any information concerning the Company or its
Subsidiaries provided to such third party which was not previously provided to
Parent, and the Company shall not take any of the actions referred to in the
foregoing clause (I) or (II) unless it shall have delivered to Parent a prior
written notice advising Parent that it intends to take such action. In
addition, the Company shall notify Parent promptly (but in no event later than
forty-eight (48) hours) after receipt by the Company (or any of its
Representatives) of any Takeover Proposal or any request for information
relating to the Company or any of its Subsidiaries or for access to the
business, properties, assets, books or records of the Company or any of its
Subsidiaries by any third party with respect to a Takeover Proposal. The
Company shall (i) provide the identity of the third party making any such
Takeover Proposal, indication or request (to the extent disclosure of the
identity of such third party is not otherwise prohibited by the Company's
confidentiality obligations to third parties in effect prior to the date
hereof) and the terms and conditions of any such Takeover Proposal, indication
or request, (ii) keep Parent reasonably informed, on a reasonably prompt and
timely basis, of the status and details of any such Takeover Proposal,
indication or request and (iii) promptly (but in no event later than forty-
eight (48) hours after receipt) advise Parent of any changes to the material
terms of such Takeover Proposal, indication or request.

  

  

For purposes of this Agreement, the term "Takeover Proposal" means any
proposal, inquiry or offer (whether or not in writing) from any Person (other
than Parent or Merger Sub or any of their Affiliates) with respect to, in a
single transaction or series of transactions, any (i) merger, consolidation,
share exchange, other business combination or similar transaction involving
the Company, (ii) sale, lease, contribution or other disposition, directly or
indirectly (including by way of merger, consolidation, share exchange, other
business combination, partnership, joint venture, sale of capital stock of or
other equity interests in a Subsidiary of the Company or otherwise), of any
business or asset or assets of the Company or any of its Subsidiaries
representing 20% or more of the consolidated net income, revenues or assets
(whether determined by reference to book value or fair market value) of the
Company and its Subsidiaries, taken as a whole, (iii) issuance, sale or other
disposition, directly or indirectly, to any Person (or the stockholders or
owners of any Person) or "group" (as defined under Section 13(d) of the
Exchange Act) of securities (or options, rights or warrants to purchase, or
securities

  

  

 

 

 

  

 

49  

  

 

 

 

  

  

convertible into or exchangeable for, such securities) or any interest in such
securities representing 20% or more of the outstanding shares of Company
Common Stock or of the voting power of the Company's capital stock, (iv)
transaction in which any Person (or the stockholders of any Person) shall
acquire, directly or indirectly, Beneficial Ownership, or the right to acquire
Beneficial Ownership, or formation of any "group" (as defined under Section
13(d) of the Exchange Act) which beneficially owns or has the right to acquire
Beneficial Ownership of, 20% or more of the outstanding shares of Company
Common Stock or of the voting power of the Company's capital stock or (v)
combination of the foregoing.

  

  

For purposes of this Agreement, the term "Superior Proposal" means any bona
fide written offer, which was not solicited after the date hereof and did not
result from a breach of Section 6.2(a), made by any Person (other than Parent
or Merger Sub or any of their Affiliates) that, if consummated, would result
in such Person (or in the case of a direct merger between such Person and the
Company, the stockholders of such Person) acquiring, directly or indirectly,
more than 50% of the outstanding shares of Company Common Stock or of the
voting power of the Company's capital stock or all or substantially all the
assets of the Company and its Subsidiaries, taken as a whole, and which offer
the Board of Directors of the Company reasonably determines in good faith
(after consultation with its outside legal counsel and financial advisor) (i)
provides a higher value from a financial point of view to the stockholders of
the Company than the consideration payable in the Offer and the Merger (taking
into account all of the terms and conditions of such proposal and this
Agreement, as well as any proposal by Parent to amend the terms of this
Agreement pursuant to Section 6.2(d)), (ii) is reasonably likely to be
completed in a timely fashion, taking into account the conditionality and
likelihood of consummation and all financial, legal, regulatory and other
aspects of such proposal and (iii) if a cash transaction (whether in whole or
in part), for which the consideration is fully committed or reasonably
determined by the Board of Directors of the Company to be available.

  

  

(b) Neither the Board of Directors of the Company nor any committee thereof
shall (i) withhold, withdraw (or not continue to make), change, qualify or
modify in a manner adverse to Parent or Merger Sub, or propose publicly to
withhold, withdraw (or not continue to make), change, qualify or modify in a
manner adverse to Parent or Merger Sub, the Company Recommendation or any
approval or recommendation by any such committee regarding this Agreement, the
Offer and the Merger, or approve or recommend, or propose publicly to approve
or recommend any Takeover Proposal, or resolve or agree to take any such
action, (ii) fail to include the Company Recommendation in the Schedule 14D-9,
(iii) approve or recommend, or propose publicly to approve, recommend or
permit the Company or any of its Affiliates to enter into, any letter of
intent, memorandum of understanding, agreement in principle, acquisition
agreement, merger agreement, option agreement, joint venture agreement,
partnership agreement or other agreement constituting or related to, or which
is intended to or is reasonably likely to lead to, any Takeover Proposal
(other than a confidentiality agreement in accordance with Section 6.2(a)),
(iv) fail to enforce or grant any waiver or release under any standstill or
similar agreement with respect to any class of equity securities of the
Company or any of its Subsidiaries unless the Board of Directors of the
Company determines after consulting with its outside legal counsel that the
failure to waive such provision would be inconsistent with its fiduciary
duties under Applicable Law; provided, that the Company shall not enforce and
hereby waives any provision of any such agreement that would prohibit a third
party from communicating

  

  

 

 

 

  

 

50  

  

 

 

 

  

  

confidentially an Acquisition Proposal to the Company's Board of Directors or
(v) approve any transaction under, or any Person becoming an "interested
stockholder" under, Section 203 of the DGCL (any such action or resolution or
agreement to take such action in clauses (i) - (ii) above being referred to
herein as an "Adverse Recommendation Change"). It is agreed that any violation
of the restrictions on the Company set forth in this Section 6.2 by any
officer or director of the Company (or any other Representative of the Company
that is authorized, intentionally sanctioned or intentionally caused by the
Company) shall be deemed a breach of this Section 6.2 by the Company.
Notwithstanding the foregoing and anything in this Agreement to the contrary,
but subject to Section 6.2(d), at any time prior to the Offer Closing, the
Board of Directors of the Company may, following receipt of a Superior
Proposal received after the date hereof and after determining in good faith,
after consultation with its outside legal counsel and financial advisor, that
the failure to take such action would be inconsistent with its fiduciary
duties to the stockholders of the Company under applicable Law, (A) effect an
Adverse Recommendation Change or (B) cause the Company to terminate this
Agreement in accordance with Section 9.1(h) in order to enter into a binding
agreement providing for such Superior Proposal; provided, that immediately
before and as a condition to any such termination, the Company pays to Parent
the fee required by Section 9.3(b).

  

  

(c) Notwithstanding anything to the contrary contained herein, but subject to
Section 6.2(d), the Board of Directors of the Company may, at any time prior
to the Offer Closing, effect an Adverse Recommendation Change for a reason
unrelated to a Takeover Proposal (it being understood and agreed that any
Adverse Recommendation Change proposed to be made in relation to a Takeover
Proposal may only be made pursuant to and in accordance with the terms of
Section 6.2(a) and (b)) if the Board of Directors of the Company has
determined in good faith, after consultation with its outside legal counsel,
that, in light of material facts, events or circumstances that have developed
since the date of this Agreement that were not known or reasonably foreseeable
to the Company prior to the date hereof, the failure to take such action would
be inconsistent with the fiduciary duties owed by the Board of Directors of
the Company to the stockholders of the Company under applicable Law.

  

  

(d) The Board of Directors of the Company shall not make an Adverse
Recommendation Change pursuant to Section 6.2(b) or Section 6.2(c) (or
terminate this Agreement pursuant to Section 9.1(h)), unless (i) if such
Adverse Recommendation Change is to be made in relation to a Takeover
Proposal, such Takeover Proposal constitutes a Superior Proposal, (ii) the
Company promptly provides written notice to Parent at least four (4) Business
Days before taking such action of its intention to do so and containing (1) in
the case of any action intended to be taken in relation to a Takeover
Proposal, the material terms of such Takeover Proposal, including the most
current version of the proposed agreement under which such Takeover Proposal
is proposed to be consummated and the identity of the Person making the
Takeover Proposal (to the extent disclosure of the identity of such third
party is not otherwise prohibited by the Company's confidentiality obligations
to third parties in effect prior to the date hereof) or (2) in the case of any
action intended to be taken in circumstances not involving or relating to a
Takeover Proposal, a reasonably detailed description of the underlying facts
giving rise to, and the reasons for taking, such action and (iii) Parent does
not make, within four (4) Business Days after its receipt of that written
notification, an offer that (1) in the case of any action intended to be taken
in relation to a Takeover Proposal causes the Takeover Proposal, as

  

  

 

 

 

  

 

51  

  

 

 

 

  

  

determined by the Company's Board of Directors in good faith, after
consultation with its outside legal counsel and financial advisor, to no
longer constitute a Superior Proposal, or (2) in the case of any action
intended to be taken in circumstances not involving or relating to a Takeover
Proposal, obviates, in the good faith view of the Company's Board of
Directors, after consultation with its outside legal counsel, the need for
such Adverse Recommendation Change. It is understood that in the case of any
action intended to be taken in relation to a Takeover Proposal, any amendment
to the financial terms or other material terms of such Takeover Proposal shall
require a new written notification from the Company under this Section 6.2(d),
except that the Company's advance written notice obligation shall be reduced
to forty-eight (48) hours (rather than the four (4) Business Days otherwise
contemplated by the immediately preceding sentence). The Company agrees that,
during any four (4)-Business Day or forty-eight (48)-hour period, as
applicable, referred to in this Section 6.2(d), the Company and its
Representatives shall negotiate in good faith with Parent and its
Representatives regarding any revisions proposed by Parent to the terms of the
transactions contemplated by this Agreement.

  

  

(e) Nothing contained in this Section 6.2 or elsewhere in this Agreement shall
prohibit the Company from (i) taking and disclosing to the stockholders of the
Company a position contemplated by Rule 14d-9 (including Item 1012(a) of
Regulation MA promulgated under the Exchange Act) and Rule 14e-2(a)
promulgated under the Exchange Act and (ii) making any disclosure to its
stockholders if, in the good faith judgment of the Board of Directors of the
Company (after consultation with outside legal counsel), (A) failure to so
disclose would be inconsistent with its fiduciary duties under applicable Law
or (B) such disclosure is required under the federal securities Laws;
provided, however, that the taking of any such position or making of any such
disclosure or statement (other than a "stop, look and listen" letter or
similar communication contemplated by Rule 14d-9(f) under the Exchange Act)
shall be subject to and only taken in compliance with Section 6.2(b), Section
6.2(c) and Section 6.2(d), as applicable.

  

  

(f) Nothing contained in this Section 6.2 shall prohibit the Company from
responding to any unsolicited proposal or inquiry solely by advising the
Person making such proposal or inquiry of the terms of this Section 6.2.

  

  

ARTICLE VII 
 

  

  

ADDITIONAL AGREEMENTS

  

  

Section 7.1 Access to Information; Confidentiality.

  

  

(a) Prior to the Closing Date, the Company shall, and shall cause each of its
Subsidiaries to, afford to Parent and to Parent's Representatives reasonable
access upon reasonable advance notice and during normal business hours to all
their respective properties, assets, books, records, Contracts, Permits,
documents, information, directors, officers and employees, but only to the
extent that such access does not unreasonably interfere with the business or
operations of the Company and its Subsidiaries, and the Company shall, and
shall cause each of its Subsidiaries to, furnish to Parent any information
concerning its business, assets, liabilities, employees and other aspects of
the Company and its Subsidiaries as Parent may reasonably request, including
information concerning the Company's compliance with its obligations under
clause (A) of Section 6.1(a) related to the development of subcutaneous and
low-volume intravenous formulations of Cinryze (and the Company shall keep
Parent reasonably informed on a reasonably current basis, and consider in good
faith Parent's views, with respect thereto); provided, however, that the
Company shall not be required to (or to cause

  

  

 

 

 

  

 

52  

  

 

 

 

  

  

any of its Subsidiaries to) afford such access or furnish such information to
the extent that doing so is restricted under applicable Law or otherwise would
result in the loss of attorney-client privilege (provided, that the Company
shall use its reasonable efforts to allow for such access or disclosure in a
manner that does not result in a loss of attorney-client privilege) or is
restricted pursuant to any confidentiality agreement or similar agreement or
arrangement to which the Company or any Company Subsidiary is a party (which
such person shall use commercially reasonable efforts to cause such
counterparty thereto to waive) and provided, further, that any such access or
disclosure shall be conducted at Parent's expense during normal business hours
and shall be subject to supervision by the Company's or the applicable
Subsidiary's personnel. Notwithstanding anything to the contrary herein, (i)
Parent and Merger Sub shall not be permitted prior to the Closing Date to
contact any of the Company's or its Subsidiaries' vendors, customers,
suppliers, contract counterparties, joint venture partners or, other than as
expressly contemplated by this Agreement, Governmental Entities regarding the
operations of the Company or its Subsidiaries without receiving the prior
written consent of the Company, which will not be unreasonably withheld and
(ii) prior to the Closing Date, Parent and Merger Sub shall not have the right
to conduct any environmental testing, sampling or analysis at, on, under or
from any real property of the Company or its Subsidiaries.

  

  

(b) Parent will hold, and will direct its Representatives to hold, any and all
information received from the Company confidential in accordance with the
Confidentiality Agreement.

  

  

Section 7.2 Reasonable Best Efforts.

  

  

(a) Each party from whom a filing under the HSR Act would be required in order
for the transactions contemplated hereby to be consummated lawfully shall, as
promptly as practicable (but in no event later than ten (10) Business Days)
following the date hereof, file with the Federal Trade Commission (the "FTC")
and the Antitrust Division of the United States Department of Justice (the
"DOJ") all materials initially required to be filed under the HSR Act in
connection with this transaction ("HSR Filing"). As promptly as practicable
following the date hereof, each party shall make all other filings necessary
or appropriate under any other applicable foreign Competition Law in
connection with the transactions contemplated hereby (including submitting a
draft application for the approval of the transaction to the UK Office of Fair
Trading ("OFT") no later than two (2) Business Days following the date
hereof). To the extent permitted by applicable Law, the parties hereto shall
request expedited treatment of any such filings, furnish to one another such
necessary information and reasonable assistance as the other may require in
connection with its preparation of such filings, and give each other advance
notice of and a meaningful opportunity to review, and take into account each
other's reasonable comments with respect to, such filings. Neither Parent nor
the Company shall voluntarily withdraw its respective HSR Filing without the
prior written consent of the other party. After any filing or submission under
the HSR Act or other Competition Law, to the extent permitted by applicable
Law, the parties hereto shall keep one another apprised of the status of, and
give each other advance notice of, and a meaningful opportunity to review and
take into account each other's reasonable comments, all communications with,
and all inquiries or requests for additional information from, the FTC, the
DOJ or any other applicable Governmental Entity, and shall comply promptly
with any such reasonable inquiry or request. To the extent permitted by the
relevant Governmental Entity, the parties hereto shall give each other advance
notice of and permit each other to attend all in-

  

  

 

 

 

  

 

53  

  

 

 

 

  

  

person or telephonic meetings or conferences between one or more of the
parties hereto and one or more Governmental Entity under the HSR Act or other
Competition Law.

  

  

(b) Upon the terms and subject to the conditions set forth in this Agreement,
each of the parties hereto agrees to use its reasonable best efforts to take,
or cause to be taken, all actions that are necessary, proper or advisable
under applicable Laws and regulations to consummate and make effective the
Offer, the Merger and the other transactions contemplated by this Agreement,
including using its reasonable best efforts to accomplish the following: (i)
the satisfaction of the conditions precedent set forth in Exhibit A and
Article VIII, (ii) the obtaining of all necessary actions or nonactions,
waivers, consents, approvals, clearances, orders and authorizations from, and
the giving of any necessary notices to, Governmental Entities and other
Persons, (iii) the taking of all reasonable steps to provide any supplemental
information requested by a Governmental Entity, including participating in
meetings with officials of such entity in the course of its review of this
Agreement, the Offer, the Merger or the other transactions contemplated by
this Agreement, and (iv) the execution and delivery of any additional
instruments necessary to consummate and make effective the Offer, the Merger
and the other transactions contemplated by this Agreement. In connection with
and without limiting the generality of the foregoing, each of the Company and
its Board of Directors shall, if any state takeover statute or similar statute
or regulation is or becomes applicable to this Agreement or any of the Offer,
the Merger and the other transactions contemplated by this Agreement, use its
reasonable best efforts to ensure that the Offer, the Merger and the other
transactions contemplated by this Agreement may be consummated as promptly as
practicable on the terms contemplated hereby and otherwise to minimize the
effect of such statute or regulation on this Agreement, the Offer, the Merger
and the other transactions contemplated by this Agreement.

  

  

(c) In furtherance and not in limitation of the foregoing, if any objections
are asserted with respect to the Offer, the Merger or any other transaction
contemplated hereby under any Competition Law or if any suit is instituted (or
threatened to be instituted) by the FTC, the DOJ or any other applicable
Governmental Entity or any private party, challenging the Offer, the Merger or
any of the transactions contemplated hereby as violative of any Competition
Law, or which would otherwise prohibit or materially impair or materially
delay the consummation of the transactions contemplated hereby, each of
Parent, Merger Sub and the Company shall use reasonable best efforts to
resolve any such objections or suits so as to permit consummation of the
transactions contemplated by this Agreement as expeditiously as reasonably
practicable; in this context, "reasonable best efforts" shall include, without
limitation, (i) defending any lawsuits or other legal proceedings, whether
judicial or administrative, that challenge this Agreement, the Offer, or the
consummation of the Merger or any other transaction contemplated hereby; (ii)
seeking to have lifted, vacated or reversed any stay, injunction, temporary
restraining order, or other restraint entered by any court or other
Governmental Entity; (iii) divesting, disposing of, or transferring any assets
or entities; (iv) granting licenses; (v) entering into hold-separate
agreements; (vi) making commitments as to future conduct or operations; and
(vii) agreeing to do or permitting to be done any of the foregoing; provided,
however, that notwithstanding anything to the contrary in this Agreement, (A)
Parent and its Subsidiaries shall not be required to take any of the actions
described in the foregoing clauses (iii) through (vii) (insofar as clause
(vii) relates to the foregoing clauses (iii) through (vi)) (x) with respect to
Firazyr or Cinryze (including any alternative low volume formulation of
Cinryze or any formulation utilizing

  

  

 

 

 

  

 

54  

  

 

 

 

  

  

subcutaneous administration) or (y) to the extent that such action or actions
unrelated to Firazyr or Cinryze (including any alternative low volume
formulation of Cinryze or any formulation utilizing subcutaneous
administration) would reasonably be expected to be, individually or in the
aggregate, materially adverse to the Company (and its Subsidiaries) and Parent
(and its Subsidiaries), taken as a whole (provided, that, for such purposes,
impacts on Parent, the Company or any of their respective Subsidiaries will be
aggregated) (any such action described in this clause (A), a "Burdensome
Condition") and (B) neither the Company nor any of its Subsidiaries nor Parent
nor any of its Subsidiaries or Affiliates shall be obligated to, and the
Company shall not without Parent's prior written consent, become subject to,
or consent or agree to or otherwise take any action with respect to, any
requirement, condition, understanding, agreement or order of a Governmental
Entity to sell, hold separate, divest, dispose of or transfer any assets,
grant any license or conduct or change its business unless such requirement,
condition, understanding, agreement or order is binding on the Company or any
of its Subsidiaries or on Parent or any of its Subsidiaries or Affiliates, as
the case may be, only in the event the Offer Closing occurs.

  

  

(d) Notwithstanding anything in this Agreement to the contrary, to the extent
permitted by applicable Law, Parent shall control and lead all communications,
defense, litigation, negotiations and strategy relating to the HSR Act or any
other Competition Law relating to any of the transactions contemplated hereby;
provided, that, subject to Section 7.2(a), each Party shall be responsible for
and control its HSR Filing, its filing with OFT, if any, and its responses to
Governmental Entities with respect to such filings; and provided, further,
that Parent shall consult with and consider in good faith the comments of the
Company in connection with any such communication, defense, litigation,
negotiation or strategy relating to the HSR Act or any other Competition Law
and, to the extent reasonably practicable and to the extent permitted by
applicable Law, shall give the Company the opportunity to attend and
participate in any meeting or conference with any Governmental Entity or, in
connection with any proceeding by a private party, with any other Person
relating to the HSR Act or any other Competition Law regarding any of the
transactions contemplated hereby.

  

  

(e) Without limiting the foregoing, the Company shall give Parent the
opportunity to participate in the defense of any litigation against the
Company and/or its directors, officers, employees, advisors or agents relating
to the Offer, the Merger or the other transactions contemplated by this
Agreement, and will obtain the prior written consent of Parent prior to
settling or satisfying, or offering to settle, any such claim, it being
understood and agreed that the Company shall control such defense and that
this Section 7.2(e) shall not give Parent the right to direct such defense,
except to the extent that Parent or Merger Sub is named as a defendant in such
litigation and in that case solely as to the defense of Parent and Merger Sub.

  

  

Section 7.3 Notification of Certain Matters. Each party hereto shall promptly
notify the other party hereto of (a) its discovery of any occurrence, or non-
occurrence, of any event that would be likely to cause any condition to the
obligations of any party to effect the Offer, the Merger or any other
transaction contemplated by this Agreement not to be satisfied; (b) any
written notice or other written communication from any Person alleging that
the consent of such Person is required in connection with the Offer, the
Merger or any of the other transactions contemplated by this Agreement; (c)
any suits, actions or proceedings commenced or threatened

  

  

 

 

 

  

 

55  

  

 

 

 

  

  

that relate to the consummation of this Agreement, the Offer, the Merger or
any of the other transactions contemplated by this Agreement of which such
party has Knowledge; and (d) the failure of the Company or Parent, as the case
may be, to comply with or satisfy any covenant, condition or agreement to be
complied with or satisfied by it pursuant to this Agreement which would
reasonably be expected to result in any condition to the obligations of any
party to effect the Offer, the Merger or any other transaction contemplated by
this Agreement not to be satisfied; provided, however, that the delivery of
any notice pursuant to this Section 7.3 shall not cure any breach of any
representation, warranty, obligation, covenant or agreement contained in this
Agreement or otherwise limit or affect the remedies available hereunder to the
party receiving such notice.

  

  

Section 7.4 Director and Officer Indemnification, Exculpation and Insurance.

  

  

(a) Parent and Merger Sub agree that the certificate of incorporation and
bylaws of the Surviving Corporation shall contain provisions no less favorable
with respect to all rights to indemnification, advancement of expenses and
exculpation from liabilities for acts or omissions occurring at or prior to
the Effective Time in favor of both the current and former directors and/or
officers of the Company and its Subsidiaries than are provided in the
Company's and its Subsidiaries' respective certificates of incorporation or
bylaws (or comparable organizational documents) as of the date of this
Agreement, which provisions shall not be amended, repealed or otherwise
modified for a period of six (6) years from the Effective Time in any manner
that would affect adversely the rights of individuals who were directors,
officers or employees of the Company and its Subsidiaries at or prior to the
Effective Time. Parent and Merger Sub further agree that any indemnification
or other agreements of the Company (as in effect on the date of this
Agreement) shall be assumed by the Surviving Corporation in the Merger,
without further action, at the Effective Time, and shall survive the Merger
and shall continue in full force and effect in accordance with their terms,
and such agreements shall not be modified in any manner that would affect
adversely the rights of individuals who were directors, officers, employees or
agents of the Company and its Subsidiaries at or prior to the Effective Time.
From and after the Effective Time, Parent hereby irrevocably and
unconditionally guarantees the payment and performance obligations of the
Surviving Corporation under this Section 7.4(a).

  

  

(b) From the Offer Closing through the sixth anniversary of the Effective
Time, Parent shall, or shall cause the Surviving Corporation to, maintain in
effect the Company's current directors' and officers' liability insurance
covering each Person currently covered by the Company's directors' and
officers' liability insurance policy for acts or omissions occurring prior to
the Effective Time on terms with respect to such coverage and amounts no less
favorable than those of such policy in effect on the date of this Agreement;
provided, that Parent or the Surviving Corporation may (i) substitute therefor
policies of any reputable insurance company or (ii) satisfy its obligation
under this Section 7.4(b) by causing the Company to obtain, on or prior to the
Closing Date, prepaid (or "tail") directors' and officers' liability insurance
policy at Parent's expense, in each case, the material terms of which,
including coverage and amount, are no less favorable to such directors and
officers than the insurance coverage otherwise required under this Section
7.4(b); provided, further, that Parent and the Surviving Corporation shall not
be required to pay an annual premium (or, in the case of a prepaid policy
obtained pursuant to

  

  

 

 

 

  

 

56  

  

 

 

 

  

  

clause (ii), an aggregate amount) for such insurance in excess of 300% of the
annual premium currently paid by the Company for such insurance; and provided,
further, that if the annual premium of such insurance coverage exceeds such
amount, Parent or the Surviving Corporation shall be obligated to obtain a
policy with the greatest coverage available, with respect to matters occurring
prior to the Effective Time, for a cost not exceeding such amount.

  

  

(c) Notwithstanding anything herein to the contrary, if any claim, action,
suit, proceeding or investigation (whether arising before, at or after the
Effective Time) is made against any individual who is now, or who has been at
any time prior to the date hereof, or who becomes prior to the Effective Time,
a director, officer, employee or agent of the Company, on or prior to the
sixth anniversary of the Effective Time, the provisions of this Section 7.4
shall continue in effect until the final disposition of such claim, action,
suit, proceeding or investigation.

  

  

(d) The provisions of this Section 7.4 are (i) intended to be for the benefit
of, and will be enforceable by, each indemnified party, his or her heirs and
his or her representatives and (ii) in addition to, and not in substitution
for, any other rights to indemnification or contribution that any such Person
may have by Contract or otherwise. Parent shall pay all expenses, including
reasonable attorneys' fees, that may be incurred by the persons referred to in
this Section 7.4 in connection with their successful enforcement of their
rights provided in Section 7.4.

  

  

(e) In the event that the Surviving Corporation or any of its successors or
assigns (i) consolidates with or merges into any other Person and is not the
continuing or surviving corporation or entity of such consolidation or merger
or (ii) transfers or conveys all or substantially all its properties and
assets to any Person, or if Parent dissolves the Surviving Corporation, then,
and in each such case, Parent shall cause proper provision to be made so that
the successors and assigns of the Surviving Corporation assume the obligations
set forth in this Section 7.4.

  

  

Section 7.5 Public Announcements. The parties agree that the initial press
release(s) to be issued with respect to the transactions contemplated by this
Agreement shall be in the form(s) agreed to by the parties. Except with
respect to any Adverse Recommendation Change made in accordance with the terms
of this Agreement, Parent and Merger Sub, on the one hand, and the Company, on
the other hand, shall, to the extent reasonably practicable, consult with each
other before making, and give each other a reasonable opportunity to review
and comment upon, any press release or other public statements (including
broad-based employee communications) with respect to this Agreement, the
Offer, the Merger and the other transactions contemplated by this Agreement,
and shall not issue any such press release or make any such public statement
prior to such reasonably practicable consultation, except as may be required
by applicable Law, listing authority (including the U.K. listing authority),
court process or by obligations pursuant to any listing agreement with any
U.S. or U.K. securities or share exchange market or securities quotation
system to which such party is subject, in which case the party required to
make the release or announcement shall use its commercially reasonable efforts
to allow each other party reasonable time to comment on such release or
announcement in advance of such issuance.

  

  

 

 

 

  

 

57  

  

 

 

  

 

  

Section 7.6 Merger Sub Compliance. Parent shall cause Merger Sub or the
Surviving Corporation, as applicable, to perform all of its respective
agreements, covenants and obligations under this Agreement and prior to the
Closing Merger Sub shall not engage in any activities of any nature except as
provided in or contemplated by this Agreement.

  

  

Section 7.7 Section 16(b). The Company shall take all steps reasonably
required to cause the transactions contemplated by this Agreement and any
other dispositions of equity securities of the Company in connection with the
transactions contemplated by this Agreement by each individual who is a
director or officer of the Company subject to Section 16 of the Exchange Act
to be exempt under Rule 16b-3 under the Exchange Act.

  

  

Section 7.8 Rule 14d-10 Matters. Notwithstanding anything in this Agreement to
the contrary, the Company will not, after the date hereof, enter into,
establish, amend or modify any plan, program, agreement or arrangement
pursuant to which compensation is paid or payable, or pursuant to which
benefits are provided, in each case to any Company Employee unless, prior to
such entry into, establishment, amendment or modification, the Compensation
Committee shall have taken all such steps as may be necessary to (a) approve
as an Employment Compensation Arrangement each such plan, program, agreement
or arrangement and (b) satisfy the requirements of the non-exclusive safe
harbor under Rule 14d-10(d)(2) under the Exchange Act with respect to such
plan, program, agreement or arrangement.

  

  

Section 7.9 Company Benefit Plan Matters.

  

  

(a) For a period of two (2) years following the Offer Closing (or if shorter,
during the period of employment), Parent shall provide, or shall cause to be
provided, to each employee of the Company and its Subsidiaries who is employed
as of immediately prior to the Offer Closing (collectively, the "Company
Employees"), compensation (including base salary and cash incentive
opportunities, but excluding equity incentive opportunities) and benefits
(including paid time off, defined contribution retirement and welfare
benefits) which are substantially comparable in the aggregate to the
compensation (including base salary and cash and incentive opportunities, but
excluding equity incentive opportunities) and benefits (including paid time
off, defined contribution retirement and welfare benefits) provided to such
Company Employee immediately prior to the Offer Closing. In addition, if any
Company Employee (other than those who are party to a Change of Control
Agreement with the Company, whose rights shall be governed by the terms of
such agreements) incurs a qualifying termination of employment in accordance
with the terms and conditions of the severance arrangement listed on Section
7.9(a) of the Company Disclosure Schedule within two (2) years following the
Offer Closing, Parent shall provide, or shall cause to be provided, severance
payments and benefits to such Company Employee in accordance with the terms
and conditions of such severance arrangement (taking into account such Company
Employee's service as required pursuant to Section 7.9(b) below). Following
the two- (2) year period referenced in this Section 7.9(a), each Company
Employee shall be eligible to receive compensation and benefits, including
severance benefits, which are substantially similar to those provided at the
time to then similarly situated employees of Parent and its Subsidiaries.

  

  

 

 

 

  

 

58  

  

 

 

 

  

  

(b) For purposes of vesting, eligibility to participate and benefit accrual
under the employee benefit plans of Parent and its Subsidiaries providing
benefits to any Company Employees after the Offer Closing (the "New Plans"),
each Company Employee shall be credited with his or her years of service with
the Company and its Subsidiaries or predecessors before the Offer Closing, to
the same extent as such Company Employee was entitled, before the Offer
Closing, to credit for such service under any similar employee benefit plan or
the Company or its Subsidiaries in which such Company Employee participated or
was eligible to participate immediately prior to the Offer Closing (and to the
extent there is not a similar employee benefit plan of the Company or its
Subsidiaries, service as recognized for purposes of the Company's 401(k) plan
as in effect immediately prior to the Offer Closing); provided, that service
of a Company Employee prior to the Offer Closing Date with the Company and its
Subsidiaries or predecessors shall not be recognized for the purpose of any
entitlement to participate in, or receive or accrue benefits with respect to,
any defined benefit pension plans, retiree medical programs or other retiree
welfare benefit programs maintained by Parent or its Affiliates. In addition,
(i) each Company Employee shall be immediately eligible to participate,
without any waiting time, in New Plans that are welfare benefit plans (other
than retiree medical programs or other retiree welfare benefit programs) to
the extent coverage under such New Plan is comparable to an Employee Plan in
which such Company Employee participated immediately before the Offer Closing
(such plans, collectively, the "Old Plans") other than limitations or waiting
periods that would have been in effect with respect to such Company Employee
under the applicable Old Plan immediately prior to the Offer Closing and (ii)
for purposes of each New Plan providing medical, dental, pharmaceutical and/or
vision benefits to any Company Employee, (A) Parent shall cause all pre-
existing condition exclusions and actively-at-work requirements of such New
Plan to be waived for such Company Employee and his or her covered dependents,
unless such conditions would not have been waived under the comparable Old
Plan in which such employee participated immediately prior to the Offer
Closing and (B) Parent shall cause any eligible expenses incurred by such
Company Employee and his or her covered dependents during the portion of the
plan year of the Old Plan ending on the date such employee's participation in
the corresponding New Plan begins to be taken into account under such New Plan
for purposes of satisfying all deductible, coinsurance and maximum out-of-
pocket requirements applicable to such employee and his or her covered
dependents for the applicable plan year as if such amounts had been paid in
accordance with such New Plan. In no event shall anything contained in this
Section 7.9(b) result in any duplication of benefits for the same period of
service.

  

  

(c) Parent hereby acknowledges that the consummation of the Offer and the
Merger constitutes a change of control or change in control, as the case may
be, for all purposes under the Employee Plans.

  

  

(d) Prior to the Offer Closing, the Company shall take all actions that may be
necessary or appropriate to cause the Company's 401(k) Employee Savings Plan
(the "Company 401(k) Plan") to terminate as of the date immediately preceding
the Offer Closing Date. All resolutions, notices or other documents issued,
adopted or executed in connection with such termination shall be subject to
Parent's prior review and comment. As of the Offer Closing Date, Parent shall
have in place a tax qualified defined contribution retirement plan in which
Company Employees who were eligible to participate in the Company 401(k) Plan
immediately prior to the

  

  

 

 

 

  

 

59  

  

 

 

 

  

  

Offer Closing Date are eligible to participate (the "Parent 401(k) Plan"). The
Parent 401(k) Plan shall permit each such Company Employee with an account
balance in the Company 401(k) Plan to make rollover contributions of "eligible
rollover distributions" (within the meaning of Section 401(a)(31) of the Code)
to the Parent 401(k) Plan, in the form of cash or loan promissory notes as
applicable, in an amount equal to all or any portion of the account balance
distributed to such Company Employee from the Company 401(k) Plan.

  

  

(e) To the extent not previously paid by the Company prior to the Offer
Closing, no later than five (5) Business Days following the Offer Closing
Date, the Company shall make a cash payment to each employee of the Company or
its Subsidiaries who is a participant in the Company's U.S. Cash Bonus Plan
("Bonus Plan") as of the date hereof, in full satisfaction of each such
employee's rights under such plan, in an amount equal to (i) the amount
determined by the Company prior to the Offer Closing Date to be payable to
such employee with respect to the 2013 calendar year under the Bonus Plan,
based on the Company's performance through the earlier of December 31, 2013
and the Offer Closing Date and (ii) a fraction, the numerator of which is the
number of days elapsed in the 2013 calendar year through the Offer Closing and
the denominator of which is 365. To the extent not paid prior to the Offer
Closing, each Company Employee who participates in a cash incentive plan set
forth on Section 7.9(e) of the Company Disclosure Schedule (each, a "2013
Bonus Plan") will be eligible to receive a payment under such 2013 Bonus Plan
for the performance period ending on December 31, 2013, if the Company
Employee remains employed by the Company, Parent or the Surviving Corporation,
as applicable, through the required date set forth in such 2013 Bonus Plan or
if the Company Employee is terminated by the Company, Parent or the Surviving
Corporation, as applicable, without "cause" (as defined in the severance
arrangement listed on Section 7.9(a) of the Company Disclosure Schedule)
following the Offer Closing. In the event the Offer Closing occurs prior to
December 31, 2013, each 2013 Bonus Plan will continue to be maintained in
accordance with the terms thereof through December 31, 2013. Payments under
the 2013 Bonus Plans will in all cases be determined in accordance with the
terms of the 2013 Bonus Plans and the Company\'s historical practices for
making such payments and will reflect a participant's individual targets (as
applicable).

  

  

(f) Following the date of this Agreement, the Company and Parent (and their
Affiliates) shall reasonably cooperate and use good faith efforts in all
matters reasonably necessary to effect this Section 7.9, including (i)
exchanging information and data relating to employee benefits and employee
benefit plan coverages (except to the extent prohibited by applicable Law) and
(ii) making any and all required communications with Company Employees.

  

  

(g) Nothing in this Section 7.9 shall be treated as an amendment of, or
undertaking to amend, any benefit plan. The provisions of this Section 7.9 are
solely for the benefit of the respective parties to this Agreement and,
without limiting the generality of Section 10.7 nothing in this Section 7.9,
express or implied, shall confer upon any Company Employee, or legal
representative or beneficiary thereof or any other Person, any rights or
remedies, including any right to employment or continued employment for any
specified period, or compensation or benefits of any nature or kind whatsoever
under this Agreement or a right in any employee or beneficiary of such
employee or other Person under an Employee Plan that such

  

  

 

 

 

  

 

60  

  

 

 

 

  

  

employee or beneficiary or other Person would not otherwise have under the
terms of that Employee Plan.

  

  

Section 7.10 Convertible Notes. The Company shall comply, in all material
respects, with the terms of the Indenture, dated as of March 19, 2007, as
amended pursuant to the First Supplemental Indenture, dated as of March 26,
2007, in each case between the Company and Wilmington Trust Company, N.A., as
trustee (the "Indenture"), with respect to any right of holders to convert the
Convertible Notes or with respect to the Company's obligation to repurchase
the Convertible Notes from the holders thereof as a result of the transactions
contemplated hereby, including the delivery of any and all appropriate notices
required by the terms of the Indentures. Prior to taking any of the foregoing
actions, the Company shall consult with and reasonably cooperate with Parent
with respect to the action and the intended manner and form thereof. Parent
shall be given a reasonable opportunity to review any notice, announcement,
certificate or legal opinion before such document is provided to the trustee
under the Indenture, and the Company shall give reasonable and good faith
consideration to any comments made by Parent.

  

  

Section 7.11 Call-Spread Warrants and Company Hedge Options. The Company
shall, and shall cause its Representatives to, cooperate with Parent at
Parent's request in connection with any discussions, negotiations or
agreements with Credit Suisse International, Credit Suisse, New York Branch,
Wells Fargo Bank, National Association, Goldman Sachs International, any of
their respective Affiliates or any other Person (including each other
counterparty to the Call-Spread Warrants and the Company Hedge Options) with
respect to any determination or computation in connection with the Call-Spread
Warrants or the Company Hedge Options, including with respect to any cash
amounts or shares of Company Common Stock that may be receivable, issuable,
deliverable or payable by the Company pursuant the Call-Spread Warrants or the
Company Hedge Options. The Company shall not, and shall cause its
Representatives not to, enter into any discussions, negotiations or agreements
with respect to the foregoing without Parent's prior written consent, and
shall keep Parent fully informed of all such discussions and negotiations.

  

  

Section 7.12 Termination of Credit Facility. The Company shall terminate the
Credit Agreement, dated as of September 9, 2011, among the Company, JPMorgan
Chase Bank, N.A., as administrative agent, and the other lenders party thereto
(the "JPM Credit Facility") at or immediately prior to the Offer Closing, and
shall use reasonable best efforts to obtain prior to the Offer Closing payoff
letters (or confirmation that no amounts are then outstanding under the JPM
Credit Facility) from the lenders under the JPM Credit Facility in form and
substance reasonably satisfactory to Parent with respect thereto, including,
subject to the payment of any applicable payoff amount, the release of all
Liens granted in connection with the JPM Credit Facility.

  

  

Section 7.13 Sanquin Matters. To the extent permitted by applicable Law and
the Company's relevant contractual obligations, the Company shall keep Parent
reasonably informed on a reasonably current basis of (i) any developments,
discussions or negotiations related to or arising out of any inspections of
the facilities maintained by Stichting Sanquin Bloodvoorziening or any of its
Affiliates, including Sanquin Plasma Products and C.A.F. - D.C.F.
(collectively, "Sanquin"), (ii) any communications or notices from the FDA
(including on Form FDA 483) or

  

  

 

 

 

  

 

61  

  

 

 

 

  

  

any other Health Authority in respect of such inspections (including any such
communication or notice disclosed to the Company by Sanquin) and (iii) any
responses made to any such communications or notices, including in connection
with the Warning Letter sent from the FDA to Sanquin on August 29, 2013.
Without limiting the generality of the foregoing, to the extent permitted by
applicable Law and (if applicable) the relevant Health Authority, in each case
in connection with the aforementioned matters, the Company shall (w) promptly
inform Parent of any communication or notice received after the date hereof
from Sanquin or any Health Authority, (x) to the extent reasonably practicable
under the circumstances, consult with and consider in good faith the views of
Parent prior to requesting that Sanquin take any action, (y) prior to
submitting or making any communication, correspondence, filing or response to
any Health Authority or Sanquin, give Parent a meaningful opportunity to
review, as reasonably in advance as practicable under the circumstances, and
consider in good faith Parent's comments to, any such communication,
correspondence, filing or response, and (z) consult with Parent in advance of,
and give Parent's representatives the opportunity to attend, any in-person or
telephonic meeting or conference with Sanquin or any Health Authority, the
primary purpose of which is to discuss the matters described in the
immediately preceding sentence, subject to reasonable restrictions on the
number of persons attending on Parent's behalf, which shall not be less than
two (2), and with respect to other calls or meetings in which the matters
described in the immediately preceding sentence are discussed, reasonably
update Parent regarding such discussions.

  

  

Section 7.14 Takeover Statutes. If any "fair price," "moratorium," "business
combination," "control share acquisition" or other form of anti-takeover
statute or regulation shall become applicable to the Offer, the Merger or the
other transactions contemplated by this Agreement after the date of this
Agreement, the Company and the members of its Board of Directors shall grant
such approvals and take such actions as are reasonably necessary so that the
Offer, the Merger and the other transactions contemplated hereby may be
consummated as promptly as practicable on the terms contemplated herein and
otherwise act to eliminate or minimize the effects of such statute or
regulation on the Merger, and the other transactions contemplated hereby.

  

  

Section 7.15 Stock Exchange Delisting. After the Offer Closing, the Company
shall use its reasonable best efforts to take, or cause to be taken, all
actions, and do or cause to be done all things, reasonably necessary, proper
or advisable on its part under Applicable Law and the rules and policies of
NASDAQ to enable the delisting by the Surviving Corporation of the Company
Common Stock from NASDAQ and the deregistration of the Company Common Stock
under the Exchange Act as promptly as practicable after the Effective Time,
and in any event no more than ten (10) days thereafter.

  

  

ARTICLE VIII

  

  

CONDITIONS TO CONSUMMATION OF THE MERGER

  

  

Section 8.1 Conditions to Each Party's Obligation to Effect the Merger. The
respective obligation of each party to effect the Merger is subject to the
satisfaction or (to the extent permitted by Law) waiver on or prior to the
Closing Date of the following conditions:

  

  

 

 

 

  

 

62  

  

 

 

 

  

  

(a) No Injunctions or Legal Restraints. No order, injunction, judgment, decree
or ruling (whether temporary, preliminary or permanent) enacted, promulgated,
issued or entered by any Governmental Entity or Law (collectively, "Legal
Restraints") that has the effect of preventing the consummation of the Merger
shall be in effect; and

  

  

(b) Purchase of Company Common Stock in the Offer. The Offer shall have been
consummated and Merger Sub shall have previously accepted for payment, or
caused to be accepted for payment, in accordance with the terms of this
Agreement, all shares of Company Common Stock validly tendered and not
withdrawn pursuant to the Offer.

  

  

ARTICLE IX

  

  

TERMINATION, AMENDMENT AND WAIVER

  

  

Section 9.1 Termination. This Agreement may be terminated, and the
transactions contemplated by this Agreement may be abandoned, at any time
prior to the Effective Time (in each case upon written notice (other than in
the case of Section 9.1(a) below) from the terminating party to the non-
terminating party specifying the subsection of this Section 9.1 pursuant to
which such termination is effected):

  

  

(a) subject to Section 1.3, by mutual written consent of Parent, Merger Sub
and the Company;

  

  

(b) by either Parent or the Company, if:

  

  

(i) the Offer Closing shall not have occurred prior to August 12, 2014 (the
"Termination Date") for any reason; provided, however, that if, as of the
Termination Date, one or more of the conditions set forth in clause (ii) or
paragraph (a) or (b) of clause (iii) of Exhibit A shall not have been
satisfied or waived, then, upon notice given by Parent or the Company not
later than 6:00 p.m., Eastern time, on the Termination Date, the Termination
Date shall be extended to and including October 14, 2014, which date shall
thereupon constitute the Termination Date for all purposes of this Agreement;
and provided, further, that the right to terminate this Agreement under this
Section 9.1(b)(i) (or extend the Termination Date pursuant to the preceding
proviso) shall not be available to any party whose failure to perform any of
its obligations under this Agreement has resulted in the failure of the Offer
Closing to occur prior to such date;

  

  

(ii) any Legal Restraint (other than a temporary restraining order) that has
the effect of preventing the consummation of the Offer or the Merger shall be
in effect and shall have become final and nonappealable; provided, however,
that the right to terminate this Agreement under this Section 9.1(b)(ii) shall
not be available to any party whose failure to perform any of its obligations
under this Agreement has resulted in such Legal Restraint being or remaining
in effect; or

  

  

(iii) any Legal Restraint that has the effect of delaying the consummation of
the Offer or the Merger beyond the Termination Date shall be in

  

  

 

 

 

  

 

63  

  

 

 

 

  

  

effect and shall have become final and nonappealable; provided, however, that
the right to terminate this Agreement under this Section 9.1(b)(iii) shall not
be available to any party whose failure to perform any of its obligations
under this Agreement has resulted in such Legal Restraint being or remaining
in effect;

  

  

(c) prior to the Offer Closing, by Parent, in the event an Adverse
Recommendation Change has occurred (whether or not in compliance with Section
6.2) or if, at any time after the receipt or public announcement of an
Takeover Proposal, the Board of Directors of the Company shall have failed to
publicly reaffirm the Company Recommendation as promptly as practicable (but
in any event within five (5) Business Days) after receipt of any written
request from Parent to do so;

  

  

(d) prior to the Offer Closing, by Parent, if the Company shall have
intentionally and materially breached its obligations under Section 6.2;

  

  

(e) prior to the Offer Closing, by Parent, if the Company shall have breached
in any material respect any of its representations or warranties or failed to
perform in any material respect any of its obligations, covenants or
agreements contained in this Agreement, which breach or failure to perform (i)
would give rise to the failure of a condition set forth in paragraph (d) or
(e) of clause (iii) of Exhibit A and (ii) is incapable of being cured by the
Company by the Termination Date or, if capable of being cured by the Company
by the Termination Date, the Company does not commence to cure such breach or
failure within five (5) Business Days after its receipt of written notice
thereof from Parent and cure such breach or failure within thirty (30) days
after its receipt of written notice thereof from Parent;

  

  

(f) prior to the Offer Closing, by the Company, if Parent or Merger Sub shall
have breached in any material respect any of its representations or warranties
contained in this Agreement or Parent or Merger Sub shall have failed to
perform in any material respect all obligations, covenants or agreements
required to be performed by them under this Agreement at or prior to the Offer
Closing, in each case, which breach or failure to perform (i) is incapable of
being cured by Parent or Merger Sub by the Termination Date or, if capable of
being cured by Parent by the Termination Date, Parent and Merger Sub do not
commence to cure such breach or failure within five (5) Business Days after
their receipt of written notice thereof from the Company and cure such breach
or failure within thirty (30) days after their receipt of written notice
thereof from the Company and (ii) in any way would reasonably be expected to
prevent, materially impede or materially delay the consummation by Parent or
Merger Sub of the Offer, the Merger or the other transactions contemplated by
this Agreement;

  

  

(g) prior to the Offer Closing, by Parent or the Company, if the Offer has
expired in accordance with its terms and has not been extended by Merger Sub,
and Merger Sub has not accepted for payment within three (3) Business Days
following such expiration all shares of Company Common Stock validly tendered
and not validly withdrawn (provided, that the right to terminate this
Agreement under this Section 9.1(g) shall not be available to Parent if Parent
or Merger Sub is then in breach of its obligation hereunder to accept such
shares for payment); and

  

  

 

 

 

  

 

64  

  

 

 

 

  

  

(h) prior to the Offer Closing, by the Company in accordance with the terms
and subject to the conditions of Section 6.2(b) and Section 6.2(d).

  

  

Section 9.2 Effect of Termination In the event of termination of this
Agreement by either the Company or Parent as provided in Section 9.1, this
Agreement shall forthwith become void and have no effect, without any
liability or obligation on the part of Parent, Merger Sub or the Company or
their respective Subsidiaries, officers or directors, except that (a) Section
7.1(b), Section 9.3, this Section 9.2 and Article X shall survive such
termination and (b) the termination of this Agreement shall not relieve or
release any party hereto from any liability arising out of its willful breach
(subject to Section 9.3(e)) of this Agreement or any fraud.

  

  

Section 9.3 Fees and Expenses.

  

  

(a) Except as expressly set forth in this Section 9.3, all fees and expenses
incurred in connection with this Agreement, the Offer, the Merger and the
other transactions contemplated by this Agreement shall be paid by the party
incurring such fees or expenses, whether or not the Offer or the Merger is
consummated.

  

  

(b) In the event that this Agreement is terminated (i) by Parent pursuant to
Section 9.1(c) or Section 9.1(d) or (ii) by the Company pursuant to Section
9.1(h), then, in each such case, the Company shall pay Parent a fee equal to
$127,140,000 (the "Termination Fee") by wire transfer of same-day funds to an
account designated by Parent, which payment shall be made (x) in the case of a
termination by Parent pursuant to Section 9.1(c) or Section 9.1(d), within two
(2) Business Days after such termination and (y) in the case of a termination
by the Company pursuant to Section 9.1(h), immediately before and as a
condition to such termination.

  

  

(c) In the event that (i) prior to the termination of this Agreement, any
Takeover Proposal (for purposes of this Section 9.3(c), substituting 50% for
the 20% thresholds set forth in the definition of Takeover Proposal) is
publicly proposed or publicly disclosed or otherwise communicated to the Board
of Directors of the Company and not publicly and unconditionally withdrawn,
(ii) this Agreement is terminated by Parent or the Company pursuant to Section
9.1(b)(i) or Section 9.1(g) (unless Parent or Merger Sub was, at the time of a
termination by the Company pursuant to Section 9.1(g), in breach of its
obligation to accept for payment shares of Company Common Stock) or by Parent
pursuant to Section 9.1(e) and (iii) within twelve (12) months after
termination of this Agreement, (A) the Company enters into any acquisition
agreement or other definitive agreement or Contract providing for, or the
Board of Directors recommends to the Company's stockholders, any Takeover
Proposal (regardless of whether such Takeover Proposal is the same Takeover
Proposal referred to in clause (i)) or (B) a transaction in respect of any
Takeover Proposal shall have been consummated (regardless of whether such
Takeover Proposal is the same Takeover Proposal referred to in clause (i)),
then the Company shall pay to Parent the Termination Fee upon the occurrence
of the applicable event described in clause (iii)(A) or (B).

  

  

(d) If this Agreement is terminated pursuant to Section 9.1(b) and, at the
time of such termination, (A) one or more of the conditions set forth in
clause (ii) or paragraph (a) or (b) of clause (iii) of Exhibit A shall not
have been satisfied or waived solely as a result of

  

  

 

 

 

  

 

65  

  

 

 

 

  

  

applicable Competition Law or any Burdensome Condition and (B) all of the
other conditions set forth in clauses (ii) and (iii) of Exhibit A have been
satisfied or waived (or in the case of conditions that by their nature are to
be satisfied at the Closing, would be satisfied if the Offer Closing were to
occur on the date of such termination), then Parent shall pay to the Company
in immediately available funds $200,000,000 (the "Reverse Termination Fee")
immediately before, and as a condition to, any such termination by Parent and
otherwise as promptly as reasonably practicable (and in any event within two
(2) Business Days) following such termination; provided, that no Reverse
Termination Fee shall be payable by Parent pursuant to this Section 9.3(d) if
the Company's failure to perform any of its obligations under this Agreement
has materially contributed to the failure of the conditions set forth in
clause (ii) or paragraph (a) or (b) of clause (iii) of Exhibit A to be
satisfied.

  

  

(e) Notwithstanding anything to the contrary in this Agreement (including in
Section 9.2, Section 10.7(b) and Section 10.12), the parties agree that (i)
the payment of the Termination Fee shall be the sole and exclusive remedy
available to Parent and Merger Sub with respect to this Agreement in the event
the Termination Fee becomes due and payable under the terms of this Agreement,
and, upon payment of the Termination Fee, the Company shall have no further
liability to Parent and Merger Sub hereunder and (ii) the payment of the
Reverse Termination Fee shall be the sole and exclusive remedy available to
the Company with respect to this Agreement in the event the Reverse
Termination Fee becomes due and payable under the terms of this Agreement,
and, upon payment of the Reverse Termination Fee, Parent and Merger Sub shall
have no further liability to the Company hereunder.

  

  

ARTICLE X

  

  

GENERAL PROVISIONS

  

  

Section 10.1 No Other Representations or Warranties; Investigation by Parent.
Parent and Merger Sub each acknowledges and agrees that (a) it has had an
opportunity to discuss the business of the Company with the Company, (b) it
has been afforded the opportunity to ask questions of and receive answers from
the Company and (c) except for the representations and warranties contained in
Article IV, and without limiting Parent's or Merger Sub's remedies in the case
of fraud or intentional misconduct, neither Parent nor Merger Sub has relied
upon or otherwise been induced by, any other express or implied representation
or warranty with respect to the Company or with respect to any information
made available to Parent or Merger Sub in connection with the transactions
contemplated by this Agreement. The Company makes no representations and
warranties except as set forth in Article IV. Moreover, except in the case of
fraud or intentional misconduct, (x) neither the Company, the Company's
Subsidiaries, nor any of their respective directors, officers, employees,
affiliates, agents or Representatives nor any other Person will have or be
subject to any liability or obligation to Parent, Merger Sub or any other
Person resulting from the distribution to Parent or Merger Sub, or Parent's or
Merger Sub's use of, any such information, including any information,
documents, projections, forecasts or other material made available to Parent
or Merger Sub in the data rooms or management presentations in connection with
the transactions contemplated by this Agreement, unless any such information
is included or incorporated in a representation or warranty contained in
Article IV, and (y) Parent and Merger Sub each acknowledges that neither the
Company nor any other

  

  

 

 

 

  

 

66  

  

 

 

 

  

  

Person makes any representations or warranties whatsoever with respect to any
projections or forecasts that may have been provided to Parent or any of its
Representatives.

  

  

Section 10.2 Nonsurvival of Representations and Warranties. None of the
representations and warranties in this Agreement or in any instrument
delivered pursuant to this Agreement shall survive the Effective Time. This
Section 10.2 shall not limit any covenant or agreement of the parties which by
its terms contemplates performance after the Effective Time. The
Confidentiality Agreement shall survive any termination of this Agreement, and
the provisions of such Confidentiality Agreement shall apply to all
information and material delivered by any party hereunder.

  

  

Section 10.3 Amendment. Subject to Section 1.3, this Agreement may be amended
by the parties hereto at any time, whether before or after the Offer Closing
shall have occurred, provided, however, that after the Offer Closing, there
shall be no amendment that decreases the Merger Consideration and there shall
be made no amendment that by Law requires approval by stockholders of the
Company without approval of such stockholders. This Agreement may not be
amended except by an instrument in writing signed on behalf of each of the
parties hereto.

  

  

Section 10.4 Extension; Waiver. At any time prior to the Effective Time, the
parties may, subject to Section 1.3, (a) extend the time for the performance
of any of the obligations or other acts of the other parties, (b) waive any
inaccuracies in the representations and warranties contained herein or in any
document delivered pursuant hereto or (c) waive compliance with any of the
agreements or conditions contained herein; provided, however, that there shall
be made no waiver that by Law requires approval by stockholders of the Company
without the approval of such stockholders. Any agreement on the part of a
party to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such party which specifically sets
forth the terms of such extension or waiver. The failure or delay by any party
to this Agreement to assert any of its rights under this Agreement or
otherwise shall not constitute a waiver of such rights nor shall any single or
partial exercise by any party to this Agreement of any of its rights under
this Agreement preclude any other or further exercise of such rights or any
other rights under this Agreement.

  

  

Section 10.5 Notices. All notices or other communications required or
permitted to be given hereunder shall be in writing and shall be delivered by
hand or sent by facsimile or sent, postage prepaid, by registered, certified
or express mail or reputable overnight courier service and shall be deemed
given when so delivered by hand or sent by facsimile (which is confirmed), or
if mailed, three (3) days after mailing (one (1) Business Day in the case of
express mail or overnight courier service), as follows (or at such other
address for a party as shall be specified by notice given in accordance with
this Section 10.5).

  

  

 

 

 

  

 

67  

  

 

 

 

  

  

if to Parent or Merger Sub, to:

  

  

Shire Pharmaceutical Holdings Ireland Limited

  

Riverwalk, Citywest Business Campus

  

Dublin 24

  

Ireland

  

Facsimile: +353 (0) 1 429 7701

  

     |  

Attention:

  |  

Michael Garry

   
---|---|--- 
 

  

Anne Marie Dempsey

  

  

with copies (which shall not constitute notice) to:

  


 

  

Hampshire International Business Park

  

Basingstoke, Hampshire

  

RG24 8EP, UK

  

Facsimile: +44 1256 894 710

  

Attention: General Counsel

  

  

Davis Polk and Wardwell LLP

  

450 Lexington Avenue

  

New York, New York 10017

  

Facsimile: (212) 701-5800

  

     |  

Attention:

  |  

George R. Bason, Jr.

   
---|---|--- 
 

  

William J. Chudd

  

  

if to the Company, to:

  

  

ViroPharma Incorporated

  

730 Stockton Drive

  

Exton, Pennsylvania 19341

  

Facsimile: (610) 458-7380

  

     |  

Attention:

  |  

J. Peter Wolf

   
---|---|--- 
 

  

  

with copies (which shall not constitute notice) to:

  

  

Skadden, Arps, Slate, Meagher and Flom LLP

  

1440 New York Avenue, NW

  

Washington, D.C. 20005

  

Facsimile: (202) 393-5760 (confirmed by email

  

eileen.nugent@skadden.com and michael.rogan@skadden.com)

  

     |  

Attention:

  |  

Eileen T. Nugent

   
---|---|--- 
 

  

Michael P. Rogan

  

  

Section 10.6 Counterparts. This Agreement may be executed in one or more
counterparts (including by facsimile or pdf), all of which shall be considered
one and the same

  

  

 

 

 

  

 

68  

  

 

 

 

  

  

agreement and shall become effective when one or more such counterparts have
been signed by each of the parties and delivered to the other parties.

  

  

Section 10.7 Entire Agreement; No Third-Party Beneficiaries. This Agreement
together with the Exhibits and Appendix hereto, the Company Disclosure
Schedule and the Parent Disclosure Schedule, constitutes the entire agreement
and supersedes all prior agreements and understandings, both written and oral,
among the parties with respect to the subject matter of this Agreement, except
for the Confidentiality Agreement. Nothing in this Agreement, express or
implied, is intended to confer upon any Person other than the parties hereto
(and their respective successors and assigns) any rights (legal, equitable or
otherwise) or remedies, whether as third-party beneficiaries or otherwise,
except (a) for the third-party beneficiaries contemplated by Section 7.4, (b)
that, subject to Section 9.3(e), the Company shall have the right to pursue
damages on behalf of its stockholders (which the parties acknowledge and agree
may include to the extent proven the benefit of the bargain lost by such
stockholders (taking into consideration relevant matters, including other
combination opportunities and the time value of money)) in the event of
Parent's or Merger Sub's fraud or willful breach of this Agreement, which
right is hereby acknowledged by Parent and Merger Sub, and (c) from and after
the Effective Time, holders of shares of the Company Common Stock shall have
the right to receive the Merger Consideration pursuant to the terms and
conditions of Article III.

  

  

Section 10.8 Assignment. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned, in whole or in part,
whether by merger, operation of Law or otherwise, by Parent, Merger Sub or the
Company without the prior written consent of the other parties except that
Parent or Merger Sub may transfer or assign its rights and obligations under
this Agreement, in whole or from time to time in part, to (i) one or more of
its Affiliates at any time and (ii) after the Effective Time, to any Person;
provided, that such transfer or assignment shall not relieve Parent or Merger
Sub of its obligations hereunder or enlarge, alter or change any obligation of
any other party hereto or due to Parent or Merger Sub. Subject to the
preceding sentence, this Agreement shall be binding upon, inure to the benefit
of and be enforceable by the parties hereto and their respective successors
and assigns.

  

  

Section 10.9 Governing Law. This Agreement shall be governed by, and construed
in accordance with, the Laws of the State of Delaware, regardless of the Laws
that might otherwise govern under applicable principles of conflicts of Laws
thereof or that would cause the Laws of any jurisdiction other than the State
of Delaware to apply.

  

  

Section 10.10 Consent to Jurisdiction; Service of Process; Venue.

  

  

(a) Each of the parties hereto irrevocably and unconditionally submits to the
exclusive jurisdiction of the Delaware Court of Chancery (and if jurisdiction
in the Delaware Court of Chancery shall be unavailable, the federal court of
the United States of America sitting in the State of Delaware) for the
purposes of any suit, action or other proceeding arising out of this Agreement
or any transaction contemplated by this Agreement (and agrees that no such
action, suit or proceeding relating to this Agreement shall be brought by it
or any of its Subsidiaries except in such courts).

  

  

 

 

 

  

 

69  

  

 

 

 

  

  

(b) Process in any such suit, action or proceeding may be served on any party
anywhere in the world, whether within or without the jurisdiction of any such
court. Without limiting the foregoing, each party agrees that service of
process on such party in the manner provided for notices in Section 10.5 shall
be deemed effective service of process on such party.

  

  

(c) Each of the parties hereto irrevocably and unconditionally waives (and
agrees not to plead or claim) any objection to the laying of venue of any
action, suit or proceeding arising out of this Agreement or the transactions
contemplated by this Agreement in the Delaware Court of Chancery (and if
jurisdiction in the Delaware Court of Chancery shall be unavailable, the
federal court of the United States of America sitting in the State of
Delaware) or that any such action, suit or proceeding brought in any such
court has been brought in an inconvenient forum. Parent waives any right to
assert sovereign immunity or any similar defense available to it by virtue of
its domicile in Ireland.

  

  

Section 10.11 Waiver of Jury Trial. Each party hereto hereby waives, to the
fullest extent permitted by applicable Law, any right it may have to a trial
by jury in respect of any suit, action or other proceeding directly or
indirectly arising out of, under or in connection with this Agreement. Each
party hereto (a) certifies that no Representative of any other party has
represented, expressly or otherwise, that such party would not, in the event
of any action, suit or proceeding, seek to enforce the foregoing waiver and
(b) acknowledges that it and the other parties hereto have been induced to
enter into this Agreement, by, among other things, the mutual waiver and
certifications in this Section 10.11.

  

  

Section 10.12 Specific Enforcement. The parties agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the parties hereto shall be entitled to an
injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement in the Delaware Court
of Chancery (and if jurisdiction in the Delaware Court of Chancery shall be
unavailable, the federal court of the United States of America sitting in the
State of Delaware), this being in addition to any other remedy to which they
are entitled at Law or in equity. Each party agrees that it will not oppose
the granting of an injunction, specific performance or other equitable relief
on the basis that the party seeking such injunction, specific performance or
other equitable relief has an adequate remedy at law or that any award of
specific performance is not an appropriate remedy for any reason at law or
equity. In the event that any party seeks an injunction or injunctions to
prevent breaches of this Agreement or to enforce specifically the terms and
provisions of this Agreement, such party shall not be required to provide any
bond or other security in connection with any such injunction or other
Judgment.

  

  

Section 10.13 Consents and Approvals. For any matter under this Agreement
requiring the consent or approval of any party to be valid and binding on the
parties hereto, such consent or approval must be in writing and executed and
delivered to the other parties by a Person duly authorized by such party to do
so.

  

  

Section 10.14 Severability. If any provision of this Agreement or the
application of any such provision to any Person or circumstance shall be held
invalid, illegal or unenforceable in

  

  

 

 

 

  

 

70  

  

 

 

 

  

  

any respect by a court of competent jurisdiction, all other conditions and
provisions of this Agreement shall nevertheless remain in full force and
effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner adverse to any party. Upon
such determination that any term or other provision is invalid, illegal or
unenforceable in any respect, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner to the end that the transactions
contemplated hereby are fulfilled to the extent possible.

  

  

Section 10.15 Joint and Several Liability; Obligation of Parent. Parent and
Merger Sub hereby agree that they will be jointly and severally liable for all
covenants, agreements, obligations and representations and warranties made by
either of them in this Agreement. Whenever this Agreement requires Merger Sub
to take any action, such requirement shall be deemed to include an undertaking
on the part of Parent to cause Merger Sub to take such action and a guarantee
of the payment and performance thereof.

  

  

Section 10.16 Parent Holdco Guarantee.

  

  

(a) Parent Holdco irrevocably and unconditionally guarantees to the Company
the due and punctual performance of the obligations of Parent and Merger Sub
hereunder (the "Guaranteed Obligations") subject to the conditions hereunder.
If, for any reason whatsoever, Parent or Merger Sub shall fail or be unable to
duly, punctually and fully pay or perform the Guaranteed Obligations, Parent
Holdco will forthwith pay or perform, or cause to be paid or performed, the
Guaranteed Obligations. Parent Holdco hereby waives diligence, presentment,
demand of payment, filing objections with a court, any right to require
proceeding first against Parent or Merger Sub, any right to require the prior
disposition of the assets of Parent or Merger Sub to meet their respective
obligations, notice, protest and all demands whatsoever. This is a guarantee
of payment and performance and not collectability.

  

  

(b) Parent Holdco is a legal entity duly organized, validly existing and (to
the extent applicable) in good standing under the Laws of its jurisdiction of
organization. Parent Holdco has all requisite corporate power and authority
and has taken all corporate action necessary in order to execute, deliver and
perform its obligations under this Agreement. This Agreement has been duly
executed and delivered by Parent Holdco and is a valid and binding agreement
of Parent Holdco, enforceable against it in accordance with its terms, except
as such enforcement may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or other Laws affecting creditors' rights generally
or by principles of equity (regardless of whether enforcement is sought in a
proceeding at law or in equity). Parent Holdco hereby makes the
representations and warranties set forth in Section 5.7 with respect to
itself. Parent Holdco owns directly one hundred percent (100%) of the issued
and outstanding capital stock of Parent.

  

  

(c) Parent Holdco shall not transfer or assign, in whole or in part, any of
its obligations under this Section 10.16.

  

  

 

 

 

  

 

71  

  

 

 

 

  

  

ARTICLE XI

  

  

DEFINITIONS AND EXHIBITS

  

  

Section 11.1 Definitions. For purposes of this Agreement:

  

  

(a) "Affiliate" means, with respect to any Person, any other Person directly
or indirectly controlling, controlled by or under common control with such
first Person;

  

  

(b) "Beneficial Ownership" has the meaning assigned thereto in Section 13(d)
of the Exchange Act and the rules and regulations thereunder;

  

  

(c) "Business Day" means any day on which the principal offices of the SEC in
Washington, D.C. are open to accept filings or, in the case of determining a
date when any payment is due, any day on which banks are not required or
authorized by applicable Law to close in New York, New York; provided, that in
connection with the Offer, Business Day shall have the meaning set forth in
Rule 14d-1(g)(3) under the Exchange Act;

  

  

(d) "Call-Spread Warrants" means warrants to purchase shares of Company Common
Stock pursuant to (i) the Confirmation of Issuer Warrant Transaction, dated
March 20, 2007, between the Company and Credit Suisse International and Credit
Suisse, New York Branch, as agent for Credit Suisse International (as amended
by the Amendment to Confirmation of Issuer Warrant Transaction, dated as of
March 22, 2007, and as further amended by the Agreement with respect to Issuer
Warrant Transaction Reference No. 50302803, dated March 19, 2009) and (ii) the
Confirmation of Issuer Warrant Transaction, dated March 20, 2007, between the
Company and Wells Fargo Bank, National Association (as amended by the
Amendment to Confirmation of Issuer Warrant Transaction, dated as of March 22,
2007, and as further amended by the Agreement with respect to Issuer Warrant
Transaction Reference No. OTC032307202-204C, dated March 19, 2009);

  

  

(e) "Change of Control Agreement" means an individual Change of Control
Agreement by and between the Company and an executive of the Company,
substantially in the form previously filed with the SEC;

  

  

(f) "Company Hedge Options" means options to purchase shares of Company Common
Stock pursuant to (i) the Confirmation of Convertible Bond Hedge Transaction,
dated March 20, 2007, between the Company and Credit Suisse International and
Credit Suisse, New York Branch, as agent for Credit Suisse International, as
amended by the Agreement of Partial Termination of Convertible Bond Hedge
Transaction Reference No. 50302802, dated March 19, 2009, and (ii) the
Confirmation of Convertible Bond Hedge Transaction, dated March 20, 2007,
between the Company and Wells Fargo Bank, National Association, as amended by
the Agreement of Partial Termination of Convertible Bond Hedge Transaction
Reference No. OTC03207201-204C, dated March 19, 2009;

  

  

  

 

 

 

  

 

72  

  

 

 

 

  

  

  

(g) "Intellectual Property Rights" means (i) national and multinational
statutory invention registrations, patents, patent applications issued or
applied for in any jurisdiction (including all certificates of invention,
provisional applications, non-provisional applications, substitutions,
divisionals, continuations, continuations-in-part, reissues, extensions,
supplementary protection certificates, reexaminations and the equivalents of
any of the foregoing in any jurisdiction, and all inventions disclosed in each
such registration, patent or patent application), (ii) trademarks, trade
dress, trade names, brand names, certification marks, domain names, service
marks and other indications of origin, the goodwill associated with the
foregoing and all registrations in any jurisdiction of, and applications in
any jurisdiction to register, the foregoing, including any extension,
modification or renewal of any such registration or application, (iii)
copyrights, including all registrations or applications for registration for
copyrights in any jurisdiction, and any renewals or extensions thereof, (iv)
trade secrets and confidential information and rights in any jurisdiction to
limit the use or disclosure thereof by any Person, (v) know-how, inventions,
discoveries, ideas and improvements, proprietary data (including in new drug
applications, investigational drug applications and other pre-clinical and
clinical trial data), specifications, assays, methods, formulae, designs,
technology, software, standard operating procedures, research records and
similar data and information, (vi) moral rights, database rights, design
rights, industrial property rights, publicity rights and privacy rights and
(vii) any similar intellectual property or proprietary rights;

  

  

 

 

(h) "Key Products" means (a) the products known as Cinryze (including any
alternative low volume formulation of Cinryze or any formulation utilizing
subcutaneous administration), Plenadren, Buccolam, Vancocin and Maribavir and
(b) the non-toxigenic strain of C. difficile (VP20621) and any products
containing such strain;

 

  

  

(i) "Knowledge," as it relates to the Company, means with respect to any
matter in question, the actual knowledge of any of those individuals listed on
Section 11.1(i) of the Company Disclosure Schedule;

 

  

  

(j) "Material Adverse Effect" means any state of facts, condition, change,
development or event (each, an "Event") that, individually or in the
aggregate, (i) results in or is reasonably likely to result in a material
adverse effect on the business, assets, liabilities, properties, financial
condition or results of operations of the Company and its Subsidiaries, taken
as a whole or (ii) prevents, materially impedes or materially delays the
consummation of the Offer or the Merger to a date following the Termination
Date, excluding, in the case of clause (i) above, any adverse effect to the
extent resulting from: (A) any Events generally affecting the industry in
which the Company primarily operates, or the economy, or financial, capital,
currency exchange or commodities markets, or business, regulatory, market or
political conditions in the United States or elsewhere in the world; (B) any
Events arising from or otherwise relating to any natural disaster, act of God,
outbreak or escalation of hostilities, act of terrorism or war; (C) any
failure, in and of itself, by the Company to meet any internal or published
projections, forecasts or revenue or earnings predictions (whether such
projections, forecasts or predictions were made by the Company or independent
third parties); (D) any Events resulting from or arising out of any change in
GAAP or changes in applicable Law or the interpretation thereof by
Governmental Entities, in each case after the date hereof; (E) any Events
(including any loss of employees or any loss of, or any disruption in,
supplier, customer, licensor, licensee, partner or similar relationships)
attributable to the announcement or pendency of the Offer, the Merger or any
of the other transactions contemplated by this Agreement or the

  

  

 

 

 

  

 

73  

  

 

 

 

  

  

identity of Parent or Merger Sub; (provided, that the exception in this clause
(E) shall not apply to the term "Material Adverse Effect" as used in, or as
used in clause (iii)(d) of Exhibit A with respect to, any representation or
warranty in this Agreement to the extent that the purpose of such
representation or warranty is to address the execution and delivery of this
Agreement or the announcement or pendency of the Offer, the Merger or any of
the other transactions contemplated by this Agreement); (F) any Events
resulting from changes in the market price or trading volume of the Company
Common Stock; (G) the determination by, or delay of a determination by, the
FDA or any other Health Authority, or any panel or advisory body empowered or
appointed thereby, after the date of this Agreement, with respect to the
approval or non-approval of new products, new methods of delivery or new
dosages for existing products, of the Company or its Subsidiaries or any of
the Company's Collaboration Partners or competitors; (H) the result of any
clinical trial sponsored by the Company, any of the Company's Subsidiaries or
any of the Company's Collaboration Partners or competitors; or (I) any action
by the Company that is expressly required by this Agreement or taken at the
written request of Parent or Merger Sub; except in the case of clauses (A),
(B) and (D), any Event which disproportionately affects, individually or
together with other Events, in a material way, the Company and its
Subsidiaries when compared to other Persons operating in the industry in which
the Company and its Subsidiaries operate (it being understood that the
exclusions set forth in clauses (C) and (F) shall not prevent or otherwise
affect a determination that any Event underlying or that contributed to such
failure or change has resulted in or contributed to a Material Adverse
Effect);

  

  

(k) "Permitted Liens" means (i) Liens consisting of zoning or planning
restrictions, easements, permits and other restrictions or limitations on the
use of real property or irregularities in title thereto, which do not
materially impair the value of such properties or the use of such property by
the Company or any of its Subsidiaries in the operation of its respective
business, (ii) Liens for Taxes not yet due and payable, or Taxes that are
being contested in good faith and for which adequate reserves have been
recorded, (iii) Liens for assessments and other governmental charges or
landlords', carriers', warehousemen's, mechanics', repairmen's, workers' and
similar Liens incurred in the ordinary course of business, consistent with
past practice, in each case for sums not yet due and payable or due but not
delinquent or being contested in good faith by appropriate proceedings, (iv)
Liens incurred in the ordinary course of business, consistent with past
practice, in connection with workers' compensation, unemployment insurance and
other types of social security or to secure the performance of tenders,
statutory obligations, surety and appeal bonds, bids, leases, government
contracts, performance and return of money bonds and similar obligations, (v)
Liens incurred in the ordinary course of business consistent with past
practice that are not reasonably likely to adversely interfere in any material
respect with the use of properties or assets encumbered thereby, (vi) Liens
arising by virtue of the transactions contemplated under this Agreement and
(vii) Liens securing the indebtedness for borrowed money under the JPM Credit
Facility;

  

  

(l) "Person" means any natural person, corporation, limited liability company,
partnership, joint venture, trust, business association, Governmental Entity
or other entity;

  

  

(m) "Service Provider" means any director, officer, employee or individual
independent contractor of the Company or any of its Subsidiaries; and

  

  

 

 

 

  

 

74  

  

 

 

 

  

  

(n) a "Subsidiary" of any Person shall mean any other Person (i) more than 50%
of whose outstanding shares or securities representing the right to vote for
the election of directors or other managing authority of such other Person
are, now or hereafter, owned or controlled, directly or indirectly, by such
first Person, but such other Person shall be deemed to be a Subsidiary only so
long as such ownership or control exists or (ii) which does not have
outstanding shares or securities with such right to vote, as may be the case
in a partnership, joint venture or unincorporated association, but more than
50% of whose ownership interest representing the right to make the decisions
for such other Person is, now or hereafter, owned or controlled, directly or
indirectly, by such first Person, but such other Person shall be deemed to be
a Subsidiary only so long as such ownership or control exists.

  

  

Section 11.2 Exhibits, Appendix and Schedules; Interpretation. The headings
contained in this Agreement or in any Exhibit, Appendix or Schedule hereto and
in the table of contents to this Agreement are for reference purposes only and
shall not affect the meaning or interpretation of this Agreement. Any
capitalized terms used in any Schedule, Appendix or Exhibit but not otherwise
defined therein, shall have the meaning as defined in this Agreement. When a
reference is made in this Agreement to an Article, Section, Subsection,
Exhibit, Appendix or Schedule, such reference shall be to a Section or Article
of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated.
For all purposes hereof, the terms "include," "includes" and "including" shall
be deemed followed by the words "without limitation." The words "hereof,"
"hereto," "hereby," "herein" and "hereunder" and words of similar import when
used in this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement. The term "or" is not exclusive. The
word "extent" in the phrase "to the extent" shall mean the degree to which a
subject or other thing extends, and such phrase shall not mean simply "if."
The definitions contained in this Agreement are applicable to the singular as
well as the plural forms of such terms. References to any statute shall be
deemed to refer to such statute as amended from time to time and to any rules
or regulations promulgated thereunder. Any Contract defined or referred to
herein or in any Contract that is referred to herein means such Contract as
from time to time amended, modified or supplemented; provided, that with
respect to any Contract listed on any schedules hereto, all such amendments,
modifications or supplements must also be listed in the appropriate schedule.
References to a Person are also to its permitted successors and assigns.
References to matters disclosed in the Filed Company SEC Documents are made
without giving effect to any amendment to any such Filed Company SEC Document
filed on or after the date hereof. The mere inclusion of an item in the
Company Disclosure Letter as an exception to a representation or warranty
shall not be deemed an admission that such item represents a material
exception or material fact, event or circumstance or that such item has had,
would have or would reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. The parties have participated jointly in
the negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of
any provisions of this Agreement.

  

  

  

[Signature page follows] 
 

  

 

 

 

  

 

75  

  

 

 

 

  

  

IN WITNESS WHEREOF, Parent, Merger Sub and the Company have caused this
Agreement to be signed by their respective officers thereunto duly authorized,
all as of the date first written above.

  

 

  

    

SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED

  |   
---|--- 
   |   
   |  |  |   
 By: | /s/ Michael Garry |   
   | Name:  | Michael Garry |   
   | Title:  | Director |   
 

  

 

  

 

 

  

    

 

VENUS NEWCO, INC.

 

  |   
---|--- 
   |   
   |  |  |   
 By: | /s/ Jeffrey Poulton |   
   | Name:  | Jeffrey Poulton |   
   | Title:  | President |   
 

  

 

 

  

  

 

 

    

SHIRE PLC

  

(solely for the purposes of Section 10.16)

  |   
---|--- 
   |   
   |  |  |   
 By: | /s/ Graham Hetherington |   
   | Name:  | Graham Hetherington |   
   | Title:  | Chief Financial Officer |   
 

  

 

  

 

 

  

 

    

 

VIROPHARMA INCORPORATED

 

  |   
---|--- 
   |   
   |  |  |   
 By: | /s/ Vincent J. Milano |   
   | Name:  | Vincent J. Milano |   
   | Title:  | President and CEO |   
 

 

 

  


 

  


 

  

[Signature page to Agreement and Plan of Merger]

  

  

 

 

 

  

   

  

 

 

 

  

  

APPENDIX A

  


 

  

DEFINED TERMS

  

  

 

 

   2013 Bonus Plan |  

Section 7.9(e)

   
---|--- 
  

Adverse Recommendation Change

  |  

Section 6.2(b)

   
  

Affiliate

  |  

Section 11.1(a)

   
  

Agreement

  |  

Preamble

   
  

Arrangements

  |  

Section 4.21

   
  

Beneficial Ownership

  |  

Section 11.1(b)

   
 Bonus Plan |  

Section 7.9(e)

   
 Burdensome Condition |  

Section 7.9(c)(vii)

   
  

Business Day

  |  

Section 11.1(c)

   
  

Call-Spread Warrants

  |  

Section 11.1(d)

   
  

Certificate

  |  

Section 3.1(c)

   
  

Certificate of Merger

  |  

Section 2.3

   
  

Change of Control Agreement

  |  

Section 11.1(d)

   
  

Closing

  |  

Section 2.2

   
  

Closing Date

  |  

Section 2.2

   
  

Code

  |  

Section 1.1(g)

   
  

Collaboration Partner

  |  

Section 4.20(a)

   
  

Company

  |  

Preamble

   
  

Company 401(k) Plan

  | Section 7.9(d)  
  

Company Bylaws

  |  

Section 4.1

   
  

Company Charter

  |  

Section 2.5(a)

   
  

Company Common Stock

  |  

Recitals

   
  

Company Disclosure Schedule

  |  

Article IV

   
  

Company Employees

  |  

Section 7.9(a)

   
  

Company Financial Advisor

  |  

Section 4.22

   
  

Company Hedge Options

  |  

Section 11.1(f)

   
  

Company PSUs

  |  

Section 4.3(b)

   
  

Company Recommendation

  |  

Section 4.4

   
  

Company RSUs

  |  

Section 4.3(b)

   
  

Company SEC Documents

  |  

Section 4.7(a)

   
  

Company Stock Options

  |  

Section 4.3(b)

   
  

Company Stock Plans

  |  

Section 4.3(b)

   
  

Compensation Committee

  |  

Section 4.21

   
  

Competition Law

  |  

Section 4.6

   
  

Confidentiality Agreement

  |  

Section 1.2(c)

   
  

Continuing Director

  |  

Section 1.3(f)

   
  

Contract

  |  

Section 4.5

   
  

Convertible Notes

  |  

Section 4.3(b)

   
  

Covered Securityholders

  |  

Section 4.21

   
  

DGCL

  |  

Recitals

   
  

Dissenting Shares

  |  

Section 3.4

   
  

Dissenting Stockholder

  |  

Section 3.4

   
  

DOJ

  |  

Section 7.2(a)

   
  

Effective Time

  |  

Section 2.3

   
  

Employee Plans

  |  

Section 4.16(a)

   
 

  

  

 

 

 

  

 

A-1  

  

 

 

  

 

     

Employment Compensation Arrangement

  |  

Section 4.21

   
---|--- 
  

Environmental Claim

  |  

Section 4.15(c)

   
  

Environmental Law

  |  

Section 4.15(c)

   
  

Environmental Permit

  |  

Section 4.15(c)

   
  

ERISA

  |  

Section 4.16(e)

   
  

ERISA Affiliate

  |  

Section 4.16(e)

   
  

Event

  |  

Section 11.1(j)

   
  

Exchange Act

  |  

Section 1.1(a)

   
  

Expiration Date

  |  

Section 1.1(b)

   
  

FDA

  |  

Section 4.20(a)(iv)(i)

   
  

Filed Company SEC Documents

  |  

Article IV

   
  

FTC

  |  

Section 7.2(a)

   
  

GAAP

  |  

Section 4.7(a)

   
  

Governmental Entity

  |  

Section 4.6

   
  

Guaranteed Obligations

  |  

Section 10.16

   
  

Hazardous Material

  |  

Section 4.15(c)

   
  

Health Authority

  |  

Section 4.20(g)

   
  

Health Law

  |  

Section 4.20(g)

   
  

HSR Act

  |  

Section 4.6

   
  

HSR Filing

  |  

Section 7.2(a)

   
  

Incentive Stock Option

  |  

Section 3.3(a)(i)

   
  

Indenture

  |  

Section 7.10

   
  

Information Statement

  |  

Section 4.6

   
  

Intellectual Property Rights

  |  

Section 11.1(g)

   
  

International Plan

  |  

Section 4.16(a)

   
  

IRS

  |  

Section 4.16(b)

   
  

IT Assets

  |  

Section 4.19(h)

   
  

JPM Credit Facility

  |  

Section 7.12

   
  

Judgment

  |  

Section 4.5

   
  

Key Products

  |  

Section 11.1(h)

   
  

Knowledge

  |  

Section 11.1(i)

   
  

Law

  |  

Section 4.5

   
  

Legal Restraints

  |  

Section 8.1(a)

   
  

Liens

  |  

Section 4.2

   
  

Material Adverse Effect

  |  

Section 11.1(j)

   
  

Material Contract

  |  

Section 4.12(b)

   
  

Medicine

  |  

Section 4.20(a)(i)

   
  

Merger

  |  

Recitals

   
  

Merger Consideration

  |  

Section 3.1(c)

   
  

Merger Sub

  |  

Preamble

   
  

Minimum Tender Condition

  |  

Exhibit A

   
  

NASDAQ

  |  

Section 4.6

   
  

New Plans

  |  

Section 7.9(b)

   
  

Offer

  |  

Recitals

   
  

Offer Closing

  |  

Section 1.1(c)

   
  

Offer Closing Date

  |  

Section 1.1(c)

   
  

  

 

 

 

  

 

A-2  

  

 

 

  

 

  

    

Offer Conditions

  |  

Section 1.1(a)

   
---|--- 
  

Offer Documents

  |  

Section 1.1(e)

   
  

Offer Price

  |  

Recitals

   
 OFT |  

Section 7.2(a)

   
  

Old Plans

  |  

Section 7.9(b)

   
  

Option Cash Payment

  |  

Section 3.3(a)(i)

   
  

Parent

  |  

Preamble

   
  

Parent 401(k) Plan

  |  

Section 7.9(d)

   
  

Parent Approval

  |  

Section 5.2

   
  

Parent Disclosure Schedule

  |  

Article V

   
  

Parent Holdco

  |  

Preamble

   
  

Parent Insider

  |  

Section 1.3(f)

   
  

Paying Agent

  |  

Section 3.2(a)

   
  

Permits

  |  

Section 4.13(a)

   
  

Permitted Liens

  |  

Section 11.1(k)

   
  

Person

  |  

Section 11.1(l)

   
  

Preferred Stock

  |  

Section 4.3(a)

   
  

PSU Cash Payment

  |  

Section 3.3(a)(iii)

   
  

Purchase Plan

  |  

Section 4.3(b)

   
  

Release

  |  

Section 4.15(c)

   
  

Representatives

  |  

Section 6.2(a)

   
 Reverse Termination Fee |  

Section 9.3(d)

   
  

RSU Cash Payment

  |  

Section 3.3(a)(ii)

   
  

Sanquin

  |  

Section 7.13

   
  

Schedule 14D-9

  |  

Section 1.2(b)

   
  

SEC

  |  

Section 1.1(b)

   
  

Secretary of State

  |  

Section 2.3

   
  

Securities Act

  |  

Section 4.7(a)

   
  

Service Provider

  |  

Section 11.1(m)

   
  

Social Security Act

  |  

Section 4.20(a)(iii)

   
  

SOX

  |  

Section 4.7(a)

   
  

Subsidiary

  |  

Section 11.1(n)

   
  

Superior Proposal

  |  

Section 6.2(a)

   
  

Surviving Corporation

  |  

Section 2.1

   
  

Takeover Proposal

  |  

Section 6.2(a)

   
  

Tax

  |  

Section 4.18(m)

   
  

Tax Returns

  |  

Section 4.18(m)

   
  

Tax Sharing Agreement

  |  

Section 4.18(m)

   
  

Taxes

  |  

Section 4.18(m)

   
  

Termination Date

  |  

Section 9.1(b)(i)

   
  

Termination Fee

  |  

Section 9.3(b)

   
  

WARN

  |  

Section 4.17(d)

   
 

 

  

  

 

 

 

  

 

A-3  

  

 

 

 

  

 

  

EXHIBIT A

  

  

OFFER CONDITIONS

  

  

Notwithstanding any other provisions of this Agreement, Merger Sub shall not
be required to, and Parent shall not be required to cause Merger Sub to,
accept for payment or, subject to any applicable rules and regulations of the
SEC, including Rule 14e-1(c) under the Exchange Act, pay for any tendered
shares of Company Common Stock if:

  

  

(i) there shall not be validly tendered and not validly withdrawn prior to the
Expiration Date that number of shares of Company Common Stock (excluding
shares tendered pursuant to notices of guaranteed delivery for which shares
have not been delivered) which, when added to the shares of Company Common
Stock already owned by Parent and its Subsidiaries, represents at least a
majority of the total number of outstanding shares of Company Common Stock as
of the Expiration Date (the "Minimum Tender Condition");

  

  

(ii) any waiting period or review period (and any extension thereof)
applicable to the Offer or the Merger under any Competition Law (including
with respect to any HSR Filing and any filing with the OFT) shall not have
been terminated or shall not have expired and any other approval that is
required to consummate the Offer or the Merger under any Competition Law shall
not have been obtained (or any such waiting period or review period shall have
terminated or expired, or any such approval shall have been obtained, subject
to or conditioned upon the imposition of a Burdensome Condition);

  

  

(iii) any of the following events shall exist on the Expiration Date or
immediately prior to the Offer Closing:

  

  

(a) there shall be any Law or Judgment enacted, enforced, amended, issued, in
effect or deemed applicable to the Offer, by any Governmental Entity (other
than the application of the waiting period provisions of any Competition Law
to the Offer or to the Merger) the effect of which is to directly or
indirectly make illegal or otherwise prohibit or materially delay consummation
of the Offer or the Merger;

  

  

(b) there shall exist or be instituted or pending any claim, suit, action or
proceeding by any Governmental Entity seeking any of the consequences referred
to in paragraph (a) above or seeking to impose a Burdensome Condition;

  

  

(c) there shall have occurred following the execution of the Agreement any
Event which, individually or in the aggregate, has had or would reasonably be
expected to have a Material Adverse Effect;

  

  

(d) (1) (A) any of the representations and warranties of the Company set forth
in Section 4.3 shall not be true and correct in all but de minimis respects,
(B) any of the representations and warranties of the Company set forth in
Section 4.4, Section 4.22, Section 4.23, Section 4.24 or in the first sentence
of Section 4.1 that are qualified as to materiality or Material Adverse Effect
shall not be true and correct in all respects, and

  

  

 

 

 

  

 

EXHIBIT A-1  

  

 

 

 

  

  

any such representations or warranties that are not so qualified shall not be
true and correct in any material respect or (C) the representations and
warranties of the Company in set forth Section 4.10(c) shall not be true and
correct in all respects, in each case as of the date of the Agreement and at
all times prior to the Offer Closing as if made at and as of such time, except
to the extent such representations and warranties relate to an earlier time
(in which case on and as of such earlier time);

  

  

(2) any representations and warranties of the Company set forth in the
Agreement (other than those listed in the preceding clause (1)) shall not be
true and correct as of the date of the Agreement and at all times prior to the
Offer Closing as if made at and as of such time, except to the extent such
representations and warranties relate to an earlier time (in which case on and
as of such earlier time), except in the case of this clause (2) to the extent
that the facts or matters as to which such representations and warranties are
not so true and correct (without giving effect to any qualifications and
limitations as to "materiality" or "Material Adverse Effect" set forth
therein), individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect; or

  

  

(e) the Company shall have failed to perform in any material respect any
obligation, agreement or covenant required to be performed by it under the
Agreement and such failure to perform shall not have been cured;

  

  

(f) Parent and Merger Sub shall not have received a certificate executed by a
duly authorized officer of the Company dated as of the Expiration Date
confirming on behalf of the Company that the conditions set forth in clauses
(c), (d) and (e) of paragraph (iii) of this Exhibit A are duly satisfied
immediately prior to the Offer Closing;

  

  

(g) the Company shall have entered into a definitive agreement or agreement in
principal with any Person (other than Parent or Merger Sub) with respect to a
Takeover Proposal; or

  

  

(h) the Company Board of Directors shall have made an Adverse Recommendation
Change; or

  

  

(iv) the Company and Parent shall have reached an agreement that the Offer or
the Agreement be terminated, or the Agreement shall have been terminated in
accordance with its terms.

  

  

The foregoing conditions shall be in addition to, and not a limitation of, the
rights of Parent and Merger Sub to extend, terminate and/or modify the Offer
pursuant to the terms of the Agreement.

  

  

The foregoing conditions are for the sole benefit of Parent and Merger Sub,
may be asserted by Parent or Merger Sub regardless of the circumstances
(including any action or inaction by Parent or Merger Sub, provided, that
nothing herein shall relieve any party hereto from any obligation or liability
such party has under the Agreement) giving rise to any such

  

  

 

 

 

  

 

EXHIBIT A-2  

  

 

 

 

  

  

conditions and may be waived by Parent or Merger Sub in whole or in part at
any time and from time to time in their sole discretion (except for the
Minimum Tender Condition), in each case, subject to the terms of the Agreement
and the applicable rules and regulations of the SEC. The failure by Parent or
Merger Sub at any time to exercise any of the foregoing rights shall not be
deemed a waiver of any such right and each such right shall be deemed an
ongoing right which may be asserted at any time and from time to time.

  

  

  

  

 

EXHIBIT A-3

 

    

  

 

     '

